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ABSTRACT 
Androgens, in particular dihydrotestosterone (DHT), are crucial for 
maintaining the structure and functions (sperm maturation and storage) of the 
epididymis. DHT is synthesized from testosterone by steroid 5a-reductase 
(Srd5aR) type 1 and type 2. Srd5aR1 and srd5aR2 have different tissue-specifie 
distribution patterns and distinct genetic and biochemical properties. Srd5aR2 
mRNA is more abundant than that of srd5aR1 in several sex accessory tissues, 
most dramatically in the epididymis, where it is predominantly expressed in the 
caput region. 
The two main objectives of this thesis are to elucidate the transcriptional 
and epigenetic regulation of srd5aR2 in the rat epididymis and to identify 
androgen-dependent genes in epididymal principal cells. 
ln the first objective, the 5'upstream region of srd5aR2 was cloned and 
analyzed. The gene's transcriptional start site was localized, regulatory elements 
and the core promoter were mapped, and the transcription factors SP1, and to a 
lesser extent SP3, were found to interact with srd5aR2 in the rat caput 
epididymidis and mouse proximal caput epididymidis (PC-1) cell line. The 
epigenetic regulation of srd5aR2 by DNA methylation was subsequently 
examined and contrasted to that of srd5aR 1 in tissues where the isozymes are 
differentially expressed. DNA methylation levels fluctuated along the 5'upstream 
region of both genes. Tissue-specifie variations in adenine and cytosine 
methylation were also identified for srd5aR1 and srd5aR2, respectively. These 
studies constitute the first analysis of the 5'upstream region of srd5aR2, at both 
the transcriptional and epigenetic levels. 
ln the second objective, the direct effects of androgens on principal cell 
gene expression were examined in PC-1 cells. The majority of androgen-
regulated genes displayed an early or late transient increase in expression levels 
following androgen withdrawal. When DHT was added back to the media, a 
differential ability of rescue was seen among androgen-regulated genes 
depending on time of supplementation. This rescue ability was severely 
compromised after 4 days of androgen deprivation. These results provide novel 
insights into the response of principal cells to androgens. 
Together, the two objectives of this thesis impart greater understanding 
into the mechanisms of androgen action in the epididymis. 
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RÉSUMÉ 
Les androgènes, et en particulier la dihydrotestostérone (DHT), sont 
cruciaux pour maintenir la structure et les fonctions de l'épididyme. La DHT est 
synthétisée à partir de la testostérone par la 5a-reductase (Srd5aR) de type 1 et 
de type 2. Srd5aR 1 et Srd5aR2 diffèrent par leur expression dans différents 
tissus ainsi que par leurs propriétés génétiques et biochimiques. L'ARNm codant 
pour Srd5aR2 est plus abondant que celui codant pour Srd5aR1 dans divers 
tissus de l'appareil reproducteur, surtout dans l'épididyme où il est exprimé à un 
niveau particulièrement élevé dans la tête. 
Les deux objectifs de ma thèse sont de comprendre les mécanismes de 
régulation de la transcription et de l'épigénome de Srd5aR2 dans l'épididyme de 
rat et d'identifier les gènes régulés par les androgènes dans les cellules 
principales de l'épididyme. 
Dans la première partie, la région 5' en amont de Srd5aR2 a été clonée et 
analysée. Le site de l'initiation de la transcription, les éléments régulateurs ainsi 
que le promoteur ont été localisés. Nous avons montré que SP1 , et plus 
faiblement SP3, interagissent avec Srd5aR2 dans la tête de l'épididyme du rat 
ainsi que dans une lignée de cellules dérivée de la tête de l'épididyme de souris 
(PC-1). Les régulations épigénétiques mesurées par la méthylation de l'ADN ont 
été analysées pour Srd5aR2 et de Srd5aR1 dans les tissus où ces isoenzymes 
sont exprimés différemment. Le niveau de méthylation fluctue le long de la région 
5' en amont de chacun des deux gènes. Selon le tissu, des variations spécifiques 
du niveau de méthylation des adénines et cytosines ont aussi été observées pour 
Srd5aR1 et Srd5aR2 respectivement. 
Dans la deuxième partie, nous avons analysé l'effet direct des androgènes 
sur l'expression de gènes dans la lignée cellulaire PC-1. Si l'on retire les 
androgènes, la majorité des gènes régulés par ceux-ci présente une 
augmentation transitoire précoce ou tardive de leur expression. La DHT, ajoutée 
dans les cultures, permet de restaurer le niveau d'expression de certains gènes. 
111 
Cette capacité varie en fonction du temps de supplémentation et est sévèrement 
compromise après 4 jours sans androgènes. 
L'ensemble de ces données permet de mieux comprendre les 
mécanismes d'action des androgènes dans l'épididyme. 
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PREFACE 
Thesis Format 
This is a manuscript-based thesis, which conforms to section I.C. of the 
"Thesis Preparation and Submission Guidelines" of the Faculty of Graduate 
Studies and Research at McGili University. This thesis is comprised of five 
chapters. Chapter one is a general introduction; it is a comprehensive review of 
the epididymis, androgens, in particular testosterone and dihydrotestosterone, 
and the steroid 5a-reductases. This chapter concludes with a rational for the 
studies presented in this thesis and the objectives of the thesis. Chapters two to 
four are data chapters bridged by connecting text to ensure that the thesis has 
continuity. Chapters two and four are published manuscripts, and chapter 3 is a 
thesis chapter in the form of a manuscript. Chapter two was published in Biology 
of Reproduction: Seenundun S, Robaire B. (2005) Cloning and characterization 
of the 5alpha-reductase type 2 promoter in the rat epididymis. Biol Reprod 
72:851-61. Chapter four was published in Endocrinology: Seenundun S, Robaire 
B. (2007) Time-dependent rescue of gene expression by androgens in the mouse 
proximal caput epididymidis-1 cell line after androgen withdrawal. 
Endocrinology 148:173-88. The copyright agreements of the respective 
publishers, Biology of Reproduction by the Society for the Study of Reproduction 
(http://www.biolreprod.org/) and Endocrinology by the Endocrine Society 
(http://endo.endojournals.org/) allow these manuscripts to be included in this 
thesis provided they are for non-commercial use. Chapter five is a discussion of 
the overall results and includes ideas for future studies; it is followed by a list of 
original contributions. References are provided at the end of each chapter. The 
appendix contains the ethics certificates for work on animal subjects and for the 
use of radioactive materials and the proprietary rights notices for Biology of 
Reproduction and Endocrinology. 
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CHAPTER 1 
Introduction 
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1. The Epididymis 
The epididymis is an extratesticular component of the male reproductive 
system present in ail mammals. It is derived from the Greek words "epi" and 
"didymoi" literally signifying "on twins (testes)" (1). As its name implies, 
epididymides occur as pairs; each one lies on the posterior surface of each testis. 
Its structure, functions, culture, and gene expression are explored in this section. 
1.1. Structure 
1.1.1. Gross Anatomy 
The epididymis is a single highly convoluted tubule linking the efferent 
ducts of the testis to the vas deferens (Fig. 1) (2). Its length is species-specific; 
when unwound, this tubule can measure 1 m in mice (3), 3 m in rats (4), 3 to 6 m 
in humans (5), and up to 80 m in horses (6). It takes spermatozoa approximately 
7 to 10 days to travel from one end of the tubule to the other (7). 
The epididymis is generally divided into four regions: initial segment, caput 
(head), corpus (body), and cauda (tail) (Fig. 1) (as reviewed in (2, 7)). These 
divisions are based on the anatomical, morphological, biochemical, and 
functional differences between regions. It has been suggested that the initial 
segment, similar to the efferent ducts, is derived from the mesonephric tubule 
while the rest of the epididymis is derived from the mesonephric duct (as 
reviewed in (8-10)). Other schemes have been proposed to divide this tissue. 
Some schemes take into account the characteristic cells found in the 
intermediate zone between the initial segment and the caput epididymidis, and 
others, the further division of each region into discrete, intraregional segments 
separated by connective tissue septae (11-14). While some schemes have 
identified 6 segments in the mouse epididymis and 13 in the rat epididymis (15), 
another group has identified 10 anatomically distinct segments in the mouse 
epididymis (16) and 19 in the rat epididymis (17). In my thesis, 1 will use the most 
common scheme where the tissue is divided into the above mentioned 4 regions. 
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Figure 1. Diagrammatie Representation of the Testieular Exeurrent Duet 
System 
The testicular excurrent ducts of the male reproductive system conduct 
spermatozoa from their site of production to their site of ejaculation. Briefly, 
spermatozoa produced in the seminiferous tubules collect into the rete testis, and 
leave the testis through the efferent ducts. These ducts consist of 4 to 20 tubules, 
depending on the species, and converge at the epididymis. The epididymis is 
morphologically and functionally subdivided into 4 major regions: initial segment, 
caput, corpus, and cauda epididymidis. Spermatozoa remain in the epididymis 
until ejaculation at which time they empty into the vas deferens, a straight 
muscular tube. Reproduced from reference (7). 
TESTtS 
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Transversally, the epididymis consists of three major compartments: a lumen, an 
epithelium, and an inter-tubular compartment (Fig. 2) (as reviewed in (2, 7». The 
lumen is composed of spermatozoa and a fluid whose composition is highly 
specialized and region-specific. This unique microenvironment is created by the 
active secretion and absorption of water, ions, organic solutes, and proteins by 
the epithelium along the duct as weil ~s by the blood-epididymis barrier. The 
epididymal epithelium is made up of several cell types that will be discussed in 
the next section. Peritubular myoid cells line the epithelium, and the tubule is 
surrounded by connective tissue as weil as an interstitium containing blood 
vessels, Iymphatics, and nerves (1 ). 
1.1.2. Cell Types of the Epithelium 
Six cell types are found in the epididymal epithelium: principal, clear, basal, 
halo, narrow, and apical cells (Fig. 2) (as reviewed in (1,2,7». Their presence 
and distribution in the epididymis are region-specific. 
As its na me implies, principal cells are the major cell type of the tissue. 
They outnumber the other cells combined bya ratio of at least 3 to 1 (18). These 
tall columnar cells are very active in protein synthesis, in the transport and 
secretion of small organic molecules, and in the absorption and secretion of fluid 
and small particulate matter (7). Principal cells also display structural and 
functional differences in the different regions of the epididymis, which directly 
contribute to the continuously changing composition of the luminal fluid along the 
duct (2, 19, 20). 
Basal cells are the second most abundant cell type and, like principal cells, 
are found throughout the epididymal epithelium (7). They are fiat, elongated cells 
that adhere to the base ment membrane, and they have thin, attenuated 
processes that extend along the membrane and, at times, towards the lumen. 
Basal cells do not act as stem cells to replenish principal cells in the epididymis 
as they do in other tissues. They are scavengers that protect sperm. It has also 
been suggested that basal cells play a role in regulating electrolyte and water 
transport by principal cells (21). 
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Clear cells are large cells that span the caput, corpus, and cauda 
epididymidis epithelium (7). They have endocytic properties and can actively 
remove materials from the lumen, including the cytoplasmic droplet shed by 
spermatozoa as they transit through the duct. They are also thought to mediate, 
along with narrow cells, the acidification of the luminal fluid. 
Narrow cells and apical cells are confined to the initial segment of the 
epididymis (7). They differ in their morphological appearance, relative distribution, 
and protein expression profiles. Both have endocytic properties but little else is 
known about their respective functions. 
Halo cells are the primary immune cells in the epididymis (7). These small 
cells present throughout the epithelium consist of helper T lymphocytes, cytotoxic 
T lymphocytes, and monocytes. 
1.1.3. The Blood-Epididymis Barrier 
The blood-epididymis barrier is formed by tight junctions located in the 
apical region of adjacent principal cells (7, 22, 23). Several integral membrane 
proteins (e.g., cadherins, claudins, and occludins) and a number of peripheral 
membrane proteins (e.g., zonula occludens, symplekin, cingulin, cytoskeletal 
elements) have been implicated in the formation and maintenance of these tight 
junctions (22-25). This barrier is crucial for maintaining the specialized luminal 
microenvironment for maturing spermatozoa and keeps luminal fluid separate 
from blood plasma (7). It has also been suggested to serve as an extension of 
the blood-testis barrier to protect immunogenic spermatozoa from the immune 
system and possibly from toxic substances (7). 
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Figure 2. Schematic Organization of the Major Cell Types in the Epididymis 
The three compartments of the epididymis as weil as the relative position and 
distribution of the main cell types of the tissue are illustrated. The major functions 
associated with each of the main cell types are also identified. Adapted from 
reference (7). 
HALOCELL 
- Immune functions 
CLEAR CEll 
- Takes up luminal 
components 
- Unknown function 
• Protective role 
and secretion 
MYOID CEll l
Fft i· - Major role in absorption 
SPERMATOZOA 
INTERSTITIUM 
SMOOTH MUSCLE 
CAPILLARIES 
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1.2. Functions 
The epididymis has four main functions; it facilitates the transport of 
spermatozoa, promotes sperm maturation, stores sperm, and protects them from 
harmful substances (as reviewed in (1, 7». 
1.2.1. Sperm Transport 
The epididymis is a major component of the testicular excurrent duct 
system and transports spermatozoa fram the efferent ducts of the testis to the 
vas deferens (7). Spermatozoa are propelled into the epididymis by testicular 
fluid and possibly by the beat of the ciliated cells of the efferent ducts. Once in 
the epididymis, they are subjected to a number of factors drastically reducing fluid 
flow: the epithelium is lined by immotile stereocilia, there is massive fluid intake in 
the efferent ducts and initial segment of the epididymis, and they need to be 
transported against increasing hydrostatic pressure. The mechanism responsible 
for overcoming these factors has been primarily attributed to the rhythmic 
muscular contractions of smooth muscle surrounding the epididymal epithelium. 
There is an increase in the thickness of smooth muscle and adrenergic 
innervation from the proximal to the distal regions of the tubule (26). The rate of 
contraction is influenced by several hormonal (e.g., androgen, estrogen) and 
neuronal factors (e.g., oxytocin, vasopressin), as weil as by prostaglandins, 
adrenergic and cholinergie drugs, and temperature (7). 
1.2.2. Sperm Maturation 
Spermatozoa acquire forward motility and fertilizing ability as they are 
transported along the duct such that sperm released from the epididymis can 
ascend the female genital tract, undergo the acrosome reaction, bind to and 
penetrate the zona pellucida and zona-free vitellus, and achieve syngamy with 
the oocyte (7). Classical studies in the 1960s showed that this maturation is not 
only a function of time but a consequence of their exposure to a highly 
specialized luminal environment. There is sorne species variation as to the exact 
region where spermatozoa first acquire their fertilizing potential, but they are 
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usually fertile by the time they reach the distal corpus/proximal cauda 
epididymidis (7). There is also an increase in the percentage of motile 
spermatozoa in the cauda epididymidis. Furthermore, sperm isolated from this 
region are also more vigorous and have gained the ability to swim in a straight 
path. This is in sharp contrast to sperm isolated from the caput region which 
display a circular swimming pattern (7). 
A number of structural and biochemical changes associated with sperm 
maturation also take place during epididymal transit (1,27,28). One of the most 
prominent changes is the migration of the cytoplasmic droplet, a remnant of the 
cytoplasm associated with testicular sperm, from the neck to the end of the 
midpiece of the spermatozoa during transit from the caput to the corpus region. 
This droplet is then shed either within the cauda fluid or during/after ejaculation, 
depending upon the species. The spermatozoa plasma membrane also 
undergoes extensive remodeling during transit. These changes are the result of 
proteolytic processing, the action of glycolytic enzymes, and the integration of 
newly synthesized components. Other important aspects of sperm maturation 
include chromatin condensation, structural modifications in the nucleus and other 
organelles, changes in the metabolic activity of spermatozoa, and ultrastructural 
changes in the acrosome of sorne species, particularly in the'guinea pig (1). 
Possible changes in the methylation status of a number of genes have also been 
suggested to occurduring the process of sperm maturation (29). Collectively, 
these changes render sperm mature and capable of fertilization by the time they 
leave the epididymal duct. 
1.2.3. Sperm Storage 
The cauda epididymidis is the primary site for sperm storage in the 
testicular excurrent duct system of mammals; between 50 to 80% of spermatozoa 
present in the excurrent ducts are found in this region and approximately 50% of 
them are available for ejaculation (2). While their average transit time'through the 
cauda epididymidis is in the range of 3 to 10 days, spermatozoa can be stored in 
this region for more than 30 days with no apparent IOS8 of function (7). 
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Spermatozoa are kept in an immotile state by a number of species-dependent 
mechanisms until ejaculation (1). These mechanisms include the lowering of 
luminal sodium ion concentration which prevents proton efflux and a rise in 
intracellular pH that trigger motility, the maintenance of an acidic pH in the cauda 
luminal fluid of several species, and the presence of immobilin in rats and 
hamsters. Immobilin is a high molecular weight glycoprotein secreted by principal 
cells in the proximal epididymis, and it is endocytosed by clear cells in the distal 
cauda region to maintain its steady state concentrations (30). It associates with 
spermatozoa in the cauda epididymidis and immobilizes them (31). This 
mucoprotein is also thought to protect sperm from shearing during ejaculation 
(32). 
1.2.4. Sperm Protection 
As discussed in section 1.1.3., the blood-epididymis barrier restricts the 
access of immune cells and certain compounds to the lumen and maturing 
spermatozoa. The epididymis has also developed extensive defense 
mechanisms to protect spermatozoa from reactive oxygen species (ROS) (7). 
ROS are produced by spermatozoa during chromatin condensation and redox-
regulated signal transduction cascades (33-35). Spermatozoa are extremely 
susceptible to oxidative damage because of the high polyunsaturated fatty acid 
content of their plasma membrane (36-38). Numerous antioxidant enzymes and 
molecules are present in the epididymis to protect the fertilizing capacity and 
genetic integrity of spermatozoa; these include glutathione peroxidases (Gpx), 
glutathione S-transferases (GST), y-glutamyl transpeptidase (GGT), catalase, 
superoxide dismutase, and indolamine dioxygenase as weil as molecules such 
as glutathione, taurine, tryptophan, and zinc (39). In addition, defensins and 
defensin-like molecules are synthesized and secreted into the epididymal lumen 
where they play an important antimicrobial role (7). 
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1.3. CeU Culture of the Epididymis 
ln vitro cell culture systems are of central importance to our understanding 
of the cellular and molecular biology of tissues. As early as 1972 (40), attempts 
were made to culture the epididymis so that the functions and regionalization of 
the tissue could be studied in isolation. Since then, organ and primary cell culture 
methods for different regions of the tissue (reviewed in (2)), and more recently, 
immortalized ceillines have been developed (41-46). 
1.3.1. Organ Culture 
Organ culture offers several advantages that are of particular significance 
for studies of the epididymis. For instance, the endocrine environment of the 
epididymis can be precisely defined and is easily manipulated, the tissue retains 
its hormone-responsiveness, and the histological architecture is preserved (2). 
Important contributions have been made using static and continuous f10w organ 
cultures in various species. They include, the establishment of the requirement of 
androgens, more precisely of dihydrotestosterone (DHT), for sperm maturation 
(47), the demonstration that DHT action is mediated via the synthesis of RNA and 
proteins (48), and that a number of proteins potentiallY important for sperm 
maturation are DHT-dependent (49-51). Different aspects of sperm maturation, 
as weil as protein synthesis and secretion, have also been studied (51-54). 
These cultures, however, could only be maintained for a few days and access to 
the lumen is limited. 
1.3.2. Primary Epithelial CeU Culture 
Primary cultures of epithelial cells provide a simplified model system for 
the analysis of epithelial cell metabolic activities and regulation. Synthesis and 
secretion of specifie components can not only be monitored under defined 
conditions, but they can also be attributed to a particular cell type. Cultures of 
epididymal epithelial cells have been generated from a variety of species, 
including rats (55-57), mice (58), hamsters (59), rams (60), bulls (61, 62), dogs 
(63), boars (64), and humans (65,66). Although these cells flatten and form 
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monolayers in culture, they retain some of their structural features such as 
surface microvilli, prominent Golgi apparatus, abundant rough and smooth 
endoplasmic reticula, lipid droplets, and multivesicular bodies (56, 57, 67). They 
also maintain some of their functional characteristics including ion secretion and 
reabsorption (68-70), testosterone metabolism (56, 71), expression of epididymal 
genes (55, 63), and protein secretion (e.g. alkaline and acid phosphatases, 
glycosidases, and glutathione-related enzymes) (58,65,66,72). In addition, 
enhanced sperm survival and an increase in progressive sperm motility have 
been shown in co-culture studies with epididymal epithelial cells (73,74). 
Despite their usefulness, primary cell cultures have important limitations 
for the study of epididymal functions. They have a short half-life in vitro; they 
divide very slowly and can lose their differentiated phenotype after a few 
passages (57, 71, 75). In addition, there is a lack of reproducibility between 
cultures, and they are often contaminated with various cell types including 
fibroblasts. 
1.3.3. Immortalized Cell Lines 
The complexity and high degree of differentiation of the epididymal 
epithelium has made the task of developing a continuous and stable supply of its 
epithelial cells particularly challenging. Some of the difficulties stem from the 
many cell types forming the epithelium, the regulation of the tissue's differentiated 
state by circulating androgens and paracrine factors entering the lumen with 
testicular fluid, and the low mitotic index of principal cells (76). The slow 
proliferation of principal cells is maintained in vitro (57, 71, 75) unless the cultures 
are contaminated with fibroblasts, or unless they are derived from a fetal or 
pubertal epididymis (67, 77, 78). In addition, transformation of the epididymis in 
vivo is a rare event (79-81) and there is no report of tumor-derived immortal cell 
lines from this tissue. Consequently, until recently, hormone-responsive gene 
expression in the epididymis was studied in cervical Hela and prostatic PC-3 
cells (82). Figure 3 iIIustrates the different stable epididymal epithelial cell lines 
that have since been developed. 
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Figure 3. Chronological Order of the Development of Epididymal Epithelial 
Cell Unes 
The immortalized epithelial cell lines of the epididymis are illustrated in the 
chronological order of their development. 
IMCE 
canine epid. (41) 
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mouse caput epid. (44) 
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mouse caput epid. (43) 
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rat caput epid. (46) 
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PC1, DC1, DC2, and DC3 
mouse caput epid. (42) 
MEPC5 
mouse caput epid. (45) 
12 
1.3.3.1. Approaches Used 
Three distinct approaches have been successful in generating 
immortalized cell lines in the epididymis, and two of these approaches use the 
viral oncogene simian virus 40 large T-antigen (SV40L T). Unlike many other 
oncogenes that must act cooperatively to fully transform cells, the T -antigen 
alone can convert primary cells to tumorigenic cells (83). Its exact mechanisms 
for immortalization and transformation are not yet known but include the 
inactivation of several tumor suppressor molecules such as p53 and 
retinoblastoma binding protein (84). Other p53-independent pathways have also 
been reported (84, 85). 
1.3.1.1.1 Immortalization of Primary Cultures with SV40L T 
The majority of epididymal cell lines available to date were generated by 
transfecting primary cultures of epithelial cells with a SV40L T plasmid in vitro. 
The first cell line generated from this tissue is derived from human fetal 
epididymis, but the cells lost their epididymis-specific appearance after a few 
passages (77). 
Ten years later, this same approach was used to generate the tirst ceU 
lines from a differentiated, adult epididymal duct epithelium. Immortalized canine 
epididymis ceillines (IMCE) are derived from the whole epididymis of mongrels 
and are epithelial in origin (41). These cells maintain the expression of some 
molecular markers abundantly expressed throughout the epididymis, including 
androgen receptor (AR) mRNA and protein. Androgen induction or modulation of 
any of the epididymal marker mRNAs studied, however, was not achieved and 
may reflect a partialloss of the differentiated phenotype. 
Subsequently, two region-specific celllines were developed using this 
approach: MEPC5 from the mouse caput epididymidis (45) and very recently, 
RCE from the rat caput epididymidis (46). MEPC5 was established as a 
conditionally immortalized cell line with a temperature-sensitive mutant of 
SV40L T (tsSV40L T) (45). This mutant contains a single nucleotide mutation, 
which results in an oncogene product that functions at the permissive 
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temperature of 33°C, but is rapidly degraded at the nonpermissive temperature of 
39°C. Therefore, the functional expression of SV40L T can be turned on or off by 
culturing cells at 33°C or 39°C. MEPC5 cells are polarized epithelial cells that 
maintain regulated permeability barrier function and express a number of 
epididymal caput-expressed genes. 
The RCE cell line is the only rat epididymal cell line available to date and 
is composed primarily of epithelial principal cells from the caput region of the 
epididymis (46). It exhibits many of the structural and functional characteristics of 
principal cells in vivo and also expresses many tight and gap junction proteins 
present in normal, intact rat epididymis. The cell line is not, however, a pure 
population of caput principal cells; principal cells from the intermediate zone and 
clear cells are also present albeit, at very low levels. In addition, RCE cells only 
have a limited response to androgen stimulation. 
1.3.3.1.2. In vivo Immortalization of Epididymal Epithelial Cells 
Immortalization of epididymal epithelial cells has also been achieved by 
introducing SV40L Tinto one-cell embryos using transgenic techniques. Two 
different strategies were used to prevent growth of aggressive tumors that would 
prematurely kill the transgenic mouse. 
The first one used an approach similar to the one described above and 
introduced a temperature-sensitive mutant of the oncogene (tsSV40L T) into mice 
(86). These transgenic mice do not express the SV40L T (or have reduced 
expression) at the non-permissive body temperature; immortalization is achieved 
only when the cells are cultured at the permissive temperature (86). This strategy 
resulted in the first cell lines expressing markers with a region-specifie pattern of 
expression. Proximal caput (PC-1) and distal caput (DC-1, DC-2, and DC-3) 
epididymidis celllines were established in 2002 and are derived from four 
sequential segments of the mouse caput epididymidis (42). These pure 
populations of epithelial cells maintain a similar polarity to principal cells in vivo in 
terms of their distribution of cellular organelles, and they retain the type of 
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junctional complexes between cells seen in principal cells. They also express a 
number of principal cell markers and are responsive to androgens. 
The other transgenic approach used directed the expression of SV40L T to 
the caput epididymidis using 5.0-kb mouse glutathione peroxidase 5 promoter 
(Gpx5-Tag1) (87). Eighteen epithelial ceillines, named mE-Cap, were generated 
and characterized (44). Despite the presence of different cell types, these cells 
maintain several specifie features of the epididymal epithelium, including the 
expression of some epididymal genes. Regulation of polyomavirus enhancer 
activator 3 (PEA3), an epididymal transcription factor, was also studied in these 
cells. Similar to the IMCE and RCE cells, the levels of AR are markedly reduced 
in mE-Cap ceillines compared to wild-type caput epididymidis. 
1.3.3.1.3. Spontaneously Immortalized Cell Lines 
ln the last approach, ceillines A and 82 were derived fram primary 
cultures of the mouse caput epididymidis and selected for their ability to 
proliferate and maintain their characteristics for a pralonged period (43). These 
spontaneously immortalized cell lines are a homogeneous cell population of 
epithelial origin; under defined conditions, they can adopt sorne of the 
characteristic features of in vivo principal cells. Several epididymis-expressed 
genes are found in the celllines; however they do not appear to be androgen-
dependent or -responsive. 
The established immortalized epithelial cell lines of the epididymis 
proliferate, maintain some of the characteristics of differentiated principal cells, 
and are transfectable. They therefore constitute valuable tools for studying the 
regulation of tissue-specifie expression. The lack of expression of certain 
epididymal marker genes observed in ail these cell lines suggests that they have 
lost part of their differentiated state. In fact, the major limitation cames fram their 
transformed nature. It is also interesting to note that ail the region-specifie 
epididymal cell lines published to date derive fram the caput region of the 
epididymis. 
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1.4. Gene Expression in the Epididymis 
Gene expression in the epididymis displays three levels of specificity: 
tissue, region, and calI. Region-specifie gene expression is a hallmark of the 
tissue, and several of its key features are explored in this section. 
1.4.1. Region-Specifie Gene Expression 
The regionalization displayed in the morphology and function of the 
epididymis is also reflected at the level of gene expression. Understanding the 
molecular basis for these region-specifie differences, and how they ultimately 
contribute to the process of sperm maturation has been pursued by many groups. 
Different approaches have been used both at the mRNA level (e.g., Northern 
blots, in situ hybridization, reverse transcriptase- polymerase chain reaction (RT-
PCR), and microarrays) and at the protein level (e.g., Western blots, 
immunohistochemistry, and protein arrays) to characterize region-specifie gene 
expression in many species (16,17,88-103). Complete lists of genes expressed 
in the different epididymal regions have recently been generated and are 
available online for further analysis (http://mrg.genetics.washington.edu, 
www.ttuhsc.edu/cbb/faculty/cornwall/default.asp, and 
www.wsu.edu/%7Egriswold/microarray/epididymis dhtl) (16,88, 104). 
Most of the molecules identified have characteristic longitudinal expression 
profiles in the tissue. Some of these genes encode secretory proteins with 
putative roles as proteases and protease inhibitors, antioxidant enzymes, 
modifying enzymes, growth factors, neuropeptides, and transporters (105). 
Others encode intracellular proteins, including transcription factors, signalling 
molecules, receptors, and kinases. Not only are the genes spatially regulated, but 
several experimental conditions including androgen withdrawal, aging, and stress 
can differentially affect their expression profiles along the tissue (104, 106-109). 
Many genes are highly expressed or exclusively expressed in the caput 
region of the epididymis and/or its initial segment (105). This is to be expected 
given that these regions are very active in terms of protein synthesis and 
secretion (2, 110). The highly restricted expression of these genes suggests that 
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they are important for early maturational events while the genes highly expressed 
in the distal regions may be important for later maturational events or play a role 
in sperm storage. Sorne genes su ch as cystatin-related epididymal 
spermatogenic (Cres) gene (91), proenkephalin (92), and lipocalin 8 (93) express 
abrupt changes in mRNA expression between epididymal regions, while others 
including A-raf (101), human epididymis gene product 4 (He4) (102), and 
glutathione peroxidase (Gpx) 5 (103) display more graduai changes. A 
characteristic checkerboard-type pattern of expression is also observed at the 
protein level for a number of genes in cross-sections of individual tubules (94, 
111, 112). These proteins are expressed at different intensities in adjacent 
principal cells; this is usually seen when a gene is first expressed along the duct 
or when its expression terminates (7). 
Region-specifie gene expression is regulated predominantly at the level of 
transcription initiation (as reviewed in (113». Consequently, many studies have 
searched for DNA cis-regulatory elements and epididymal transcription factors 
that can direct the expression of genes to the different regions. For instance, the 
1.8 kb promoter fragment of lipocalin 5 (formerly known as retinoic acid binding 
protein) was found to contain ail the information required for epididymis-specific 
and mid-distal caput-specific gene expression in transgenic mice (114). Further 
analysis of this fragment revealed that binding of Forkhead box A2 to its binding 
site was crucial for interaction with androgen receptor (AR) and eventual gene 
expression (115). 
The expression of a number of transcription factors has been examined in 
the epididymis, one of which is PEA3. PEA3 exhibits highly regionalized 
expression in the initial segment and the brain (116), and it acts as both an 
activator and repressor of Gpx5 and GGT-IV (117,118). CCAAT/enhancer-
binding protein (3 (C/ebp(3) is another transcription factor displaying region-
specificity in the epididymis (119). It is expressed in the proximal regions of the 
mouse epididymis and can regulate the expression of Cres. Pern homeobox 
protein, when expressed from a "male-specifie" proximal promoter, is expressed 
in the epididymis in an androgen-dependent manner (120). In the mouse, it is 
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mainly found in the caput region (121); in the rat, it is expressed throughout the 
duct, increasing from the caput to cauda regions (122). No response element has 
yet been identified for this factor in epididymal expressed genes. Inhibitor of DNA 
binding (Id) proteins are another group of transcription factors studied in the 
epididymis (95). They are localized to different cell types, and they are 
differentially expressed along the tissue. They can modulate the functions of 
basic helix-Ioop-helix transcription factors by forming transcriptionally inactive, 
stable dimers with these proteins (123). Investigating the expression patterns of 
these and other transcription factors in the tissue, along with their underlying 
mechanisms and interactions, will provide further insights on the differential 
expression of genes along the epididymis. 
Other levels of gene regulation have also been described in the tissue (as 
reviewed in (113)). For example, the GGT gene contains different promoters 
upstream of the coding region and the use of each promoter results in mRNA 
sequences differing in their 5' sequence. These mRNA sequences are expressed 
and regulated differentially in the rat epididymis; they also differ in their mRNA 
stability(124,125). 
1.4.2. Tissue- and Cell-Specific Gene Expression 
ln addition to being region-specifie, a number of genes such as ros1 proto-
oncogene (126), lipocalin 8 (127), and lipocalin 5 (128) are expressed exclusively 
in the adult epididymis. A high proportion of these genes, however, are 
expressed at low levels in other tissues; PEA3 (116), cystatin 8 (91), and 
cysteine-rich secretory protein 1 (Crisp1) (129, 130) belong to this category. 
Many region-specifie genes also exhibit cell-specificity; this is to be expected 
given the different functions each cell-type has in the tissue. While the vast 
majority of identified genes are expressed only in principal cells, a few genes 
have been shown to be localized to other ceU types (131-133). Laser capture 
microscopy and microarray technology should make it possible to generate 
individual gene expression profiles for the different cell types. 
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2. Regulation of the Epididymis 
The structure, functions, and gene expression in the epididymis are 
regulated by a number of factors. The most important ones are hormones and 
non-steroidal factors entering the epididymis from the testis. 
2.1. Hormones 
Androgens are recognized as the primary regulators of epididymal 
structure and functions (134,135) and will be covered in more depth in section 3. 
A number of other hormones such as estradiol, retinoids, and oxytocin have also 
been postulated to play a role in regulating the tissue's functions (136-138). The 
role of these hormones, however, has not been as weil characterized as that of 
androgens. 
2.1.1. Estradiol 
The existence of an estrogen receptor-like protein in epididymal tissues 
has been known for at least 25 years, but early studies suggested that estradiol 
was more important during development of the epididymis than in adult function 
(139,140). It was only in the 1990s with the discovery that testicular germ cells 
and epididymal sperm contain cytochrome P450 aromatase and synthesize 
estradiol that estradiol was hypothesized to have important functions in the adult 
male reproductive tract (as reviewed in (141)). Subsequent studies localized the 
aromatase enzyme to cytoplasmic droplets in the sperm tail with decreasing 
expression as sperm traverse the tissue (142, 143). These findings suggest that 
germ cells provide estradiol to the epididymis and this hormone, in turn, regulates 
the tissue's functions. While some conflicting data on the immunolocalization of 
estrogen receptor (ER)a and ERB remain (144-149), a general pattern has 
emerged. In both mice and rats, ERa is primarily found in narrow, apical and 
some basal cells of the initial segment, in principal cells and clear cells of the 
caput epididymidis, and in clear cells of the distal regions (7). In contrast to the 
high levels of ERa present in the efferent ducts and initial segment, ERB is found 
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throughout the entire epididymis but is most abundant in the corpus and cauda 
regions of the tissue (7). 
Gene knockout studies were used to elucidate the functional role of 
estradiol in the efferent ducts and epididymis (7). ERa knockout mice are infertile; 
their seminiferous tubules appear normal until puberty but atrophy in the adult. 
The cause of this atrophy is an increase in back-pressure due to the inability of 
the efferent ducts and initial segment to reabsorb the large volume of fluid 
secreted by the testis. This reabsorption process is therefore believed to be 
controlled by estradiol and is proposed to be mediated by the cystic fibrosis 
transmembrane conductance regulator receptor (150). The function of ER~ in the 
epididymis, on the other hand, awaits further investigation because ER~ knockout 
mice are fertile and appear to have a normal testis and epididymis (151). 
2.1.2. Retinoids 
Retinoids are highly potent molecules with pleiotropic action in a wide 
range of biological processes during development and in the adult (as reviewed 
in (152)). They are most likely involved in the regulation of epididymal function for 
the following two reasons (7, 137). First, vitamin A deficiency results in squamous 
metaplasia of numerous epithelia including the epididymal epithelium. Second, 
most of the components of the retinoid signalling pathway have been identified in 
the epididymis and display region-specifie expression. These components include 
retinoids (retinols, retinyl ester, the active retinoids all-trans retinoic acid, and 9-
cis retinoic acid), intracellular retinoid-binding proteins (cellular retinol-binding 
protein 1 and Il and cellular retinoic acid-binding protein 1 and Il), extracellular 
retinoid-binding proteins (retinol-binding protein and lipocalin 5), as weil as the 
different isoforms of the nuclear retinoic acid receptor (RAR). Despite the lack of 
phenotype observed in most single gene knockouts as a result of functional 
redundancy, gene knockout studies have been useful in elucidating the role of 
retinoids in the epididymis. Expression of a dominant negative mutant of RARa 
results in a loss of organization of the columnar epithelium lining the cauda 
epididymidis, vacuolization, and its transformation by squamous metaplasia (153, 
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154). This aberrant transformation is followed by blockage or rupture of the duct, 
inflammation, and infertility. Severe dysplasia or complete agenesis of the 
epididymis is also observed in RARa/y double-null mutants (155). 
2.1.3. Oxytocin 
Oxytocin, a neurohypophysial hormone secreted by hypothalamic 
magnocellular neurons, was traditionally thought of as a 'female' hormone due to 
its role in parturition and milk ejection. It has since been found to play important 
roles in male reproduction and, in particular, the epididymis (as reviewed in (7, 
138)). Oxytocin receptors have been localized to peritubular cells as weil as to 
principal and basal cells of the epididymal epithelium in a species- and region-
specifie manner. Oxytocin was found by several in vitro and in vivo studies to 
modulate the basal contractility of the epididymal duct and therefore regulate 
sperm transport. This effect is in part regulated by estrogens through the 
upregulation of the oxytocin receptor gene and protein (156). Oxytocin also 
promotes the formation of DHT by stimulating 5a-reductase activity in the initial 
segment of the tissue (157). Although the exact mechanism has not yet been 
elucidated, stimulation of 5a-reductase activity has been suggested to be 
mediated through tyrosine kinase activation and enzyme phosphorylation (158). 
2.2. Testicular factors 
The regulation of epididymal function is also dependent on non-steroidal 
factors coming from the testis (159). These factors enter the epididymis through 
the efferent ducts and regulate epididymal gene expression through a type of 
paracrine regulation. This type of regulation is termed "Iumicrine" since it occurs 
in a duct/tubal system. 
Efferent duct ligation (EDL) and orchidectomy followed by androgen 
replacement are two methods widely used to study this type of regulation. 
Removal of luminal testicular factors results in epithelial apoptosis in the rat initial 
segment within 24 hours (160-162). More specifically, apoptosis is detected 12 
hours after EDL in the proximal region of the initial segment and by 18 and 24 
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hours after EDL, apoptotic nuclei occur at a rate of approximately 50 times that 
found in control tissues (161). The wave of apoptosis is essentially finished by the 
third day, at which point luminal diameters and epithelial heights have both been 
reduced to 40% to 50% of control values. A smaller wave of apoptosis is also 
detected in the middle initial segment and peaks at day 3. Apoptosis is localized 
to principal cells in the initial segment and is independent of p53, a key apoptotic-
pathway molecule for many tissues and conditions (161). 
The dependence of the initial segment on nonsteroidal testicular factors is 
also reflected in epithelial gene expression. These factors are necessary in the 
region-specifie expression of a number of genes including, proenkephalin (163), 
5ex-reductase type 1 (164), Cres (91), GGT-IV (124), Gpx5 (165;166), PEA3 (118), 
and A-raf (101). They can also stimulate protein synthesis and secretion in the 
proximal regions of the rat epididymis (167, 168). 
Androgen-binding protein (ABP) is one of the few nonsteroidal testicular 
factors that have been proposed to act on the epididymis (7). It is produced in the 
testis by Sertoli cells; 20% is released into the blood, and the rest is secreted into 
the seminiferous tubules where it binds testosterone. ABP is then transported into 
the epididymis and is internalized through a receptor-mediated process by 
epithelial cells of the initial segment and caput epididymidis. Luminal fluid ABP is 
thought to regulate the bioavailability of androgens in the extracellular space of 
the testis and epididymis, protect androgens from metabolism, and facilitate 
androgen uptake in the male reproductive tract. ABP has also been suggested to 
play a role in protein synthesis in the caput epididymidis, act as a regulator of 
nuclear steroid 5a-reductase, and enhance the function of ovine epididymal 
principal cells in culture (7). 
Fibroblast growth factor (FGF)-2 and possibly other FGFs synthesized in 
the adult testis have been postulated to regulate GGT mRNA-IV (169,170), a 
gene highly expressed in the rat initial segment (124). These growth factors are 
thought to act upon ex and ~ forms of FGF receptor-1 Ille localized on the apical 
cell surface of principal cells (170). This interaction would stimulate signal 
transduction cascades (e.g., Ras/ERK pathway) and the activation of 
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downstream transcription factors which may include members of the PEA3 family 
(171). PEA3 is also highly expressed in the initial segment and can bind 
PEA3/Ets binding motifs derived from the GGT mRNA-IV promoter region (172). 
Spermatozoa or spermatozoa-associated factors have also been proposed 
to regulate gene expression in the initial segment. Severallines of evidence have 
indicated that the opioid peptide precursor proenkephalin is regulated by such 
factors (163). In fa ct , many molecules are known to bind to spermatozoa and are 
then released in the epididymis. For instance, testicular spermatozoa stain 
positively for growth factor receptors (173) and, as speculated in a recent review, 
these growth factors dissociate from the sperm surface in the epididymis and can 
stimulate their cognate receptors on the apical cell surface of the epididymal 
epithelium (7). 
3. Androgens 
Androgens are nonaromatized C19 steroids capable of both promoting 
growth of the ventral prostate in castrated animais and influencing serum 
concentrations of gonadotropins luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH) in a gonadectomized male (174). In males, the two major 
physiological androgens are testosterone and its more pote nt metabolite 5a-
dihydrotestosterone (DHT). They mediate a wide range of developmental and 
physiological responses and are especially important in the male reproductive as 
weil as nonreproductive systems (175). 
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3.1. Steroidogenesis, Metabolism, and Regulation 
Testosterone production, secretion, and metabolism, as weil as the 
regulation of testosterone biosynthesis by the hypothalamic-pituitary axis, are 
reviewed in this section. 
3.1.1. Steroidogenesis in Leydig Cells 
ln males, androgens are produced predominantly by Leydig cells of the 
testis and at much lower levels by cortical cells of the adrenal glands (176). 
Figure 4 illustrates the pathway of testosterone biosynthesis from cholesterol 
(177). Cholesterol is the precursor of androgens and other steroids; it can enter 
Leydig cells or other steroidogenic cells bound to low-density or high-density 
lipoproteins (LOL or HOL), or it can be synthesized de novo (178, 179). The 
proportion that is taken up by the cells or synthesized from acetate is species-
dependent. Intracellular free cholesterol can then be esterified and stored in 
cytoplasmic lipid droplets or transported to the mitochondria and converted to 
pregnenolone. This step is catalyzed by cytochrome P450 side chain cleavage 
(P450scc) and is the principal committing and rate-limiting step in steroid 
biosynthesis; it is also regulated by LH in Leydig cells and by adrenocorticotropic 
hormone in the adrenals (178). Pregnenolone is subsequently converted to 
progestins and androgens in the smooth endoplasmic reticulum. The final step in 
testosterone biosynthesis is catalysed by 17j3-hydroxysteroid dehydrogenase 3 
(17j3-HSD3), an enzyme exclusively expressed in Leydig cells (178). 
Consequently, androgen formation is limited to dehydroepiandrosterone (DHEA) 
and androstenedione in adrenal glands. 
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Figure 4. Testosterone Biosynthesis Pathway trom Cholesterol 
Testosterone is synthesized from cholesterol in Leydig cells through the f14 or f15 
pathway (177). The designation f14 and f15 refer to the location of the double 
bond in the steroid, and the preferred route is both age- and species-specific 
(177). P450ssc is found in the mitochondria while the other enzymes of the 
pathway are located in the smooth endoplasmic reticulum. The enzymes shown 
are: P450scc: cytochrome P450 cholesterol side chain c1eavage (EC 1.14.15.6); 
313-HSD: 313-hydroxysteroid dehydrogenase/ f15-f14 isomerase (EC 1.1.1.51 and 
EC 5.3.3.1); P450c17: cytochrome P450 17a-hydroxylase/17, 20 Iyase (EC 
1.14.99.9); 1713-HSD: 1713-hydroxysteroid dehydrogenase (EC 1.1.1.64). Adapted 
from reference (177). 
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3.1.2. Secretion, Transport, and Metabolism 
Since steroids are highly lipophilic, they are readily diffusible through the 
cell membrane immediately after synthesis (179). As a result, the rate of 
secretion by steroidogenic cells is regulated by the rate of steroidogenesis. Only 
1-3% of total testosterone circulates freely in the blood. The vast majority is 
transported in plasma mainly bound to albumin or to a carrier protein called sex 
hormone-binding globulin (SHBG), also known as testosterone-estradiol binding 
globulin (180). SHBG is a 95 kDa ~-globulin with a single steroid-binding site 
(180). This glycoprotein shares the same primary structure as ABP, and both are 
products of a single gene; they differ only with respect to the types of 
oligosaccharides attached to them (181, 182). The binding affinity of testosterone 
to albumin is about 1 % of that of SHBG, but since albumin concentration is much 
higher in the blood than SHBG, their binding capacity for testosterone is about 
the same (180). Testosterone dissociates from binding proteins in capillaries; this 
is the result of structural modifications in the hormone binding site following 
interactions of the binding proteins with the endothelial glycocalix (180). 
Testosterone can then diffuse freely into target cells and bind receptors to exert 
their biological effects. 
Testosterone is the precursor of two important hormones. It can be 
reduced to DHT by steroid 5a-reductase (srd5aR) (EC 1.3.1.22) or aromatized to 
17~-estradiol by cytochrome P-450 aromatase (EC 1.14.14.1) in target tissues 
(Fig. 5). Both reactions are irreversible and rate-limiting (183, 184). DHT and 
estradiol can also inhibit each other's enzyme activity in vitro in several rat 
tissues but often at higherthan physiological concentrations (185-190). These 
steroids have different cellular receptors and consequently, different biological 
activities in their respective target tissues. 
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Figure 5. Active Metabolites of Testosterone 
Testosterone (T) can be reduced to dihydrotestosterone (DHT) or aromatized to 
estradiol (E2) in peripheral tissues. Adapted from reference (177). 
Testosterone (T) 
Dihydrotestosterone (DHT) Estradiol (E2) 
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Testosterone can also be metabolized in the blood to inactive 17 -ketosteroids 
called androsterone and etiocholanolone. These metabolites can be excreted in 
free forms or are conjugated to a glucuronide or sulfate group mostly in the liver 
and kidneys before excretion (176). Similarly, DHT can be modified at the 17~­
hydroxy or 3-keto position to render it inactive. The 5a-reduction of testosterone 
renders its 3-oxo group more susceptible to reduction by 3a- (EC 1.1.1.50) and 
3~-HSD (EC 1.1.1.145) and to sulfation and glucuronylation (183). 
3.1.3. The Hypothalamus-Pituitary Axis 
ln males, the gonadotropins LH and FSH control steroidogenesis and 
gametogenesis respectively, in the testis (191). They are produced and secreted 
by the gonadotropic cells of the anterior pituitary in response to the hypothalamic 
gonadotropin-releasing hormone (GnRH). Since GnRH secretion is pulsatile, 
gonadotropin release also occurs in discrete peaks; this is particularly more 
evident for LH due to its shorter half-life in circulation (180). LH binds G-protein 
coupled membrane receptors on L,eydig cells and stimulates the production and 
secretion of testosterone through an increase in cyclic adenosine 
monophosphate (cAMP) and subsequent activation of protein kinases (180). 
Although the molecular events responsible are largely unknown, phosphorylation 
of proteins involved in cholesterol transport and/or side chain cleavage, as weil 
as stimulation of mRNA and protein synthesis of P450 enzymes of the 
steroidogenic pathway, are involved (180). They ultimately lead to the conversion 
of cholesterol to pregnenolone. 
The functions of FSH are beyond the scope of this section but are 
thoroughly reviewed in the following references (180, 192, 193). 80th androgen 
production and gamete maturation are regulated by the hypothalamus and 
pituitary through a negative feedback mechanism (Fig. 6) (175). Testosterone 
also inhibits the secretion of both GnRH and gonadotropins. Similarly, estrogen 
produced by Leydig cells also feedback to reduce LH stimulation of testosterone 
biosynthesis. 80th the hypothalamus and the pituitary have androgen and 
estrogen receptors. Inhibins, activins, and follistatin produced by Sertoli cells 
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modulate FSH release (191). In addition, the gonadotropins are capable of down-
regulating their receptor numbers (180). While regulation of testicular function 
and testosterone synthesis are controlled by central structures, local factors are 
also important for the modulation of hormone activity (176, 194). For instance, 
increased intracellular testosterone accumulation first results in a rapid negative 
feedback inhibition of P450c17 (cytochrome P450 17a-hydroxylase/17, 20 Iyase) 
enzyme activity followed by a down-regulation of the expression of genes in the 
steroid biosynthesis pathway (194). 
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Figure 6. Feedback Mechanisms by the Hypothalamus- Pituitary- Testis 
Axis 
The production of testosterone is regulated by the hypothalamus and pituitary. 
(-) indicates negative feedback, and (+) indicates positive feedback. GnRH: 
gonadotropin-releasing hormone; LH: luteinizing hormone; FSH: follicle-
stimulating hormone; T: testosterone; E2: estradiol. Adapted fram reference 
(175). 
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3.2. Androgen Action 
3.2.1. Mechanisms of Androgen Action 
The effects of androgens are mediated predominantly through the AR to 
regulate the expression of target genes. An increasing body of evidence suggests 
that androgens, like estrogen and progesterone, can also exert rapid nongenomic 
effects (reviewed in (195-197)). These two effects of androgens are explored in 
this section. 
3.2.1.1. Androgen Receptor (AR) 
The AR is a member of the nuclear receptor superfamily, the largest 
known superfamily of genes encoding ligand-inducible transcription factors that 
regulate complex gene networks in a wide variety of biological processes 
(reviewed in (198,199)). Its structure consists of a variable NH2-terminal 
transactivation domain, a highly conserved zinc finger-type DNA-binding domain, 
a hinge region with a nuclear localization signal (NLS), and a ligand binding 
domain (199). AR is nearly ubiquitously expressed in mammalian tissues, and it 
is regulated at both the mRNA and protein levels by androgens (reviewed in 
(200)). AR regulates the expression of androgen-responsive genes by binding as 
homodimers to androgen response elements (AREs) located mainly within the 
promoter region of target genes. AREs are found as direct (5'-
TGTTCTNNNTGTTCT-3') and inverted (5'-GGTACANNNTGTTCT-3') repeats 
(201). While the direct repeat is specifie for the AR (202;203), the indirect repeat 
can also be recognized by glucocorticoid, progesterone, and mineralocorticoid 
receptors (202,204). Classical AR functional abnormalities cause a spectrum of 
disorders of androgen insensitivity syndrome or testicular feminization mutation 
(reviewed in (205)). Male AR knockout mice exhibit female-typical external 
appearance (206). Internally, they have small inguinal testes but lack seminal 
vesicles, vas deferens, epididymis, and prostate. Their testicular and serum 
androgen levels are very low, their serum LH levels are high, but their serum 
estrogen levels appear normal. A number of clinical disorders of the AR have also 
been reported (201). 
31 
3.2.1.2. Genomic Androgen Action 
ln target cells, androgens regulate gene expression by binding to the AR. 
Testosterone either binds the AR directly or after it is reduced to DHT. DHT is 
more potent than its precursor due to its 2 to 3-fold higher affinity for the receptor 
and its 5-fold slower dissociation rate (207). These differences in ligand binding 
can potentially result in differences in ARE function, DNA activation, and 
subsequent mRNA production (208). Recent studies, using differential display 
gene arrays, have found fundamental differences in signal transduction pathways 
depending on which hormone binds to the AR (209). The expression of various 
genes was uniquely upregulated and downregulated in response to testosterone 
and DHT in the prostates of castrated rats. 
When the AR is not bound to ligand, it is bound by heat shock proteins and 
other type 2 coregulators (210). These type 2 coregulators render the AR 
competent to direct gene expression by modulating appropriate AR folding, ligand 
binding, and/or facilitating NH2/COOH-terminal interactions. As depicted in figure 
7 A, binding of testosterone/DHT to the AR promotes receptor dimerization and 
hyperphosphorylation. It also induces a conformational change that reveals the 
NLS of the receptor. The complex is proposed to be recognized by an import 
receptor such as importin-a and importin-~ and is translocated to the nucleus 
(211,212). In the nucleus, it binds AREs found in the promoter and enhancer 
sequences of target genes and interacts with general transcription factors 
associated with RNA polymerase Il as weil as with type 1 coregulators (210). 
Type 1 coregulators include both repressors and activators that function primarily 
at target gene promoters to facilitate DNA occupancy, chromatin remodelling, 
and/or recruitment of general transcription factors associated with the RNA 
polymerase Il holocomplex. 
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3.2.1.3. Nongenomic Androgen Action 
Androgen action can also occur through non-classical mechanisms in a 
number of different tissues (Fig. 7B). These nongenomic modes of action are 
principally characterized by their insensitivity to inhibitors of transcription and 
protein synthesis as weil as their rapid onset of action (within seconds to minutes) 
(197). They typically involve the rapid induction of conventional second 
messenger signal transduction cascades, including increases in free intracellular 
calcium and activation of protein kinase A (PKA), protein kinase C (PKC), and 
mitogen-activated protein kinase (MAPK). These nongenomic effects appear to 
be receptor-mediated, involving non-classical receptors and to some extent the 
AR. At unphysiologically high levels, androgen can also directly interact with 
membrane phospholipids and affect membrane fluidity (197). The initiation of 
these second messenger cascades may ultimately modulate the transcriptional 
activity of AR or other transcription factors (197). Such modulation may occur 
through direct phosphorylation of transcriptional coregulators. 
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Figure 7. Mechanisms of Androgen Action 
Androgens mediate their biological effects predominantly through the androgen 
receptor (AR) using the genomic (classical) pathway (A). They can also stimulate 
second messenger cascades in a nongenomic (non-classical) manner through 
more than one mechanism (B). These mechanisms involve stimulation of 
intracellular tyrosine kinase c-steroid receptor coactivator (Src) and sex hormone 
binding globulin receptor (SHBG-R); both these pathways can potentially induce 
the transcriptional activation of the AR. In addition to these receptors, a plasma 
membrane G protein-coupled receptor may also directly bind androgens or 
indirectly influence the activity of a membrane androgen-binding protein. While 
this protein has not been unambiguously identified, one of its effects is to 
increase intracellular calcium (Ca2+) levels. Other nongenomics mechanisms by 
which androgens mediate their rapid effects may be involved. ARE: androgen 
response element; cAMP: cyclic AMP; CaM: calmodulin; DHT: 
dihydrotestosterone; MAPK: Mitogen-activated protein kinase; PKA: protein 
kinase A; PKC: protein kinase C; Pol Il complex: RNA polymerase Il complex; 
PTK: protein tyrosine kinase; SH2: Src homology 2 domain; SH3: Src homology 3 
domain; Srd5aR: steroid 5a-reductase; T: testosterone; TFs: transcription factors. 
Adapted trom reference (197). 
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3.2.2. Androgen Action in Peripheral Tissues 
Testosterone exerts its actions in many target tissues including, bone, 
muscle, skin, central nervous system, and cardiovascular system as weil as in 
male reproductive tissues (175). The mechanisms by which it has different 
actions in diverse tissues can be attributed to the tissue-specificity of the co-
regulators involved, the specificity of DNA response elements of target genes, 
and the expression of metabolizing enzymes. While the limiting factor in 
determining the action of testosterone on cells is not clear, severallines of 
evidence indicate that it is primarily the amount of ligand and not the absolute 
number of ARs that is limiting (175). In sorne tissues, such as muscle that does 
not possess significant amounts of srd5aR, testosterone acts directly on the AR. 
ln other tissues, like the epididymis, prostate, seminal vesicles, and skin, 
testosterone is first reduced to DHT. DHT then binds the AR to regulate gene 
expression. Testosterone can also be aromatized to estradiol in tissues such as 
the brain nuclei and bone to mediate its action through the estrogen receptor. 
Both testosterone and DHT bind the same AR, but their relative 
importance in different tissues varies. The relative levels of srd5aR and 3a- and 
313-HSD found in different tissues is particularly important in determining the 
preference of one androgen over the other (176). Since DHT is the active 
metabolite in most tissues, high conversion of testosterone to DHT via the 
srd5aR pathway and low metabolism of DHT via the 3 HSD pathways are 
necessary for optimal androgen action. Conversely, srd5aR activity is low while 
3a- and 313-HSD activity is high in skeletal muscle. Consequently, higher levels of 
testosterone and other inactive metabolites are present in this tissue. 
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3.2.3. Androgen Action in the Epididymis 
Testosterone enters the epididymis via two distinct routes. It can enter 
through the efferent ducts of the testis bound to ABP, as mentioned in section 
2.2., or through the circulation (Fig. 8). In the rat epididymis, ABP concentration 
correlates weil with DHT content; it is highest in the caput and lowest in the 
cauda regions (213-215). Testosterone bound to ABP is taken up by principal 
cells of the initial segment and caput epididymidis through a receptor-mediated 
process in several species (7). Free forms of the androgen can also enter the cell 
by passive diffusion. Once inside the cell, testosterone is reduced to DHT. The 
following is some key evidence that establishes the role of DHT in mediating 
androgen action in the epididymis: i) After injection of radiolabeled testosterone, 
DHT is the active androgen present in epididymal cell nuclei (216); ii) Epididymal 
cells can synthesize 5a-reduced metabolites from testosterone in vitro (217-219); 
iii) Results from micropuncture experiments confirm that beyond the efferent 
ducts, the predominant androgens found in epididymal luminal fluid are 5a-
reduced metabolites of testosterone (220); iv) DHT is more pote nt than 
testosterone in maintaining epididymal functions in vitro (47). 
Few studies have focused on the mechanisms of androgen action 
specifically in epididymal epithelial cells, presumably because of the lack of 
appropriate tools. The characteristics and mode of action of the AR as a 
transcription factor (221, 222), however, seem to resemble those observed in 
other tissues. The AR is expressed, in a cell-type-specific manner, throughout the 
mouse and rat epididymides with slightly higher protein expression levels in the 
caput and corpus regions (223). In immunolocalization experiments, principal cell 
nuclei show the most intense staining (224). Similarly, both AR mRNA and 
protein are found throughout the human tissue with a declining concentration 
from the caput to the cauda epididymidis (224). Recently, three p160 coactivators 
of the AR were immunolocalized in the rat epididymis (225). These type 1 
coregulators exhibit cell type-specifie expression in the tissue and differential 
localization within the cell, suggesting they have specifie roles in the epididymis 
(225). 
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Figure 8. Proposed Mechanisms of Androgen Action in the Rat Epididymis 
Testosterone (T) is synthesized by Leydig cells and enters the epididymis 
through the efferent ducts bound to androgen-binding protein (ABP) (1) or 
through the circulation (Tc) (2). It is reduced to dihydrotestosterone (DHT) by 
infranuclear and apically located steroid 5a-reductase (srd5aR) in principal cells 
of the initial segment and caput epididymidis. Sertoli cells, stimulated by T, 
secrete ABP and other proteins (e.g. fibroblast growth factor (FGF)) into the 
lumen of the seminiferous tubule. These proteins enter the epididymis and 
regulate androgen- and testicular factor-regulated genes. ABP is proposed to 
regulate the infranuclear localized steroid 5a-reductase (srd5aR) enzyme, while 
circulating androgens regulate apically localized srd5aR (microsomal srd5aR). 
ER: endoplasmic reticulum. Adapted from reference (7). 
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3.3. Androgen Regulation of the Epididymis 
The structure and functions of the epididymis were shown, as early as 
1926, to be dependent on an unknown testicular substance (226); this substance 
was later identified as testosterone (227). Many groups have since sought to 
understand the role of androgens in the epididymis. Different approaches have 
been used to attain this goal, including treatment with AR antagonists to inhibit 
androgen action (228-230), treatment with srd5aR inhibitors to distinguish the 
role of testosterone from DHT (231-233), and inhibition of testosterone 
biosynthesis (106, 160, 234-238). The latter is the most popular approach and is 
most commonly achieved by removing both testes (bilateral orchidectomy) (106, 
160, 236-238). This approach results not only in a loss of androgens but also of 
testicular factors and estrogen. It is often followed by testosterone replacement to 
more specifically ascertain the role of testosterone and DHT in the tissue (160, 
236,238). This section will focus on selected key effects of androgens on 
epididymal structure and gene expression. 
3.3.1. Structure of the Epididymis 
The most obvious consequence of bilateral orchidectomy on the 
epididymis is the decrease in tissue weight; it decreases to 25% of control after 
two weeks and by a further 5% in subsequent weeks (reviewed in (224)). Unlike 
with other androgen-dependent male reproductive tissues, even 
supraphysiological levels of testosterone only partially restore epididymal weight. 
This incomplete rescue is aUributable to the loss of spermatozoa and luminal f1uid 
that make up approximately 50% of the tissue's weight (224). Removal of both 
testes also results in important morphological changes in the epididymis, 
including a decrease in luminal diameter and epithelial cell height and the 
thickening of the lamina densa of the base ment membrane (224). Principal cells 
are particularly sensitive to androgen levels. Their secretory function becomes 
compromised in an androgen-deprived state; they undergo vacuolization, loss of 
apical microvilli from their surface, lysosome accumulation, increased 
endocytosis, and the virtual disappearance of the endoplasmic reticulum (224). 
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Epididymal androgen receptors and srd5aR activity are also decreased in this 
state, suggesting that the mechanisms of androgen action are compromised 
(224). Additionally, total epididymal protein, RNA, and DNA content are reduced, 
but DNA concentration is increased (224). This increase in concentration is 
attributed to the decrease in cell volume, the principal mechanism by which the 
epithelium regresses after orchidectomy. 
The withdrawal of androgens by orchidectomy induces a wave of apoptotic 
cell death along the epididymis (Fig. 9) (160). It appears in the initial segment 18 
hours post-orchidectomy, moves down to the cauda epididymidis by 5 days, and 
disappears after 1 week. This time course corresponds to the graduai deprivation 
of the regions of testicular components. In accordance with tissue weight, the 
percentage of apoptosis-positive tubules is higher in the proximal epididymal 
regions than in the corpus and cauda epididymidis (160). Similarly, tissue 
androgen levels in the caput region are also higher than in the cauda 
epididymidis (214, 239). Apoptotic cell death is localized to principal cells but 
interestingly, only a fraction of these cells undergo apoptosis for reasons which 
remain unclear (160). Restoring circulating testosterone levels appears sufficient 
to reverse regressive changes and prevent apoptosis in the caput, corpus, and 
cauda epididymidis after orchidectomy but not in the initial segment (160). This 
inability of testosterone, even at supraphysiological levels, to reverse the 
changes associated with androgen deprivation is due to the segment's 
dependence on both androgens and testicular factors, as discussed earlier in 
section 2.2. 
Unlike other androgen-dependent tissues such as the prostate and 
seminal vesicles, androgens have no effect on the mitotic rate in the adult 
epididymis (240). This lack of effect may be due to anti-proliferative signais 
present in the epididymal epithelium. In fact, B-myc, a transcription factor known 
to inhibit cellular proliferation, is highly expressed in the proximal caput region of 
the tissue, and its expression is dependent on the presence of both androgens 
and testicular factors (89, 241). 
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Figure 9. Percent of Apoptosis-Positive Tubules in the Rat Epididymis after 
Orchidectomy 
The percentage of apoptosis positive rat epididymal tubules in the initial segment 
(IS), caput (CT), corpus (CS), and cauda (CD) regions after orchidectomy for 0.5, 
0.75, 1,2,3,4, 5,6,7, and 8 days. Data adapted from reference (160). 
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3.3.2. Gene Expression 
ln addition to epididymal histology, many functions of the tissue are 
directly or indirectly dependent on androgens. They include intermediate 
metabolism, ion transport, synthesis and secretion of a number of epididymal 
proteins, and the activity of certain enzymes (2). Transport, acquisition of 
fertilizing capacity, and storage of spermatozoa are also under androgenic control 
(2). Consequently, as one would expect, androgen withdrawal also results in the 
altered expression of many genes. Only a few of these genes, however, have 
been shown to contain functional AREs in their promoter region. Gpx5 (242, 243), 
lipocalin 5 (82), reproductive homeobox 5 (244), and Crisp1 (245) are examples 
of such genes. While some genes su ch as AR (148,246), Gpx3 (247), carbonic 
anhydrase IV (248), and lipocalin 5 (128) are regulated only by androgens; 
others, including GGT (124), Gpx5 (166,243), srd5aR (249), and PEA3 (117) are 
regulated by both androgens and other testicular factors. Expression of these 
latter genes does not return to basal levels following androgen replacement after 
orchidectomy. Certain genes such as GGT that have wide tissue distribution are 
androgen-regulated only in the epididymis (124). Moreover, GGT transcripts 
differentially respond to androgens in the different regions of the tissue. These 
findings suggest that tissue-, region-, and cell-specific AR coregulators, or a 
unique combination of AR coregulators with transcription factors, can mediate 
androgen regulation of epididymal genes. 
Microarray technology has been used to identify genes regulated by 
androgens in the epididymis (104,106,250). This approach has not only 
validated numerous studies that have focused on the androgen-regulation of 
epididymal genes, but it has also identified novel genes and overall patterns of 
gene expression following the removal of androgens. Both up- and down-
regulation of genes were observed in ail regions of the tissue following 
orchidectomy (104,106). Some genes, such as calcium-binding proteins, c-jun, 
and Gpx1 displayed the same pattern throughout the epididymis; others including 
metabolism-associated proteins, organic cation transporter N2, and sodium-
dependent neutral amino acid transporter were region-specifie (106). Region-
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specifie up-regulation, as weil as transient increase in gene expression, were also 
identified for the first time following orchidectomy using a rat stress toxicology 
complementary DNA (cDNA) array (106). Interestingly, the greatest number of 
androgen-regulated genes was observed in the caput epididymidis (104), the 
region most active in protein synthesis (251). 
4. Steroid 5a-Reductase (Srd5aR) 
Srd5aR was initially characterized in the 1950s based on its ability to 
convert deoxycorticosterone to 5a-reduced metabolites in rat liver slices (252, 
253). Subsequent work by Tomkins and others identified the enzyme's ability to 
reduce other substrates with a 3-oxo-4,5 double bond, namely testosterone, 
progesterone, and androstenedione. Srd5aR irreversibly reduces these steroids 
using NADPH as a cofactor (reviewed in (183)). 
Beginning in the 1960s, many studies established the activity, subcellular 
localization, and hormonal regulation of srd5aR enzymatic activity in several 
tissues, but its purification remained elusive due to the enzyme's extreme 
insolubility (183). While attempts to purify this protein have been unsuccessful to 
date, its cDNA was isolated from rat liver in 1989 using expression cloning in 
Xenopus laevis (254). Cross-hybridization screening of a prostate cDNA library 
was later used to isolate the human homologue (255). Severallines of evidence, 
however, suggested the presence of a second enzyme capable of catalyzing the 
same reaction (255, 256). The cDNA for this enzyme was eventually isolated 
from progressively smaller pools of independent human prostate cDNA that were 
cloned in an expression vector, transfected into cultured human cells, and 
assayed for 5a-reductase activity (257). The rat homolog for this second enzyme 
was then isolated by PCR (258). Subsequently, both isoforms of srd5aR were 
identified in mouse, dog, and monkey (259-262). 
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4.1. Srd5aR Type 1 and Type 2 (Srd5aR1 and Srd5aR2) 
Srd5aR type 1 and type 2 are intrinsic membrane proteins composed of 
254-260 amino acids with predicted molecular weights of 28-29 kDa (reviewed in 
(183)). They are approximately 46% identical in sequence and share similar gene 
structures, substrate preferences, and hydropathy profiles. The srd5aR1 and 
srd5aR2 genes consist of 5 exons with 4 intervening intronic sequences. The 
positions of the introns are essentially identical for the two genes, suggesting 
they arose by primordial gene duplication. Although the structure is shared, the 
two genes are located on separate chromosomes. A processed pseudogene 
derived from the mRNA transcript of the type 1 gene has also been identified in 
humans (263). It is unknown if an mRNA is transcribed from this pseudogene. 
Mutations in the srd5aR2 gene are responsible for srd5aR deficiency or a rare 
form of male pseudohermaphroditism characterized by male Wolffian duct 
structures but a female external genitalia and rudimentary prostate (264, 265). 
Virilization occurs in these men at puberty, when increases in serum testosterone 
levels lead to increases in serum DHT through the conversion of testosterone by 
srd5aR1 in the liver. The prostate of these 5a-reductase deficient men, however, 
remains underdeveloped. To date, more than 20 different mutations spanning the 
srd5aR2 gene have been reported, and three large clusters of population 
identified (Turkey, Dominican Republic, and New Guinea) (266-268). Preliminary 
data also suggest that the srd5aR2 gene is differentially methylated in patients 
with srd5aR deficiency (269). No mutation in the srd5aR1 has been identified in 
humans. 
While srd5aR type 1 and type 2 share sorne similarities, they differ with 
respect to their affinity for various substrates. Srd5aR2 has a 10 to 20-fold higher 
affinity than srd5a1 for testosterone, androstenedione, progesterone, and 
corticosterone (258). The isozymes can also be distinguished by their 
biochemical properties. For instance, srd5aR1 and srd5aR2 were initially 
identified by the different pH optima of their respective enzymatic activity. The 
type 1 isozyme was found to have a broad pH optimum that span the alkaline 
range (pH 6 to 8.5), while the type 2 isozyme was found to function at a narrow 
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acidic pH optimum centered around 5.0 (256-258). The acidic pH optimum of 
srd5aR2 was subsequently found to be an artifact: the result of a change in the 
enzyme's conformation and a reflection of the ionic state of charged amine acids 
in the enzyme's active site following ceillysis (270, 271). Both isozymes are now 
considered to function at neutral pH. 
Pharmacologically, the srd5aRs can be recognized by their sensitivity to 
certain 4-azasteroid inhibitors. Human srd5aR2, for example, is markedly 
inhibited by finasteride (Ki= 5 nM) compared to the type 1 isozyme (Ki= 230 nM) 
(257). Finasteride and other srd5aR inhibitors will be more thoroughly discussed 
in section 4.3.3. 
Srd5aR1 and srd5aR2 are also differentially distributed throughout the 
body (reviewed in (183)). While srd5aR2 is the predominant isoform in male 
reproductive tissues, srd5aR type 1 is found in peripheral tissues, such as the 
liver and skin, as weil as in male reproductive tissues. Unique expression 
patterns also exist in different species (183). For example, srd5aR1 is present in 
the liver of the mouse and rat, whereas both isoforms are present in human liver. 
Similarly, both isoforms are detected in the rat ventral prostate, but the type 2 
isoform is predominant expressed in the human and mouse prostates. 
Intracellularly, both isoforms are embedded in the endoplasmic reticulum. 
The proliferation of this organelle in different tissues accounts for the perinuclear 
and endoplasmic reticulum localization described for the isozymes, as weil as the 
presence of enzymatic activity in both nuclear and microsomal fractions (183). 
Mice with a null mutation for srd5aR1, srd5aR2, and for both isozymes 
have been generated in an attempt to resolve the relative roles of srd5aR type 1 
and type 2 (272, 273). The absence of the type 1 isozyme has no reported effects 
in males but causes an increase in post-implantation loss and a parturition defeet 
in females (272,274). SrdSaR2 null female mice, on the other hand, appear 
normal, but the male mice fail to virilize properly (273). Male srd5aR2 mutant 
mice have fully formed internai and external genitalia and are fertile but have 
smaller seminal vesicles and prostate (273). In the absence of both isozymes, 
female miee display the same phenotype as srd5aR1 null females and male mice 
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have a more pronounced effect on virilization than srd5aR2 null males (273). 
Consequently, srd5aR1 and srd5aR2 have been designated as female and male 
isozymes, respectively (275). However, little sol id evidence exists to support this 
theory; the modest effect described for males lacking srd5aR2 does not 
accurately resemble the human condition of srd5aR deficiency, and in-depth 
studies on these animais are still lacking. More specifically, while males carrying 
null mutations for srd5aR1 and srd5aR2 are fertile, the consequences of a 
deletion of the isozymes on spermatogenesis, spermatozoa in the epididymis, 
and the epididymis itself have not been published. 
4.2. Regulation of Srd5aR Type 1 and Type 2 in the Epididymis 
The epididymis rapidly converts testosterone to DHT (217,276) and it is 
one of the tissues with the highest level of srd5aR activity in the body (217). To 
understand how enzyme activity is regulated in this tissue, it is necessary to 
determine where and how srd5aR1 and srd5aR2 are expressed, as weil as the 
factors regulating their expression. 
4.2.1 Activity of the Enzyme 
Srd5aR enzymatic activity is present in both the nuclear and microsomal 
subcellular fractions of the adult rat epididymis and occurs in a striking positional 
gradient in the tissue (277, 278). The activity associated with the nuclear fraction 
is highest in the initial segment and declines dramatically along the tissue. In fact, 
enzymatic activity is higher in the initial segment than any other male 
reproductive tissue. In contrast to the nuclear activity, microsomal srd5aR 
enzymatic activity is present at lower levels throughout the epididymis. The 
activity of the enzyme in these two subcellular fractions is differentially regulated 
by hormones (reviewed in (224, 279». In the nuclear fraction, srd5aR activity is 
decreased following bilateral orchidectomy and cannot be maintained by 
exogenous testosterone. EDL and unilateral orchidectomy both result in a 
dramatic decrease of enzymatic activity, especially in the proximal regions of the 
tissue. It was thus proposed that nuclear epididymal srd5aR activity is regulated 
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by testicular factors, more specifically by ABP, based on similarities in its 
development profile, hormonal control, and the observation that ABP can be 
internalized by principal cells of the initial segment (279). Microsomal srd5aR 
activity, on the other hand, is regulated by circulating androgens (279). 
4.2.2. Protein 
Prior to the knowledge that there was a second isozyme, polyclonal 
antibodies against srd5aR 1 were used to characterize srd5aR protein expression 
along the rat epididymis. Srd5aR immunoreactive protein is found throughout the 
epididymis, more specifically in membranous cytoplasmic elements of principal 
cells (111). Intense srd5aR staining is seen in the proximal initial segment, 
followed by a sharp decline in staining intensity in the caput epididymidis, and a 
progressive decrease beyond that point. Srd5aR is a membrane-bound ER 
protein, but its localization within this organelle and/or the proliferation of the 
organelle itself changes along the epididymis. In the proximal initial segment, 
staining is observed specifically in the infranuclear region, whereas in the 
proximal caput epididymidis, srd5aR immunoreactivity is restricted to an oval 
region above the nuclei (111). Weak staining is noted throughout the cytoplasm 
in the other epididymal regions. Similar to the loss of enzymatic activity in nuclear 
fractions following EDL, the infranuclear immunoreactivity in the initial segment is 
eliminated after the removal of testicular factors (279). The immunoreactivity that 
remains is limited to an oval region above the nuclei, similar to that observed in 
the proximal caput epididymidis. 
Antibodies developed against the type 2 isozyme in the rat have thus far 
proven to be non-specific. Only one study has described srd5aR2 protein 
expression in the epididymis; this study found weak srd5aR2 immunoreactivity 
restricted to the cytoplasm of most epididymal cells in humans (280). 
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4.2.3. rnRNA 
Srd5aR1 and srd5aR2 are differentially expressed and regulated at the 
mRNA level in the epididymis (249). The type 1 isozyme is most abundantly 
expressed in the initial segment, with concentrations 3 to 7-fold higher than in 
other segments (164); this positional gradient corresponds to the one described 
for nuclear enzymatic activity and srd5aR1 protein. In contrast, the type 2 mRNA 
is highest in the proximal caput epididymidis, and its levels do not decline as 
dramatically as type 1 in the more distal segments (249). Srd5aR2 mRNA 
expression is higher in the epididymis than any other rat tissue (258), suggesting 
that this isozyme is particularly important in this tissue. However, despite the 
relative abundance of type 2 mRNA, its activity as a functional enzyme under 
physiological conditions may be poor in comparison to the type 1 protein. 
Srd5aR type 1 and type 2 transcripts are both regulated by testicular factors in 
the initial segment but differ in their responses; EDL results in a 60% decrease in 
type 1 mRNA but an almost 2-fold increase in type 2 transcripts (249). The 
discrepancy in the responses of the srd5aRs to the removal of testicular input is 
not clear, but it emphasizes their independent regulation. The unique responses 
of type 1 and type 2 mRNA are further demonstrated in their developmental 
profiles. While type 1 mRNA concentrations increase during postnatal 
development in a manner consistent with enzymatic activity (277,281), type 2 
mRNA levels are not altered as a function of increasing postnatal age (249). 
Interestingly, this differential regulation of srd5aR type 1 and type 2 transcripts in 
the epididymis has not been observed in any other rat tissue (249). 
4.2.4. Genetic and Epigenetic 
The basic gene structure and chromosomallocations of the human, rat, 
and mou se srd5aR type 1 and type 2 genes have been reported, but the 
promoter region, the regulatory sequences or trans-acting factors have not been 
identified for the rat genes. Similarly, limited work has been done to characterize 
the human and mouse genes (259, 282). Identifying key regulatory sequences in 
the srd5aRs genes and the transcription factors interacting with these sequences 
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will be crucial to elucidate and understand the differential regulation of srd5aR 
type 1 and type 2 mRNA in the epididymis. 
Epigenetic changes act to regulate gene expression in normal mammalian 
development, and one of these changes, DNA methylation, has been suggested 
to play a role in the differential tissue distribution of the srd5aR isozymes (283). 
Reyes et al. found the rat srd5aR2 gene to be less methylated at the cytosine 
position but more methylated at the adenine position in the testis and epididymis 
compared to the liver using restriction fragment length polymorphism (283). While 
cytosine methylation is associated with transcriptional repression (284-287), in 
vitro studies have shown adenine methylation to increase the transcription rate of 
many plant promoters (288-291). The differential methylation status of the gene 
in different tissues therefore correlates with its expression profiles in the tissues 
examined. In contrast to the type 2 gene, srd5aR type 1 gene showed no change 
in its methylation pattern in the reproductive and non-reproductive tissues 
investigated (283). Further studies are, however, required to identify regions of 
the genes that are differentially methylated and to extend this type of regulation to 
other tissues where the isozymes are differentially expressed. 
4.3. 5a-Reductase Inhibition 
The important role of DHT and 5a-reductase in androgen action imply that 
inhibitors of 5a-reductase would be useful in treating androgen sensitive 
conditions such as benign prostatic hyperplasia (BPH), early stages of prostate 
cancer, androgenic alopecia (male pattern baldness), acne, and hirsutism 
(inappropriate facial and corporal hair growth in women). The characterization of 
5a-reductase deficiency further supported the therapeutic value of srd5aR 
inhibitors. 5a-Reductase deficient men have underdeveloped prostate, less male 
pattern baldness, and almost no acne (183,264,292). Consequently, over the 
past 30 years, biomedical research has pursued the development of highly 
specifie inhibitors of one or both srd5aR isozymes that have minimal undesirable 
effects. 
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4.3.1. Inhibitors 
Finasteride (Proscar) became the first clinically available srd5aR inhibitor 
in 1992 when it was approved for the treatment of BPH (293), a disorder 
prevalent in the majority of men over the age of 55 (294). It is a selective inhibitor 
of srd5aR2 and it produces an 85-90% decrease in DHT levels within the human 
prostate and a 65-70% decrease in serum DHT levels (208,295,296). This 
decrease in DHT levels causes epithelial cell apoptosis in the prostate and a 
subsequent 20-30% reduction in gland size (208, 297). While there is an 
improvement in BPH symptoms and a decrease risk of urinary retention (293, 
298,299), the presence of srd5aR1 in the prostate and the selectivity of the drug 
for srd5aR2 account for its moderate effectiveness in the treatment of BPH (208). 
Efforts to discover compounds more effective in decreasing DHT levels resulted 
in the development of dual srd5aR inhibitors. Dutasteride (GI198745), a very 
pote nt dual srd5aR inhibitor, was marketed in 2003 for the treatment of BPH 
(300). It shows a 60-fold greater inhibition of the type 1 isozyme compared to 
finasteride, and is also pote nt against the type 2 isozyme (301). Consequently, 
rapid, near complete, and consistent DHT suppression is achieved. The clinical 
benefits of the greater suppression of serum DHT seen with dutasteride has yet 
to be compared to finasteride (302). Other dual srd5aR inhibitors su ch as FK143 
and PNU157706 are under development (303,304). 
While BPH has been the major indication for srd5aR inhibitors, other uses 
for these drugs are being investigated. The approval of finasteride was expanded 
in 1997 to include the treatment of androgenic alopecia in men at a dose of 1 
mg/day (Propecia) (305). It is the only oral medication presently available for this 
condition, and it significantly improves hair growth and density. The efficacy and 
safety of various srd5aR inhibitors are also being investigated in the prevention 
and early treatment of prostate cancer (304, 306-30B), acne (309-311), and 
hirsutism (312-314). 
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4.3.2. Effects of Srd5aR Inhibitors on the Epididymis 
The effects of srd5aR inhibition have been predominantly focused on the 
prostate; only a limited number of studies have examined the consequences of 
srd5aR inhibitors on fertility, epididymal epithelial cell function, sperm maturation, 
and epididymal gene expression [reviewed in (315)]. 
4.3.2.1. On Epididymal Structure and Function 
As early as 1981, the fertilizing ability of spermatozoa from cauda 
epididymides was shown to be severely affected after treatment with a srd5aR 
inhibitor (316). Srd5aR inhibitors were also found to cause a dramatic shift in the 
intraluminal androgen balance (233). While long term treatment with a high dose 
of finasteride resulted in a reversible loss of fertility, this effect of the drug was not 
ascribed to the epididymis. Instead, it was postulated to be a consequence of 
finasteride-induced inhibition of sex accessory gland secretions leading to 
reduced copulatory plug formation (317, 318). These studies did not, however, 
report the consequences of finasteride treatment on epididymal histology, and 
embryonic development was not allowed to progress beyond its very early 
phases (317, 318). 
The consequences of 5a-reductase inhibition on the epididymis and sperm 
maturation were only recently investigated using the dual inhibitor PNU157706. In 
addition to an observed dose-dependent reduction in epididymal weight (231), 
sperm motility and morphology were compromised after PNU157706 treatment 
(232). The percentage of motile and progressive motile sperm decreased 
significantly, and various motion parameters were altered. A markedly elevated 
proportion of cauda epididymal spermatozoa also retained their cytoplasmic 
droplet. In studies where control females were mated with treated males, fewer 
successful pregnancies and a higher rate of pre-implantation loss were 
discovered. Surviving progeny appeared unaffected (232). 
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4.3.2.2. On Gene Expression 
The effect of PNU157706 treatment on gene expression is dose-
dependent and region-specific (231). While the majority of affected genes in the 
caput, corpus, and cauda epididymidis decreased in expression, a similar number 
of genes increased and decreased in expression in the initial segment. Genes 
involved in signal transduction, fattyacid and lipid metabolism, regulation of ion 
and fluid transport, luminal acidification, oxidative defense, as weil as protein 
processing and degradation were among the most dramatically affected genes 
(231). Since these genes are involved in processes essential in the formation of 
an optimal luminal microenvironment, any changes in their expression would 
have important consequences on proper sperm maturation. In fact, both sperm 
motility and morphology are compromised in these animais (232), as described in 
section 4.3.2.1. 
5. Formulation of Project 
Androgens play important roles in male reproductive and non-reproductive 
tissues under both physiological and pathological conditions. An in-depth 
understanding of androgen action will therefore have therapeutic implications in 
various conditions including, treatment of male infertility, management of prostate 
cancer and benign prostatic hyperplasia, alopecia, and acne, as weil as provide 
insights on basic tissue physiology. The epididymis, a tissue where spermatozoa 
are matured and stored, is dependent on androgens for maintaining its structure 
and functions. Its highly specialized microenvironment and region-specificity in 
addition to its central role in producing functional sperm also make it an attractive 
target for male contraception. Understanding the mechanisms of androgen action 
in the epididymis will thus provide new therapeutic avenues for the management 
of male infertility and the development of contraceptives. 
The overall goal of this thesis is to understand the mechanisms of androgen 
action in the rat epididymis. To achieve this goal, two key aspects of androgen 
action will be investigated: the transcriptional and epigenetic regulation of 
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srd5aR2 and the consequences of androgen manipulations on gene expression 
in epididymal principal cells. 
Several lines of evidence from the literature have confirmed that the main 
androgen acting on the epididymis is DHT rather than testosterone. Furthermore, 
both isoforms of srd5aR, the enzyme catalyzing the rate-limiting step in DHT 
synthesis, are differently expressed and regulated in this tissue. While std5aR1 
and srd5aR2 mRNA and protein levels have been described in the epididymis 
under various conditions, the mechanisms involved in their differential expression 
are still poorly understood. Srd5aR2 mRNA expression is higher in the epididymis 
than any other rat tissue, and it is predominantly expressed in the caput 
epididymidis, a region very active in protein synthesis and secretion. Chapter 2 of 
this thesis will examine the transcriptional regulation of srd5aR2 in the rat 
epididymis. In this chapter, the 5' upstream region of srd5aR2 was cloned, its 
promoter region characterized, and transcription factors interacting with this gene 
in the caput epididymidis identified. 
ln addition to the regulation of genes by cis- and trans- acting elements, 
epigenetic modifications to the DNA sequence by DNA methylation have also 
been suggested to play a role in the tissue-specific expression of several genes, 
including srd5aR2. Chapter 3 explores the methylation status of the 5' upstream 
region of the srd5aR2 gene in rat tissues that differentially express the srd5aR 
isozymes and compare the methylation pattern of srd5aR2 with that of srd5aR1. 
Cytosine and adenine methylation in the 5' upstream region of srd5aR1 and 
srd5aR2 wereexamined by Southern blot analysis and by quantitative analysis of 
DNA methylation by PCR (qAMP) in caput epididymidis, ventral prostate, liver, 
and heart. 
The consequences of various androgen manipulations on the tissue's 
integrity and functions are mediated by various genes that are up- and down-
regulated. While sorne studies have focused on changes in gene expression in 
the different regions of the epididymis, the effects of androgen withdrawal and 
supplementation on the expression of genes in a particular cell type has never 
been explored. Elucidating how each cell type will respond to changes in 
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androgen levels is a crucial step in understanding the mechanisms of androgen 
action in the tissue. The development of a number of region-specifie epididymal 
cell lines has made it possible to study a pure population of principal cells, the 
cell type that is most sensitive to androgen levels, in isolation. Chapter 4 
examined the effects of androgen manipulations on mouse proximal caput 
epididymidis (PC-1) cells using cD NA microarrays. This study was expanded 
using quantitative real-time RT -PCR techniques to include mediators of androgen 
action and to confirm gene expression of selected genes. Changes in protein 
levels were also investigated. 
Together, these studies will provide a greater insight into the role of 
androgen action in the epididymis. 
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1. Abstract 
Steroid 5a-reductase converts testosterone to the more pote nt androgen, 
dihydrotestosterone. The molecular mechanisms responsible for maintaining high 
concentrations of the 5a-reductase type 2 mRNA in the caput epididymidis and 
for regulating its region-specifie expression are unknown. To gain insight into its 
transcriptional regulation, the cloning and characterization of the 5' upstream 
region of 5a-reductase type 2 were undertaken. Sequential deletion analysis was 
do ne to map the 2243-base pair (bp) cloned 5' upstream region, and the 
constructs were transfected into epididymal PC1 cells and prostatic PC3 cells. In 
both cell lines, regulatory elements and the minimal promoter were mapped to 
the 485-bp region upstream of the start codon. Primer extension and 5'RACE 
identified one transcriptional start site at 33-bp upstream of the start codon. 
Using electrophoretic mobility shift assay, a specifie complex was observed in the 
-68 to -32-bp region in the presence of nuclear extracts. Supershift and 
mutational studies confirmed the binding of SP1 and, to a lesser extent, SP3 to 
the two potential SP1 binding sites and the preference of the se proteins to one 
binding site over the other. SP1 and SP3 were both predominantly 
immunolocalized to the principal cells of the epididymis and follow distinct 
distribution patterns in this tissue. These results provide a framework crucial in 
the further investigation of the transcriptional regulation of 5a-reductase type 2 in 
the rat epididymis. 
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2. Introduction 
Testosterone, the most abundantly produced androgen, is reduced by 5a-
reductase to the more pote nt dihydrotestosterone (DHT). DHT mediates many of 
the actions ascribed to androgens, including the differentiation of the male 
external genitalia and prostate during fetal development, virilization at puberty 
and male sexual and aggressive behavior (1-3). It may also play a role in several 
endocrine disorders such as benign prostatic hyperplasia, male pattern baldness, 
acne and hirsutism (4-9). In the epididymis, a single, highly convoluted tubule 
linking the efferent ducts of the testis to the vas deferens, 5a-reductase is found 
at high concentrations (10). DHT is the main androgen responsible for 
maintaining the structure of this tissue and for carrying outits functions in sperm 
maturation and storage (11). The epididymis consists of a lumen and an 
epithelium made up of four major cell types: principal, basal, clear, and halo cells 
(11, 12). Principal cells outnumber the other cell types combined bya ratio of 
more than three to one (13) and are very active with respect to transport and 
secretion of small organic molecules, protein synthesis and secretion, and 
absorption of both f1uid and particulate matter (13). 5a-Reductase is localized ta 
this cell type (14,15). 
Steroid 5a-reductase is a membrane-bound, NADPH-dependant enzyme 
(16). Two forms ofthis enzyme have been identified, and the two isozymes have 
been named type 1 and type 2, based on their order of discovery (16-19). These 
isozymes share 46% sequence identity; they have similar gene structures, 
substrate preferences, and hydropathy profiles (17,20,21). They are, however, 
products of different genes (21-23) and differ with respect to their 'issue 
distribution profile and their pharmacological characterization (16,18-20). In 
humans, mutations in the 5a-reductase type 2 gene are responsible for 5a-
reductase deficiency, a rare form of male pseudohermaphroditism. This condition 
is characterized by internai Wolffian duct structures but female external genitalia 
(17,20,21,24). While the type 1 isozyme is more broadly distributed, 5a-
reductase type 2 mRNA is found predominantly in male sex accessory tissues 
such as the epididymis, the prostate and the seminal vesicles (5, 19, 25). In the 
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epididymis, Sa-reductase type 2 mRNA is expressed at higher levels than in any 
other rat tissue; it is predominantly expressed in the caput segment of the 
epididymis (19). The two isozymes are differentially regulated in this tissue, with 
respect to age, longitudinal distribution, and response to testicular factors (26). 
The molecular mechanisms responsible for the high levels of type 2 mRNA 
expression in the rat caput epididymidis, and for its region-, and cell-specific 
expression are unknown. To gain insight into the transcriptional regulation of Sa-
reductase mRNA type 2 gene expression, we have undertaken the cloning and 
characterization of the S' upstream region of this gene. We have also 
immunolocalized SP1 and SP3, transcription factors found to interact with the Sa-
reductase type 2 promoter, in the epididymis. 
3. Materials and Methods 
3.1. Cloning of 5a-Reductase Type 2 Upstream Region 
A Wistar-Furth genomic library prepared in the lambda bacteriophage 
Charon 3S was screened by phage plaque hybridization using a 209-bp EcoRI-
Pstl digested cDNA probe encoding the N terminus of rat Sa-reductase type 2 
(27). This probe was radiolabeled by random priming using an oligolabeling kit 
(Amersham Biosciences Inc., Baie d'Urfé, QC) with dCTP (Amersham 
Biosciences Inc.). The plate replicas were incubated overnight at 42°C in a 
formamide containing hybridization buffer (48 ml formamide, 24 ml 20XSSC, 1 ml 
Tris-HCI pH 7.6,1 ml Denhardt's solution, 20 ml dextran sulfate, 0.1 9 SDS, S ml 
distilled water and 10 mg salmon sperm DNA). After they were washed, the plate 
replicas were exposed to autoradiographic film for 2-4 days and the positive 
clones were isolated. The phages corresponding to the positive clones were 
replicated and their DNA extracted (27). The insert was isolated from the phage 
vector and submiUed to restriction analysis. A 2.6 kb BamHl/Smal fragment 
hybridizing with the 0.2 kb probe was subcloned into the BamHI/Smal site of 
pUC18 (Amersham Biosciences Inc.) and sent for sequencing. This fragment 
contains the S' upstream sequence of Sa-reductase type 2 or the 2243 base pairs 
upstream of the ATG start codon (GenBank accession AYS87954). DNA 
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sequencing and ail primer and oligonucleotide synthesis were done at the 
Sheldon Biotechnology Centre, McGiII University (Montreal, QC). 
3.2. Construction of Plasmids for Transfection 
Polymerase chain reaction (PCR) primers were used to produce 
sequentially smaller fragments in the 5' end. The sequence of these primers, 
used to generate fragments inserted in the positive and negative orientations of 
the vector, is shown in Table 1. The sense and antisense strands for fragments-
49bpATG and -25bpATG, in the positive and negative orientations, with the 
appropriate overhangs and 5' phosphorylation, are shown in Table 2. Following 
35 cycles of PCR reaction (using Ready-To-Go PCR beads from Amersham 
Biosciences Inc.), the fragments were run on a 1 % aga rose gel (2% gel for 
fragment -151bpATG), the bands were excised, and the DNA was cleaned from 
enzymatic reactions using the Qiaquick gel extraction kit from Qiagen 
(Mississauga, ON). The fragments were then double digested by Sacl and 8g/lI, 
gel extracted (Qiaquick gel extraction kit) and ligated using Ready-To-Go T4 DNA 
ligase (Amersham Biosciences Inc.) to the dephosphorylated, linear (double 
digested by the same restriction enzymes) pGL3Basic luciferase reporter vector 
(promega Corporation, Madison, WI). The two smallest fragments, -49bpATG 
and -25bpATG, were directly annealed in an annealing buffer (10 mM Tris-CI, 1 
mM EDTA, 50 mM NaCI) and ligated as described above. Next, One Shot INVa 
F' competent cells (Invitrogen-Life technologies, Carlsbad, CA) were transformed 
with the ligated products, plated onto Luria-Bertani (LB)-ampicillin plates and the 
clones were analyzed for the appropriate construct. The identity of the construct 
was further confirmed by sequencing. Maxipreps (promega Wizard kit, Promega 
Corporation, Madison, WI) were done for each construct according to the 
manufacturer's protocol. Ali enzymes, unless otherwise indicated, were 
purchased from Invitrogen-Life Technologies. 
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3.3. RNA Extraction and Northern Blot Analysis 
Adult male Sprague Dawley rats (3 months old from Charles River 
Laboratories, Inc., St. Constant, QC) were killed by decapitation and their 
epididymides and hearts were collected and immediately frozen in liquid nitrogen. 
Ali tissues were stored at -80°C until used for RNA extraction. Ali animal studies 
were conducted in accordance with the principles and procedures outlined in A 
Guide to the Care and Use of Experimental Animais prepared by the Canadian 
Council on Animal Care (McGili protocol #206). 
RNA was extracted and then DNAse-treated using the RNeasy midi kit 
from Qiagen. RNA concentration was assessed by reading the optical density at 
260nm (DU7 spectrophotometer, Beckman). From each sample, 5 fl9 of RNA 
was run on a 1 % agarose gel to assess the quality of the sample. A Northern blot 
was done to confirm the presence of 5a-reductase type 2 mRNA in the 
epididymis; RNA from heart was used as a negative control (27). 
3.4. Cell Culture, Reverse-Transcription Polymerase Chain Reaction, and 
Transfection Experiments 
PC3 cells (ATCC, Manassas, VA) were initially cultured in RPMI1640 
medium supplemented with 10% fetal bovine serum, 2 mM glutamine, and 20 flM 
gentamycin sulfate. For transfection experiments, PC3 cells were grown in 
Dulbecco Modified Eagle medium supplemented with 10% fetal bovine serum, 2 
mM glutamine, and 20 flM gentamycin sulfate. PC1 cells from the mouse 
proximal caput epididymidis (kindly provided by Dr. M.-C. Orgebin-Crist) were 
grown and transfected in Iscove Modified Dulbecco medium supplemented with 
10% fetal bovine serum, 1 mM sodium pyruvate, 0.1 mM non essential amino 
acids, 4 mM glutamine, penicillin-streptomycin (25 000 units penicillin G sodium, 
25 mg streptomycin sulfate), and 1 nM 5a-DHT. PC3 cells and PC1 cells were 
cultured at 3rc and 33°C, respectively, with 5% CO2 . Ali cell culture products 
were purchased from Invitrogen-Life Technologies. 
One-step reverse transcription (RT)-PCR (Qiagen) was done according to 
the manufacturer's protocol to confirm the presence or absence of 5a-reductase 
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type 2 mRNA in the ceillines used. Controllanes showing the endogenous level 
of expression of the gene in the rat caput epididymidis and rat epididymis were 
also included. The primers were designed using the Primer3 software 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3.cgi/); mouse 5a-reductase type 2 
forward: 5' AACACAGCGAGAGTGTGTCG 3' and reverse: 5' 
AAAGCAAAGGCTGGAACAGA 3', human 5a-reductase type 2 forward: 5' 
CAGGAAGCCTGGAGAAA TCA 3' and reverse: 
5'AGTTGGGGATCAGGATAGGG 3', rat 5a-reductase type 2 forward: 5' 
GTTGCCTTCCTTTGTGGTGT 3' and reverse: 5' CAATAATCTCGCCCAGGAAA 
3'. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers (BD 
Biosciences, Mississauga, ON) were used for a control reaction. Twenty 
microliters of sample were loaded per weil except for GAPDH, where 10 JlI of 
sample were loaded. 
Both cell lines were transiently co-transfected by the calcium phosphate 
method with the pGL3B construct, pSV (~-galactosidase vector from Promega 
Corporation), and pUC18 (27). Briefly, 1 X 105 cells were seeded onto 6-well 
plates and, after 48 h, were co-transfected with 5 Jlg of luciferase construct, 3 Jlg 
of pSV, and 2 Jlg of pUC18. The calcium-DNA precipitate was left in contact with 
the prostatic PC3 cells and proximal caput epididymidis PC1 cells for 6 and 16 h, 
respectively. The cells were then washed three times with PBS and fresh media 
was added. The cells were cultured for another 48 h, at which time they were 
harvested into 500 JlI 1X reporter Iysis buffer (Promega Corporation). Luciferase 
and ~-galactosidase activities were measured using the reporter assay system as 
directed by the manufacturer (Promega Corporation). Each sample was read 
twice using a luminometer (LUMlstar Galaxy, BMG Lab Technologies, 
Durham, NC) and the average was compared to the ~-galactosidase activity 
(absorbance read at 420nm by DU spectrophotometer; Beckman). The value 
obtained was divided by that of the negative control. For ail transfection assays, 
data are shown as the mean ± SEM of triplicate assays in three independent 
experiments. Kruskal-Wallis one-way analysis of variance on ranks was done 
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followed by Dunnett's post hoc test (P<0.05 was considered significant) to identify 
those constructs having significant luciferase activity over background. 
3.5. Primer Extension 
A 20-mer HPLC purified primer (5' GGATCAGGGTCCCCATAGTG 3') was 
labeled at the 5' end with [y_32p] ATP (Amersham Biosciences Inc.) and T4 
polynucleotide kinase according to Promega's primer extension system-AMV 
reverse transcriptase kit (Promega Corporation). The 32P-labeled primer was 
hybridized with 50 ~g of rat total RNA from caput epididymidis, whole epididymis, 
and heart as follows. RNA was heated for 10 min at B5°C and then cooled on ice. 
The annealing reaction was left overnight at 45°C in a denaturing hybridization 
solution (40 mM PIPES at pH 6.4, 1 mM EDTA, 0.4 M NaCI and BO% deionized 
formamide) to maximize annealing. The RNA/DNA template was ethanol 
precipitated and resuspended in water. Superscript Il (Invitrogen-Life 
Technologies) was used to reverse transcribe the RNA and the product was run 
on a denaturing polyacrylamide gel. The gel was exposed overnight at -BO°C to a 
Phosphorlmager plate (Molecular Dynamics Inc., Sunnyvale, CA) and visualized 
with a Phosphorlmager (Storm, Molecular Dynamics Inc.). 
3.6. 5' Rapid Amplification of cD NA Ends 
The GeneRacer kit (Invitrogen-Life Technologies) was used for 5' rapid 
amplification of cDNA ends (RACE). Briefly, rat epididymal total RNA was treated 
with calf intestinal phosphatase to cleave the 5' phosphate from truncated mRNA 
and non-mRNA species. It was then treated with tobacco acid pyrophosphatase 
to remove the 5' cap structure from intact, full-Iength mRNA. The GeneRacer 
RNA oligo was ligated to the 5' end of the mRNA and the mRNA was reverse 
transcribed by Superscript Il with an oligo dT primer (provided with the kit). 
Platinum Taq polymerase high fidelity was used for hot start, touchdown PCR, 
along with the 5.1 primer (5' GCACGAGGACACTGACATGGACTGA 3') and a 
gene-specific primer (5' GCTTCCTGAGCTGGGTGTAGTCA 3'). The product of 
this reaction was used for nested PCR with a forward nested primer (5' 
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GGACACTGACATGGACTGAAGGAGT A 3', provided with the kit) and a reverse 
gene-specifie primer (5' AGGCTTGAAGGAGTCCGTTCCCTA 3'). The PCR 
product was gel purified and cloned into the TOPO vector. TOP10 chemically 
competent E. coli cells were transformed by the ligated product and fourteen 
clones were picked from the LB-ampicillin plates for further analysis and 
sequenced. 
3.7. Identification of Putative Transcription Factor-Binding Sites 
The 2.2-kb 5' upstream region was analyzed by TRANSFAC 4.0 
(http://transfac.gbf.de/cgi-bin/matSearch/matsearch.pl) using the Matlnspector 
V2.2 program. 
3.8. Nuclear Extraction and Electrophoretic Mobility Shift Assay 
Nuclear extractions from 42-day-old rat caput epididymides and from the 
mouse proximal caput epididymal PC1 cell line were produced using the Nuclear 
Extract Kit from Active Motif (Carlsbad, CA) following the manufacturer's protocol. 
The protein concentration was determined by the Bradford method using the Bio-
Rad Protein Assay (Bio-Rad Laboratories, Hercules, CA). 
Five oligonucleotide fragments spanning the region most proximal to the 
transcriptional start site were synthesized (Table 3). Oligo 1 corresponds to the 
+5 to +34 region of the 5a-reductase type 2 gene, oligo 2 to -37 to +10, oligo 3 to 
-68 to -32, oligo 4 to -120 to -69 and oligo 5 to -174 to -120. Three more 
fragments were produced with mutations in the SP1 binding sites of oligo 3 as 
seen in Table 3. Oligo 3 SP1 (1) mutation has a mutation in the first SP1 binding 
site of the fragment, oligo 3 SP1 (2) mutation has a mutation in its second site, 
and oligo 3 double SP1 mutation contains both mutations. 
Electrophoretic mobility shift assay (EMSA) was do ne using Gel Shift 
Assay systems (Promega Corporation). The sense oligonucleotides were end-
labeled with [y-32P] dATP (Amersham Biosciences Inc.) and T4 polynucleotide 
kinase. The percent incorporation was determined and found to be >40%. The 
radioactive probes were annealed to an excess amount (3-fold molar excess) of 
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their complementary oligonucleotides, thus ensuring that virtually ail labeled 
oligonucleotides are annealed and unable to interfere with the binding reactions. 
The double-stranded probes were then purified by a spin-column (Microspin G-25 
columns, Amersham Biosciences Inc.). The reaction mixture comprised of 20 ~g 
of nuclear extracts and 1~1 gel shift binding 5X buffer (20% glycerol, 5 mM 
MgCI2, 2.5 mM EDTA, 2.5 mM DTT, 250 mM NaCI, 50 mM Tris-HCI (pH 7.5), 
0.25 mg/ml poly(dl-dC)(poly(dl-dC» in a 10 ~I volume. The components were 
preincubated at room temperature for 30 min (either with antibody or specifie 
unlabeled competitor) before addition of the radioactive probe (35 fmol). They 
were then incubated for another 30 min at room temperature. One microliter of 
the gelloading 10X buffer (250 mM Tris-HCI (pH 7.5), 0.2% bromophenol blue, 
40% glycerol) was added and the DNA-protein complexes were resolved on a 4% 
polyacrylamide (40:1 acrylamide:bisacrylamide) gel in 0.5X Tris-borate-EDTA 
buffer. The complexes were visualized with a Phosphorlmager (Storm, Molecular 
Dynamics, Inc.) after an overnight exposure to Phosphorlmager plates (Molecular 
Dynamics, Inc.) at -80°C. Unless otherwise indicated, 143-fold molar excess of 
unlabeled competing oligonucleotides were added to the reaction prior to the 
addition of the radiolabeled probe. For supershift assays, the nuclear extracts 
were preincubated with 2 ~g of either SP1 (PEP2, sc-59X), SP3 (D-20, sc-644X), 
USF-1 (C-20, sc-229X), USF-2 (C-20, sc-862X), ERa (MC-20, sc-542X), or ER~ 
(Y-19, sc-6821X) antibodies (Santa Cruz Biotechnology, Santa Cruz, CA). SP1 
and SP3 were selected because they are ubiquitous members of the Sp1 family 
of transcription factors. 
3.9. Tissue Preparation for Light Microscopy and Immunohistochemistry 
Sprague-Dawley rats (350g, n = 3) were anaesthetized byan 
intraperitoneal injection of vetalar (Ketamine HCl 115.4mg/ml, Vetrepharm 
London, ON), anased (Xylazine HCl 20 mg/ml, Novopharm Toronto, ON), and 
atravet (Acepromazine Maleate 10mg/ml, Ayerst Montreal, PQ) 20:10:1. 
Epididymides were fixed by retrograde perfusion with Bouin fixative via the 
abdominal aorta as previously described (28). The fixed epididymides were left 
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overnight in Bouin's fixative and were then dehydrated and embedded in paraffin. 
Sections, 6 IJm thick, were cut with a microtome and mounted on glass slides. 
The sections were deparaffinized in xylene and hydrated in a series of 
graded ethanol solutions. Endogenous peroxide activity was abolished in a 70% 
ethanol, 1 % hydrogen peroxide solution and free aldehyde groups were blocked 
with 300 nM glycine. The sections were incubated in 3% bovine serum albumin 
(BSA) and goat blocking serum (Vectastain Elite ABC kit, Vector Laboratories, 
Burlingame, CA) for 1 h and then with a primary antibody in the blocking solution 
overnight at 4 oC. The antibodies, SP1 and SP3, were used in a 1 :2000 dilution. 
The sections were washed three times with PBS and incubated for 30 min with a 
biotinylated goat anti-rabbit IgG secondary antibody (ABC kit). Following three 
more washes in PBS, they were incubated with the ABC reagent for 30 min and 
washed again in PBS three times. The staining was visualized by incubating 
them with 0.05% diaminobenzidine tetrahydrochloride (Bio Fx Laboratories, 
Owings-Mills, MD). The sections were washed three times in PBS and 
counterstained with 0.08% methylene blue. They were dehydrated in a series of 
graded ethanol solutions and cover slips were mounted onto the slides with 
Permount (Fisher Scientific, Pittsburgh, PA). Blocking peptide (SP1(PEP2)P, sc-
59P and SP3(D20)P, sc-644P fram Santa Cruz Biotechnology, Santa Cruz, CA) 
was added at a five-fold excess to the blocking solution during incubation with the 
primary antibody for the negative controls. 
4. Results 
4.1. A Minimal Promoter in the -151-bp Region Upstream of the ATG Codon 
Sequential deletion analysis was do ne on the 5a-reductase type 2 
promoter using the luciferase pGL3B vector to identify the minimal pramoter 
region of the gene as weil as sorne cis elernents that rnight regulate its activity. 
The empty pGL3B vector with no pramoter or enhancer sequences was used as 
a negative control. Luciferase activity is only detected if a functional pramoter is 
inserted in the praper orientation into this vector. Nine sequentially smaller 
fragments were generated fram the cloned 5' upstream region of 5a-reductase 
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type 2 and inserted into the vector in both the positive and negative orientation to 
test for promoter bidirectionality. The constructs were arbitrarily designated with 
respect to the ATG start codon (Fig. 1). 
The prostatic PC3 ceilline and the mouse proximal caput epididymidis 
PC1 ceilline were shown to express 5a-reductase type 2 mRNA by RT-PCR 
(Fig. 2). Both express it at lower levels than rat caput epididymidis and rat 
epididymis, but its presence indicates that PC1 and PC3 cells have the 
transcription factors required for 5a-reductase type 2 expression. The PC1 cell 
line also has the added advantage of being a pure culture of immortalized 
epithelial cells obtained specifically from the proximal caput epididymal segment 
(29), the region where 5a-reductase type 2 mRNA is the highest. Comparing the 
luciferase activity of the constructs in the two cell lines provides an indication as 
to whether the cis elements of the 5a-reductase type 2 gene are specific or 
common for the two tissues expressing it. 
The constructs were co-transfected by the calcium phosphate method into 
both cell lines with the ~-galactosidase vector pSV, which served as an internai 
control for transfection efficiency and pUC18, used as a carrier vector. Both the 
prostatic and the epididymal cell lines displayed the same general trend (Fig 3). 
When the fragments were inserted in the positive orientation (Fig. 3, A and B), we 
observed an increase in expression levels with decreasing fragment size until 
fragment -194bpATG, suggesting the presence of upstream repressor elements. 
The strongest repressors, regions decreasing the activity of the 5a-reductase 
type 2 promoter, were found between fragments -485bpATG and -194bpATG in 
both cell lines, where luciferase activity almost doubled between the two 
constructs. There was a decrease in expression levels between fragments -
194bpATG and -151bpATG, indicating enhancer sequences in this region. These 
enhancer sequences or regions potentiating the activity of the 5a-reductase type 
2 promoter were most pronounced in the PC1 ceilline, where a 59% decrease in 
luciferase activity was observed. Luciferase activity was subsequently lost in the 
2 smallest fragments, pGL3B-49bpATG and pGL3B-25bpATG, indicating that the 
minimal promoter is located in the 151-bp region upstream of the ATG start 
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codon. When inserted in the negative orientation (Fig. 3, C and 0), the luciferase 
activity of the fragments was minimal and only the sm aller fragments had any 
luciferase activity over the background. These data suggest that the minimal 
promoter is preferentially unidirectional, in the positive orientation and that a 
minimal promoter is found in the -151-bp region upstream of the ATG codon. 
4.2. Mapping of the Transcriptional Start Site 
Primer extension and RACE were done to identify the transcriptional start 
site of the 5a-reductase type 2 gene. Primer extension was done using a primer 
complementary to a sequence located 73-bp downstream from the ATG start 
codon. Only one 100-bp band was detected in the total epididymis and caput 
epididymidis RNA extracts, but this band was absent in the heart RNA and no 
RNA lanes (Fig. 4). The results thus suggest that the band is specifie and the 
gene has only one transcriptional start site. RACE was done to further confirm 
these findings. Of the 14 RACE clones sequenced, 4 did not sequence (clones 1, 
3,8, and 14) and the others were ail within eight nucleotides away from each 
other (Fig. 5). The close proximity of the nucleotides to each other suggests the 
presence of only one transcriptional start site; this start site is located at 
approximately 100-bp from the primer used in the primer extension experiments. 
Five clones (clones 6, 7, 11, 12, and 13) identified the most 5' nucleotide; it is 
henceforth this nucleotide that is designated position +1 or the transcriptional 
start site. The translational start site is located 34-bp downstream and is now 
referred to as position +34. 
4.3. SP1 Binding Elements in the Proximal Promoter 
A search of TRANSFAC yielded a number of potential transcription factor 
binding sites regulating 5a-reductase type 2; we focused our search to the 485-
bp proximal 5' upstream region of the gene (Fig. 6). This area corresponds to the 
region upstream of the translational start site identified in the sequential deletion 
analysis studies as having the strongest repressor and enhancer sequences. The 
transcription factor binding sites include five SP1 binding sites (two of which are 
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consensus GC-boxes), as weil as a number of AP2, AP4, USF1, USF2, IK1, IK2 
and NF1 potential binding sites. Motifs for an ER half site and a little further 
upstream for PEA3 and GATA, have also been identified. To more thoroughly 
investigate this region, oligonucleotides spanning the -174 to +34 region were 
synthesized and used to identify potential DNA-protein interactions in murine 
proximal caput epididymal cell line and in 42-day-old rat caput epididymides 
nuclear extracts. This age was selected because of the absence of spermatozoa 
in the lumen of the epididymis (30) and the high level of mRNA expression (26). 
When using oligos 2 (-37 to +10) or 5 (-174 to -120), no bands were 
visible, thus no DNA-protein complex was formed when these fragments were 
incubated with nuclear extracts from either the PC1 ceilline or 42-day-old rat 
caput epididymides (results not shown). When the ceilline nuclear extracts were 
incubated with oligo 1 (+5 to +34), a specifie band was consistently observed 
(Fig. 7 A). This band decreased in intensity with increasing amounts of specifie 
competitor (5-fold, 25-fold and 125-fold the molar concentration of the labeled 
probe), but no supershift was observed in the presence of the ERa or ER~ 
antibody. In contrast, when oligo 1 was incubated with rat caput epididymidis 
nuclear extracts, no band was observed even with increasing amounts of nuclear 
extracts (results not shown). Similarly, a specifie band was observed with oligo 4 
(-120 to -69) when it was incubated with PC1 ceilline nuclear extracts (Fig. 7B) 
but not with rat nuclear extracts (results not shown). This band disappeared in the 
presence of the unlabeled competitor (143-fold the molar concentration of the 
labeled probe), but the transcription factor(s) interacting with this segment 
remains unknown. To further ascertain its specificity, increasing amounts of 
unlabeled competitor (5-fold, 25-fold and 125-fold excess) were added to the 
nuclear extracts and a progressive decrease in intensity was observed with 
inereasing amounts of specifie eompetitor (results not shown). TRANSFAC was 
used to identify the potential transcription factor binding sites on oligo 4; of those 
identified, only antibodies against SP1 , SP3, USF1, and USF2 were available 
and previously used in similar experiments; no supershift was observed with any 
of these antibodies. 
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A specifie band was observed when oligo 3 (-68 to -32) was incubated 
with 20 J.lg of ceilline (Fig. 7C) or rat caput epididymidis (Fig. 70) nuclear 
extracts. This band was supershifted in both cases with a SP1 antibody and to a 
lesser extent with a SP3 antibody. This band disappeared in the presence of 
excess unlabeled specifie competitor but remained in the presence of excess 
unlabeled double SP1 mutated competitor (also 143-fold the molar concentration 
of the labeled probe). Because two SP1 binding sites were present on this ONA 
segment, we proceeded to identify the one(s) binding to the SP1 transcription 
factor. Two oligonucleotides were designed, each with one of the SP1 binding 
sites mutated. The fragments were analyzed by TRANSFAC to make sure no 
additional binding sites were introduced. When oligo 3 SP1 (1) mutated was used 
to compete in the reaction (143-fold the molar concentration of the labeled 
probe), a decrease in intensity was observed in the band for both the cell line and 
rat caput epididymidis nuclear extracts, suggesting a decrease in DNA-protein 
binding. When oligo 3 SP1 (2) mutated was used as a competitor in both nuclear 
extracts (at similar molar excess), the band was barely visible, indicating almost 
no interaction taking place between oligo 3 and the nuclear proteins. Therefore, 
the competition studies reveal that SP1 (and to a lesser extent SP3) bind to the -
68 to -32 region of the gene in the presence of both the cell line and the rat caput 
epididymidis nuclear extracts. Although they can bind to both sites, they appear 
to prefer the first one located at position -58 to -55 because this SP1 binding site 
is a consensus GC-box and both SP1 and SP3 have high affinities for it. 
4.4. Localization of SP1 and SP3 in the Epididymis 
SP1 and SP3 are ubiquitous transcription factors. Their localization and 
distribution along the epididymis is unknown; therefore, immunolocalization 
studies were undertaken to ascertain the specificity of 5a-reductase type 2 
mRNA expression. Both SP1 and SP3 displayed some cell- and region-
specificity. Figure 8, A and D, show the lack of staining in the caput epididymidis 
in the presence of excess peptide for SP1 and SP3, respectively; similar results 
were obtained for the cauda epididymidis (data not shown). The 
110 
immunolocalization of SP1 and SP3 are shown for the caput epididymidis (Fig. 8, 
Band E), where 5a-reductase type 2 mRNA is the most highly expressed, and 
the cauda segment (Fig. 8, C and F), where a different pattern is observed. 
Strong immunostaining for SP1 was found in the nucleus of the principal cells 
and a more moderate staining for basal cells and apical cells. Narrow cells of the 
initial segment and halo cells showed little or no staining while clear cells did not 
stain. In the proximal segments of the epididymis, SP1 was only localized to the 
nucleus in the principal cells (Fig. 8B) while, in the more distal segments, some 
perinuclear and cytoplasmic staining were also observed (Fig. 8C). The initial 
segment of the epididymis displayed the most intense overall staining, while the 
corpus epididymidis displayed the least. 
SP3 staining was less intense than that of SP1 in ail cells and regions of 
the epididymal epithelium but was very intense in sperm heads in the lumen. 
Principal cell nucleus and basal cells were immunoreactive and, to a lesser 
extent, apical and halo cells. As for SP1, no staining was observed in clear cells 
(Fig. 8F). In the corpus and cauda epididymidis, the principal cells displayed 
nuclear, both nuclear and perinuclear, or very little staining in a checkerboard-like 
pattern (Fig. 8F), similarly observed for SP1, characteristic of many proteins in 
this tissue (31-33). 
5. Discussion 
Cloning and characterizing the proximal 2243-bp of the 5' upstream 
region of rat 5a-reductase type 2 have revealed that the minimal promoter is in 
the proximal-118-bp region, and that there are regions with strong repressor (-
452 bp to -161 bp) and enhancer (-161 bp to -118 bp) activity; the transcriptional 
start site (+1) is 33-bp downstream of the start codon. Furthermore, potential 
transcription factors (SP1 and SP3) regulating gene expression have been 
identified and immunolocalized to principal cells of the epididymis. These results 
are summarized in Figure 9. The promoter region of rat 5a-reductase type 2 is 
GC-rich with a noncanonical TATA box located 30-bp upstream of the 
transcriptional start site and a CMT box on the antisense strand. 
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We used two cell lines for our sequential deletion studies, one a mouse 
proximal caput epididymal ceilline and the other a human prostate 
adenocarcinoma ceilline. The mouse proximal caput ceilline has recently been 
developed and characterized (29); it is one of only three stable epididymal cell 
lines described in the literature. The other two are immortalized cells from the 
human fetal epididymis (34) and the dog epididymis (35). Because the different 
segments of the epididymis are anatomically distinct and play different roles in 
the maturation of sperm, we opted for a ceilline that specifically originated from 
the region with the highest 5a-reductase type 2 mRNA and with close homology 
to rat. Mouse and rat 5a-reductase type 2 share 95% sequence homology (36). 
Because sequence homology between rat and human is approximately 77% (5), 
we used PC3 cells to determine if our findings could be applied to humans and to 
another tissue expressing this protein. PC3 cells are often used to study 
molecular events mediating hormone-responsive gene expression in the 
epididymis (37). Despite the low expression levels of 5a-reductase type 2 in the 
two cell lines, they constitute the best tools we have 50 far in investigating gene 
regulation in the epididymis. The 5a-reductase type 2 constructs followed the 
same general trend in both cell lines; the only notable differences between the 
two were in their expression levels and in the strength of the enhancer 
sequences. While the PC3 cell line was initiated from the bone metastasis of a 
grade IV adenocarcinoma (38), the proximal caput epididymal PC1 ceilline was 
derived from primary cultures of epididymal cells from transgenic mice harboring 
a temperature-sensitive simian virus 40 large T-antigen (29). Transcription factors 
in cancerous ceillines such as in PC3 cells may be up-regulated, thus accounting 
for the higher relative expression levels of the constructs. The decrease in 
luciferase expression levels between constructs -194bpATG and -151bpATG was 
most pronounced in the epididymal PC1 ceilline suggesting that this cis-acting 
sequence may be specifie for this tissue. 
Primer extension and RACE identified one transcriptional start site, a 
guanine that is located 33-bp upstream of the gene's translational start site. The 
fact that more than one nucleotide was identified by RACE suggests the 
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presence of a TAT A-Iess or a noncanonical TATA box promoter, as the 
transcriptional start site for these tend to be less precise than that of a canonical 
TATA box promoter. Indeed, a noncanonical TATA box is located 30-bp 
upstream of the transcriptional start site. Using human prostate poly(A)+ RNA, 
Labrie et al. (23) previously reported the transcriptional start site of 5a-reductase 
type 2 to be at 71 nucleotides upstream of the ATG initiating codon. Another 
group studying the transcriptional regulation of the gene by progesterone in the 
mouse brain used primer extension to identify the transcriptional start site at 89-
bp upstream of the ATG start codon (36). Thus, three studies, using different 
tissues from different species, identified distinct start sites. This discrepancy is 
quite surprising considering the high sequence homology between the species. 
Additionally, we found that rat and mouse share 81 % sequence homology and rat 
and human 60% sequence homology in the 2 kb of the 5' upstream region of their 
5a-reductase type 2 gene when the sequence alignment software Clustal W 
(http://www.ebLac.uk:/ciustalw/) was used. Despite close sequence homology and 
the conservation of important transcriptional elements of genes across species, 
the transcriptional start site does not correspond. The CATAAA box we identified 
as the potential non-canonical TATA box in our experiments is found downstream 
of the transcriptional start site identified previously but is present in the rat, 
mouse, and human sequence. The TATA box identified by Matsui et al. (36), 
however, is absent in the rat sequence and no TATA box is found upstream of 
the human sequence. The 5a-reductase type 2 promoter may be a TATA-Iess 
promoter where the CAT AAA box is nonfunctional. The numerous GC-boxes 
found close to the ATG start codon would support this hypothesis because they 
can play important roles in transcription initiation (39). The discrepancy may also 
be the result of different tissues using different transcriptional start sites for tighter 
transcriptional regulation, or of the incapability of the noncanonical TATA box to 
initiate transcription from only one site. The small difference in the 5' base-pair 
number of the 5' untranslated region may be too small to be reflected in transcript 
size. Using complementary methods, such as RACE and primer extension, will 
have to be done in mouse and human epididymis to test this hypothesis. 
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When the +5 to +34 (oligo 1) and the -120 to -69 (oligo 4) region of the 
gene were studied for potential transcription factor interactions, a specifie band 
was consistently observed with the murine ceilline nuclear extracts but not the 
rat caput nuclear extracts. This discrepancy in binding between the two nuclear 
extracts may be due to i) an up-regulation of transcription factors in the cell line, 
ii) the absence of those transcription factors in the rat, or iii) the consequence of a 
dilution effect. The cell line used consists of a pure population of principal cells, 
the epididymal cell type that expresses 5a-reductase type 2. In contrast, many 
cell types and connective tissue are present in the rat caput segment so, the 
same interactions may be occurring but we were unable to detect them with this 
method. 
The -68 to -32 (oligo 3) region of the gene is the region we found most 
interesting because a specifie band was consistently observed in the presence of 
both the murine cell line and the rat caput nuclear extracts. This band was 
supershifted with the SP1 antibody and to a lesser extent with the SP3 antibody. 
Competition studies using mutated fragments showed that SP1 is principally 
binding to the consensus GC box located at position -58 to -55. 
Both SP1 and SP3 belong to the Sp subgroup of the Sp/XKLF 
(specificity protein/Krüppel-like factor) family of transcription factors. This family 
shares a DNA-binding domain with three conserved Cys2His2 zinc fingers and is 
involved in growth-regulatory or developmental processes of a large number of 
tissues (40). The Sp protein subgroup additionally shares similar N-terminal 
motifs (41). SP1 and SP3 bind with similar affinities to the GC/GT-boxes that are 
commonly found in many gene promoters, including those of housekeeping 
genes (41). Despite being ubiquitously expressed, they displayed distinct 
patterns of expression between the different segments of the epididymis and 
were predominantly expressed in the nuclei of principal cells, the cell type 
expressing 5a-reductase type 2 (15). This latter observation could be anticipated 
considering the roles of principal cells in this tissue (13). The different staining 
intensities and the subcellular localization from one epididymal segment to 
another were not unexpected. While the caput epididymidis exhibits only nuclear 
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localization for both transcription factors, the cauda segment displays perinuclear 
staining as weil, suggesting differential regulation of SP1 and SP3 within this 
tissue. SP1 is one of the most pote nt transcriptional activators characterized to 
date, and it can stimulate transcription from both proximal promoters and distal 
enhancers (42). SP1 can interact with other factors in the same multigene family 
as weil as those from other families, including steroidogenic factor-1, p53, signal 
transducer and activator of transcription-1, GATA-1, activating protein-1, nuclear 
factor-KB, and estrogen receptor (43-49). These interactions along with the levels 
of SP1 could potentially explain the region-specific expression of genes regulated 
by SP1. For instance, SP1 and polyomavirus enhancer activator 3 (PEA3) are 
required for promoter activity of the TATA-Iess y-glutamyl transpeptidase (GGT) 
promoter IV gene in the rat epididymis. Both GGT and PEA3 are highly 
expressed in the initial segment of this tissue and they regulate transcription via 
possible interactions of SP1 and PEA3 with each other and/or with components 
of the general transcriptional complex (50). We have observed intense SP1 
immunostaining in the initial segment of the epididymis. In TATA-Iess promoters, 
the binding of SP1 to Ge-boxes is critical for transcription initiation and is often 
directed from multiple sites. Both SP1 and SP3, through their glutamine-rich 
regions within the amino termini, can interact with components of the general 
transcription factor TAFII130 to activate transcription (51). SP3 has been shown 
to function as both a competitive repressor of SP1-induced transcription (52) and 
a strong activator of transcription under different conditions (41). It is still not 
clearly understood why, but the SP1 :SP3 ratio is thought to play an important role 
in the regulation of transcription. Increasing the SP1 :SP3 ratio is generally 
correlated with the increased expression of response genes where those genes 
are activated by SP1 and repressed by SP3 (reviewed in (41)). In the caput 
epididymidis, SP1 immunostaining is more intense for SP1 than SP3, suggesting 
a high ratio. Thus, despite having identified ubiquitous transcription factors 
interacting with 5a-reductase type 2, the expression levels of SP1 and the 
SP1 :SP3 ratio in the principal cells of the caput epididymidis could partly account 
for the regionalization displayed by this gene. 
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Identifying the transcription factors interacting with SP1 and/or binding to 
other sites found in the 5' upstream region of the gene would also help resolve 
the transcriptional mechanisms that govern the region- and ce II-specifie 
expression of 5a-reductase type 2 in the epididymis. It could help elucidate some 
of the molecular mechanisms governing other spatially restricted genes 
expressed in the epididymis, thus allowing for a better understanding of this 
tissue. These genes include GGT mRNA IV, PEA3, glutathione peroxidase 5, 
epididymal protease inhibitor and cystatin-related epididymal specifie protein (50, 
53-56). The regionalization displayed by those genes may be the result of 
segment-specifie expression of epididymal transcription factors or of segment-
specifie interactions between ubiquitously expressed transcription factors. 
ln conclusion, these data represent the first characterization of the 5' 
upstream region of 5a-reductase type 2 and our findings form the basis from 
which future studies can be designed to study the transcriptional regulation of the 
gene. 
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Table 1. Primers used in seguential deletion analysis 
Construct Primer Sequence for + orientation Primer Sequence for - orientation 
(5' ~ 3') a (5' ~ 3') b 
-2.2KbATG TCGAGCTC- TTCAGATCT-
CTGTGCTCTGAGGTGGTTCACAG CTGTGCTCTGAGGTGGTTCACA 
-1.8KbATG TCGAGCTC- TTCAGATCT-
AGCCTTTGGAAGGCATCTAAGTG AGCCTTTGGAAGGCATCTAAGT 
-1.4KbATG TCGAGCTC- TTCAGATCT-
CAGGACTGGTTGGAGTGGATGGG CAGGACTGGTTGGAGTGGATGG 
-930bpATG TCGAGCTC- TTCAGATCT-
GGTTCAGAGAGCATCAACACCAT GGTTCAGAGAGCATCAACACCA 
-485bpATG TCGAGCTC- TTCAGATCT-
GAAGTTTTGCCAGGGCGATCCAT GAAGTTTTGCCAGGGCGATCCA 
-194bpATG TCGAGCTC- TTCAGATCT-
GCGAAATGGGCATTGCTGCTAGC GCGAAATGGGCATTGCTGCTAG 
-151bpATG TCGAGCTC- TTCAGATCT-
CCAAGGTGGGAGGCACACGG CCAAGGTGGGAGGCACACGG 
reverseATG TTCAGATCT- TCGAGCTC-
GCCTGTGGTCACAGTTGGTAGC GCCTGTGGTCACAGTTGGTAGCT 
a,b A restriction enzyme site (TCGAGCTC- for Sacl or TTCAGATCT- for 8g/ll) was added 
upstream of the primer sequence to ensure directional cloning into the multiple cloning site of 
pGL3Basic. 
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Table 2. Oligonucleotides synthesized for seguential deletion analysis 
Construct Sense strand (5' ~ 3,)a Antisense strand (5' ~ 3,)5 
-49bpATG C-GCACTCTCCGCCACGCGGGC GATCT -GCCTGTGGTCACAGTT 
(+ orientation) GGCAGCTACCAACTGTGACCACA GGTAGCTGCCGCCCGCGTGGC 
GGC-A GGAGAGTGC-GAGCT 
- 49bpATG C-CGGACACCAGTGTCAACCAT GATCT-CGTGAGAGGCGGTGCG 
(- orientation) CGACGGCGGGCGCGCACCGCC CCCGCCGTCGATGGTTGACACTGGTG 
TCTCACG-A TCCG-GAGCT 
- 25bpATG C-GCTACCAACTGTGACCACAG GA TCT -GCCTGTGGTCACAGTT 
(+ orientation) GC-A GGT AGC-GAGCT 
- 25bpATG C-CGGACACCAGTGTCAACCAT GATCT -CGATGGTTGACACTGG 
(- orientation) CG-A TGTCCG-GAGCT 
a,b Sacl and 8g111 digested sites were added on both ends for proper directional cloning. 
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Table 3. Oligonucleotides synthesized for use in EMSA 
Fragments Sense strand (5' -7 3') Antisense strand (5' -7 3') 
oligo 1 (30 bp): GGCAGCTACCAACTGTGACCACAG TCTCGCCTGTGGTCACAGTTGG 
+5=>+34 GCGAGA TAGCTGCC 
oligo 2 (47 bp): GGTGCTCCATAAAGGGGCCCCGC GCTGCCGCCCGCGTGGCGGAG 
-37=>+10 ACTCTCCGCCACGCGGGCGGCAG AGTGCGGGGCCCCTTTATGGAG 
C CACC 
oligo 3 (37 bp): TGGTCCGAGGGGCGGACACGGGG AGCACCAGACGCCACCCCGTGT 
-68=>-32 TGGCGTCTGGTGCT CCGCCCCTCGGACCA 
oligo 4 (52 bp): CGCCAAGGTGGGAGGCACACGGG GGGTTCCCTCCCCACTCTCTCC 
-120=>-69 CTGGGGTGGAGAGAGTGGGGAGG ACCCCAGCCCGTGTGCCTCCCA 
GAACCC CCTTGGCG 
oligo 5 (56 bp): AAGAACCAGACGGGCGAAATGGG CGCAGCCCGCCCTGGCTCTGC 
-174=>-120 CATTGCTGCTAGGCAGAGCCAGG CTAGCAGCAATGCCCATTTCGC 
GCGGGCTGCG CCGTCTGGTTCTT 
oligo 3 SP1(1) TGGTCCGAGGAATCGACACGGGG AGCACCAGACGCCACCCCGTGT 
mutation a TGGCGTCTGGTGCT CGATTCCTCGGACCA 
oligo 3 SP1 (2) TGGTCCGAGGGGCGGACACGGAA AGCACCAGACGCCATTCCGTGT 
mutation b TGGCGTCTGGTGCT CCGCCCCTCGGACCA 
oligo 3 double SP1 TGGTCCGAGGAATCGACACGGAAT AGCACCAGACGCCATTCCGTGT 
mutation C GGCGTCTGGTGCT CGATTCCTCGGACCA 
a, b, C Mutations in the SP1 binding sites of oligo 3 are underlined. 
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Figure 1. Constructs Used in the Sequential Deletion Experiments. 
Nine sequentially smaller constructs were generated using PCR primers (or by 
synthesizing the sense and antisense strands for the two smallest fragments). 
These constructs are named relative to their positions from the ATG start codon. 
The longest construct, pGL3B-2.2kbATG, contains the entire cloned 5' upstream 
region and the empty pGL3B vector serves as a negative control. A functional 
promoter needs to be inserted in the proper orientation for luciferase expression. 
The fragments were directionally cloned into the multiple cloning site of the 
luciferase reporter plasmid pGL3Basic in the positive and negative orientations 
(as indicated by the two arrows). 
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Figure 2. 5a-Reductase Type 2 mRNA Expression in the PC1 and PC3 Cell 
Lines. 
RT-PCR of 5a-reductase type 2 was done for both the prostatic PC3 ceilline and 
the mouse proximal caput epididymal PC 1 cell line. Control lanes show 
endogenous 5a-reductase type 2 mRNA levels in rat caput epididymidis and rat 
epididymis. GAPDH was used as a positive control for ail RNA samples (only 
results from the PC1 cells are shown). A negative control was also done for each 
RNA sample, where the reverse transcription step was omitted, to make sure the 
RNA was free from genomic contamination. 
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Figure 3. Sequential Deletion Analysis. 
The luciferase constructs were cotransfected along with the p-galactosidase pSV 
vector (to control for transfection efficiency) and pUC18 (used as a carrier vector) 
by the calcium phosphate method into the mouse proximal caput epididymal PC1 
cell line (A and C) and the prostatic PC3 cell line (B and 0) in both the positive (A 
and B) and negative (C and 0) orientations. The luciferase activity of each 
construct was normalized by its p-galactosidase activity; relative luciferase 
activity was calculated as a ratio of the normalized luciferase activity to that with 
pGL3Basic vector. Each construct was cotransfected in triplicate at three different 
times and is expressed as the mean ± SEM. Kruskal-Wallis one way analysis of 
variance on ranks was done followed by Dunnett's post hoc test to identify 
constructs with significant luciferase activity over background (P<O.05 was 
considered significant). 
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Figure 4. Identification of the Transcriptional Start Site by Primer Extension. 
Primer extension was done using a 20-bp primer complementary ta the +54 ta 
+74-bp region downstream of the ATG start codon. The primer was hybridized 
with 50 /lg of rat total RNA from the epididymis (Iane 2), the caput epididymidis 
(Iane 3), and the heart, a tissue which does not express 5a-reductase type 2 
(Iane 5). A single 100-bp band is seen in lanes 2 and 3 and is absent in lane 5. 
Markers (Ianes 1 and 7) and the control reaction provided with the kit (Iane 6) are 
also shawn. 
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Figure 5. The Rat 5a-Reductase Type 2 Transcriptional Start Site. 
The results obtained fram the primer extension and RACE experiments are put in 
the context of the 5a-reductase type 2 sequence. The region complementary to 
the HPLC-purified primer extension primer (PE HPLC primer 1) used is shown in 
bold and underlined. Of the 14 clones obtained by RACE and sent for 
sequencing, 4 clones did not sequence and the others were ail within eight 
nucleotides fram each other. The most 5' nucleotide identified is designated the 
transcriptional start site (+1), the ATG start codon is located at +34 and a 
noncanonical TATA box at -30 (their corresponding sequences are shown in bold 
and underlined). 
Figure 5 
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Figure 6. Potential Transcription Factor Binding Sites in the 5' Upstream 
Region of 5a.-Reductase Type 2. 
Although the entire cloned region was analyzed, we show the proximal 576-bp 
region upstream of the transcriptional start site. This region has the area we 
chose to focus on based on the strong repressor, enhancer, and minimal 
promoter regions identified by sequential deletion analysis. In bold are the 
potential transcription factor binding sites, as identified by TRANSFAC; they 
include sites for SP1, AP2, AP4, estrogen receptor (half-site), NF1, GATA, PEA3, 
and USF. The rectangle indicates the region spanned by the different 
oligonucleotides synthesized. 
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Figure 7. EMSA on the Proximal 5a-Reductase Type 2 Upstream Region 
Using the PC1 Cell Line and Rat Caput Epididymidis Nuclear Extracts. 
The diagram above each gel indicates the position of the oligonucleotide relative 
to the gene sequence, an arrow indicates specifie bands and supershifts, and 
lanes 1,8, 15, and 23 correspond to the negative control (no nuclear extracts). A) 
Oligo 1 (+5 to +34) was incubated with 20 Jlg of the PC 1 nuclear extracts as seen 
in lane 2. Antibody against the estrogen receptor (ER) a and ~ were added to the 
reaction as depicted in lanes 3 and 4, respectively. In lanes 5, 6, and 7 increasing 
amounts of unlabeled gel shift fragment 1 were added prior to adding the 
radiolabeled fragment. B) Oligo 4 (-120 to -69) was incubated with 20 Jlg of the 
PC1 nuclear extracts (Iane 9). A 143-fold excess unlabeled fragment was added 
to the reaction prior to the addition of the radiolabeled fragment in lane 10. 
Antibodies against USF1, USF2, SP1, and SP3 transcription factors were added 
as seen in lanes 11, 12, 13, and 14, respectively. C and D) The gels obtained 
when oligo 3 (-68 to -32) was incubated with 20 Jlg of PC1 ceilline (Iane 16) and 
20 Jlg of rat caput epididymidis nuclear extracts (Iane 24), respectively. The 
addition of antibodies against SP1 and SP3 to the reaction is seen in lanes 17, 
18, 25, and 26. Competition studies are shown in the remaining lanes, where a 
mutated unlabeled fragment was added to the reaction. The mutated fragments 
correspond to oligo 3 with its first SP1 site mutated (Ianes 19 and 27), its second 
SP1 site mutated (Ianes 20 and 28), and with both its SP1 sites mutated. 
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Figure 8. Immunolocalization of SP1 and SP3 in the Caput and Cauda 
Epididymidis. 
Light micrographs of SP1 (A-C) and SP3 (D-F) in the caput (A, B, D, E) and 
cauda (C, F) epididymidis. A and D) The negative controls (5-fold excess 
blocking peptide was added during the primary antibody incubation). Nuclear 
immunostaining of principal cells is depicted by a thick arrow, the lack of staining 
of clear cells by an arrow head, and the checkerboard-like pattern of staining 
displayed by some principal cells with a thin arrow. E, epithelium; L, lumen; IT, 
intertubular space; S, sperm; P, principal cells; n, principal cell nucleus. Bar = 
1/lm. 
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Figure 9. Schematic of the 5' Upstream Region of 5a-Reductase Type 2. 
This scheme incorporates the results obtained from sequential deletion analysis, 
primer extension, RACE, and EMSA. The rectangle at the top corresponds to the 
cloned 5' upstream sequence of the gene with the size of the different luciferase 
constructs relative to the ATG start codon at the bottom (and italicized) and 
relative to the transcriptional start site at the top. The shaded boxes indicate 
regions identified by sequential deletion as having repressor, enhancer, and 
minimal promoter activities. The gene sequence is shown from position -118 to 
+97, where a CAT AAA box, a CAA T box, and the ATG start site are in bold and 
underlined. A number of SP1 sites (including two consensus GC-boxes) are also 
in bold and the two SP1 binding sites shown to bind SP1 (and SP3 to a smaller 
extent) are depicted with an oval shaded region. 
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CONNECTING TEXT 
Transcription is controlled in part by transcription factors, which bind to 
regulatory regions of the target gene. In the previous chapter, this aspect of gene 
regulation was investigated for srd5aR2 in the rat epididymis. Given that the 
framework necessary for identifying the transcription factors interacting with the 
gene was not in place, the 2.2 kb 5' upstream region of the gene was first cloned, 
the promoter and regulatory sequences were mapped, and the transcriptional 
start site was identified. The 5' upstream of the gene was then analyzed for 
potential transcription factor binding sites, and transcription factors interacting 
with the proximal promoter region of srd5aR2 in the rat caput epididymidis and 
PC-1 cells were determined. SP1 and to a smaller extent SP3, were found to 
interact with the srd5aR2 gene and although ubiquitous, they were predominantly 
expressed in principal cells and followed distinct distribution patterns in the rat 
epididymis. 
A second level of transcriptional control is provided by the accessibility of 
transcription factors to their target genes within a highly ordered chromatin 
structure. Epigenetic changes, including DNA methylation can modulate the ease 
or probability with which transcription factors engage the regulatory regions of 
genes, and may therefore act to set thresholds that transcription factors must 
exceed to activate gene expression. This second level of regulation is 
investigated for the srd5aR2 gene and contrasted to that of srd5aR1 in the next 
chapter. In particular, the DNA methylation status of the 2.2 kb 5' upstream 
region of the two isozymes as weil as of individual sites in their respective CpG 
island and proximal promoter will be investigated in tissues where the isozymes 
are differentially expressed. These studies will help determine the role of DNA 
methylation in the tissue-specifie expression of srd5aR1 and srd5aR2. 
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CHAPTER3 
Tissue-Specifie Differences in the Methylation Status of Specifie 
Sites in the 5' Upstream Region of Steroid 5a-Reduclase Type 1 
and Type 2 
Shayesta Seenundun 1 and Bernard Robaire 1.2* 
Departments of Pharmacology & Therapeutics 1 and of Obstetrics & Gynecology2, 
McGiII University, 3655 Promenade Sir William Osier, Montreal, H3G 1 Y6, 
Quebec, Canada. 
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1. Abstract 
Steroid 5a-reductase type 1 (srd5aR1) and type 2 (srd5aR2) catalyze the 
reduction of testosterone into the more pote nt androgen, dihydrotestosterone. 
These isozymes have similar gene structures, but they are products of separate 
genes and exhibit different tissue distribution profiles; srd5aR1 is more broadly 
distributed while srd5aR2 is predominantly expressed in male sex accessory 
tissues. To establish the role of DNA methylation in the tissue-specifie expression 
of srd5aR1 and srd5aR2, cytosine and adenine methylation in the 5' upstream 
region of the isozymes were examined in the caput epididymidis, heart, liver, and 
ventral prostate. Real-time RT -PCR confirmed the expression of the isozymes in 
these tissues; srd5aR1 was highly expressedin the liver, and srd5aR2 was most 
abundant in the caput epididymidis and ventral prostate. The 5' upstream region 
of both genes was found to be predominantly cytosine methylated by Southem 
blot analysis. Quantitative analysis of DNA methylation by PCR identified regions 
along the 5' upstream sequence of both genes that were differentially methylated. 
While the se preliminary studies found no direct correlation between DNA 
methylation and gene expression, the srd5aR1 gene displayed tissue-specifie 
differences in adenine methylation at a GA TC site, upstream of the gene's CpG 
island. Significant differences in cytosine methylation were also identified 
between the caput epididymidis and liver in the promoter regionof the srd5aR2 
gene. This study provides an initial analysis of DNA methylation in the 5' 
upstream region of srd5aR1 and srd5aR2, and will help define the role of DNA 
methylation in regulating the tissue-specifie expression of srd5aR1 and srd5aR2. 
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2. Introduction 
Steroid 5a-reductase catalyzes the irreversible reduction of a variety of 
steroids containing a 3-keto 114•5 double bond. In particular, this enzyme converts 
testosterone into the more potent androgen, dihydrotestosterone (DHT), which 
plays a central role in the development of the male external genitalia and prostate 
and in virilization during puberty (1-3). DHT is also critical for androgen action in 
many androgen-dependent tissues (4) and may play a role in several endocrine 
disorders such as benign prostatic hyperplasia, prostate cancer, alopecia, acne, 
and hirsutism (5-10). 
5a-Reductase is a membrane-bound, NADPH-dependent enzyme that is 
named type 1 (srd5a1, srd5aR1) and type 2 (srd5a2, srd5aR2) according to the 
order in which they were discovered (11-14). While these two isozymes share 
similar gene structures and substrate preferences, they are products of separate 
genes and present distinct biochemical and pharmacological properties (reviewed 
in (6)). They also exhibit different expression patterns; type 1 mRNA is broadly 
distributed (6, 13), and it is found in ail tissues possessing 5a-reductase activity 
(15), while type 2 mRNA is predominantly found in male sex accessory tissues 
such as the prostate, epididymis, and seminal vesicles (6, 13). The mRNA 
expression of the two isozymes has been weil established, but the molecular 
mechanisms responsible for their differential expression have not. 
Gene expression is dependent in part on the accessibility of transcription 
factors to their binding sites, that is in turn modulated by local epigenetic 
modifications such as DNA methylation (16). DNA methylation can also regulate 
the expression of genes by recruiting methyl-CpG-binding proteins (MBPs) (17), 
which interact with transcriptional co-repressors to silence transcription and to 
modify the surrounding chromatin (18-21). DNA is methylated in eukaryotes at 
the fifth carbon of the cytosine ring and is associated with chromatin compaction. 
genomic imprinting of specifie genes, transcriptional repression of the inactive X 
chromosome in mammalian females, and chromosomal stabilization (22-24). It is 
also involved in the cell- and tissue-specifie expression of a growing number of 
genes (25-30). 
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The DNA methylation status of the rat 5a-reductase type 1 and type 2 
genes were investigated by Southem blots using the cDNA of each gene as 
probes (31). The 5a-reductase type 2 gene was less methylated at the cytosine 
position in the testis and epididymis compared to the liver, a tissue where it is not 
expressed. This gene was also more methylated in reproductive tissues at the 
adenine position; methylation at this position has been shown to increase the 
transcriptional activation of many plant promoters in vitro (32-35). No change in 
methylation was observed for the type 1 isozyme in the tissues studied (31). 
Extensive cytosine methylation was also observed in exon 4 of srd5aR2 in the 
lymphocytes of 5a-reductase deficient patients; this Ïlicrease in methylation was· 
associated with higher rates of mutation in this exon (36). While these findings 
suggest a role for DNA methylation in the regulation of 5a-reductase type 2 gene 
expression, the methylation status of the promoter region was not investigated. 
Analysis of the 5' upstream region of both the rat 5a-reductase type 1 and 
type 2 genes have revealed a CpG island; these islands are characterized by a "-
high proportion of CpG dinucleotides, and their methylation status is inversely 
correlated to gene expression (37,38). To define the role of DNA methylation in 
the regulation of the tissue-specifie expression pattern of the rat 5a-reductase 
type 1 and type 2 genes, the methylation status of their 2.2-kb 5' upstream region 
was investigated in tissues where the isozymes are differentially expressed. 
Quantitative real-time reverse transcriptase polymerase chain reaction (RT -PCR) 
were first done to confirm the differential mRNA expression levels reported for the 
two isozymes in the caput epididymidis, heart, liver, and ventral prostate. 
Southern blot analysis was then used to examine the methylation pattern of the 5' 
. upstream region in these tissues. The methylation state of individual sites 
encompassing the CpG island and gene promoter were also evaluated using 
quantitative analysis of DNA methylation by real-time PCR (qAMP) in the sa me 
tissues. These results uncovered regions that were differentially methylated along 
of the 5' upstream sequence of the srd5aR1 and srd5aR2 genes. While no direct 
correlation could be made between transcription level and DNA methylation for a 
given tissue in these studies, tissue-specifie differences in adenine methylation 
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these studies, tissue-specific differences in adenine methylation were found for 
the srd5aR1 gene, and significant differences in cytosine methylation were 
identified between the caput epididymidis and liver for the srd5aR2 gene. 
3. Materials and methods 
3.1. Animais 
Sprague-Dawley (SD) rats (42 days old; Charles River Laboratories, Inc., 
St. Constant, QC) were killed by decapitation, and their tissues were collected 
and immediately frozen in liquid nitrogen. Ali tissues were stored at -80°C until 
use for RNA and genomic DNA extraction. Ali animal studies were conducted in 
accordance with the principals and procedures outlined in A Guide to the Care 
and Use of Experimental Animais prepared by the Canadian Council on Animal 
Care (McGiII protocol #206). 
3.2. RNA and Genomic DNA Extraction 
RNA and genomic DNA were extracted from caput epididymidis, ventral 
prostate, liver, and heart using the RNeasy Midi kit (Qiagen Inc., Mississauga, 
ON) and the Wizard Genomic DNA Purification kit (Promega Corporation, 
Madison, WI), respectively, according to the corresponding manufacturer's 
instructions. Nucleic acid concentration was determined by reading the optical 
density at 260 nm (DU? spectrophotometer, Beckman, Montreal, QC), and its 
quality was assess by running 1 I-Ig of sample on a 1 % agarose gel. 
3.3. Quantitative Real-Time Reverse Transcriptase- Polymerase Chain 
Reaction (qRT-PCR) 
The expression of 5a-reductase type 1 and type 2 was quantified by real-
time qRT-PCR in caput epididymidis, ventral prostate, liver, and heart of 42 days 
old SD rats. The genes were normalized against the housekeeping gene 188 
RNA (Rn18s). Ali the primers described in this chapter were designed by Primer3 
software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_ www.cgi) with the 
exception of 18S RNA (39) and synthesized by Alpha DNA (Montreal, QC). 
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Total RNA was reverse-transcribed and amplified with the QuantiTect 
SYBR Green RT-PCR Kit (Qiagen Inc.) according to the manufacturer's 
recommendations in the LightCycler System (Roche Diagnostics, Laval, QC, 
Canada). Briefly, each qRT-PCR reaction contained 10 ng of RNA, 0.5 lJM of 
gene-specifie primers (Table 1),10 lJl of the 2X QuantiTect SYBR green RT-PCR 
master mix, and 0.2 !JI of the QuantiTect RT mix. The cycling parameters were as 
follows: reverse transcription for 20 min at 50°C, initial denaturation/enzyme 
activation for 15 min at 95°C, and 50 cycles of denaturation at 94°C for 15 s, 
annealing at 55°C for 30 s, and elongation at 72°C for 30 s. Melting curve 
analyses were dcme following each PCR to determine the output and detection 
quality (Le., formation of primer-dimers). For each analysis, gene expression was 
quantified relative to a standard curve prepared from 6 seriai dilutions of a 
standard containing equal amounts of RNA from liver and caput epididymidis. 
Each standard and RNA sample were measured in duplicate. One-way ANOVA 
followed by Bonferroni post hoc test was used to analyze significant differences 
(P < 0.05) in the steady-state expression of the genes in the tissues assayed. 
3.4. Southern Blot Analysis 
3.4.1. Methylation-Sensitive Restriction Enzyme Digestions 
Genomic DNA (n = 3) was digested with 10 units/lJg of the following 
enzymes: Hpall, Mspl, Mbol, and Sau3AI (ail enzymes were purchased from New 
England Biolabs, Ipswich, MA) for 3 h using the buffers described by the supplier. 
The samples were then ethanol precipitated and resuspended in nuclease-free 
water. DNA concentration was re-assessed to ensure equal loading in each weil. 
3.4.2. Southern Blots 
Digested genomic DNA (7.5 !Jg) were loaded onto a 1% agarose gel and 
electrophoresed at low voltage « 1 volt/cm) overnight. The following day, the gel 
was soaked in 0.25 M HCI for 10 min to depurinate the DNA. The genomic DNA 
was then transferred for 24 h to a Zeta-Probe genomic tested blotting membrane 
(Bio-Rad Laboratories, Mississauga, ON) in 0.4 M NaOH through DNA capillary 
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transfer. After transfer, the membrane was soaked in 2x SSC, air dried, and 
thoroughly dried at 80°C for 30 min. The membrane was prehybridized and 
hybridized at 55°C in a 20 mM sodium phosphate pH 7.2, 9% SOS solution, and 
washed according to the manufacturer's specifications. It was then exposed to 
film (Hyperfilm ECL; Amersham Biosciences UK, Buckinghamshire, UK) for 2-4 
days at room temperature with no intensifier screen. 
3.4.3. Probe Preparation for Southern Blots by Radioactive PCR 
The 2.2 kilobase (kb) 5' upstream region of srd5aR1 was generated by 
PCR using rat liver genomic ONA and the following gene specifie primers: 
forward 5' GGATTTAGTCCACCCAAGCA 3' and reverse 5' 
AGCTGAGGTCGAGCAGTGT A 3', and cloned into the TOPO TA cloning kit 
(Invitrogen Corporation, Burlington, ON). This plasmid was then used as a 
template to amplify the 5' upstream region of the type 1 gene by radioactive PCR 
using the same gene specifie primers. The 2.2 kb 5' upstream region of srd5aR2 
was amplified from the -2.2KbATG pGL3Basic vector described in chapter 2 
using the primers specified in the chapter. 
The radioactive probes corresponding to the 5' upstream region of 
srd5aR 1 and srd5aR2 were prepared using Platinum Pfx ONA polymerase 
(Invitrogen Corporation) according to the manufacturer's protoco!. Each reaction 
consisted of 25 ng of template ONA, 0.3 !-lM gene-specifie primers, 1 X Pfx 
amplification buffer, 1X PCRx enhancer solution, 1.5 mM magnesium sulfate, 0.3 
mM dATP, 0.3 mM dGTP, 0.3 mM dTTP, 200 uCi [a-32P]dCTP (GE Healthcare, 
Chicago, IL), and 1.25 units Platinum Pfx ONA polymerase. The cycling 
conditions consisted of an initial denaturation/enzyme activation at 94°C for 30 s, 
20 cycles of denaturation at 94°C for 30 s, annealing at 56°C for 1 min, and 
elongation at 68°C for 3 min, and an additional elongation step at 68°C for 10 
min. Unincorporated labeled nucleotides were removed with Microspin G-50 
columns (Amersham Biosciences UK), and the probe was subsequently 
denatured in boiling water for 5 min and immediately cooled on ice. 
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Approximately 45 million counts per min (cpm) of the probe were added to each 
membrane. 
3.5. Quantitative Analysis of DNA Methylation by Real-Time RT - PCR 
(qAMP) 
The qAMP assay was do ne as described by Oakes et al. (40) with the 
exception that the methylation-dependent enzyme McrBC was not used due to 
the lack of appropriate restriction sites in the regions of interest. Briefly, genomic 
DNA (n = 5) was homogenized and sheared by repeatedly passing the sample 
through a 26% gauge needle attached to a 1 ml syringe. It was then equally 
distributed into 5 tubes (2 I-Ig of genomic DNA per tube) and digested in a volume 
of 50 1-11 for 4 h with 25 units of the methylation-sensitive restriction enzymes 
Hhal, Hpall, or Mbol, or no enzyme (sham digest) according to the 
manufacturer's instructions. After digestion, each sample was diluted 8-fold in 
nuclease free water and incubated at 65° for 30 min to inactivate the enzyme. 
For each isozyme, primers were designed by Primer3 software according 
to the suggestions in the QuantiTect SYBR Green PCR kit Handbook (Qiagen 
Inc;) to flank the regions of interest and a control region (Table 2). Each region 
was 100 to 200 basepairs (bp) in length; the regions of interest spanned one or 
more unique restriction enzyme site, while the control region was devoid of any of 
the restriction enzymes used. 
Quantitative real-time PCR was done using the QuantiTect SYBR Green 
PCR Kit (Qiagen Inc.) according to the manufacturer's suggestions in the 
LightCycler System. Two microliters of digested genomic DNA were amplified in 
a total volume of 251-11. The control region was first amplified from each digested 
sample of the genomic DNA set to ensure that the templates were of equal 
concentration and that non-specific cleavage of the DNA sample had not 
occurred. A maximum variability in mean template cycle threshold (Ct) values of 
+/-0.5 cycles was accepted. Regions of interest were then amplified and their Ct 
values determined (Lightcycler software version 3). Changes in the Ct values 
(~Ct) of the digested samples were expressed relative to the sham digested 
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template within a genomic DNA set. Each PCR reaction was done in triplicate, 
and each sam pie from the same set was amplified in the same PCR run to 
decrease variability. The percent methylation for a given site was calculated 
using the formula % methylation =100(e-O·7(ACt) as described in (40). Ilthe Hhal, 
Hpall, or Mbol restriction site is methylated, these methylation-sensitive enzymes 
will be unable to cleave the genomic DNA at their appropriate recognition sites, 
and the L\Ctwill be zero with a corresponding percent methylation of 100%. 
Similarly, unmethylated restriction enzyme recognition sites will be cleaved by the 
corresponding restriction enzyme, the extent of which will be reflected by the 
change in the cycle threshold value and percent methylation. 
Statistical analyses were done by one-way ANOVA followed by Bonferroni 
post hoc test to analyze significant differences (P < 0.05) in the percent 
methylation of individual sites in the tissues assayed. 
4. Results 
4.1. Expression of Srd5aR1 and Srd5aR2 in Selected Tissues of 42 Days Old 
SDRats 
Srd5aR1 and srd5aR2 mRNA expression was examined in the caput 
epididymidis, heart, liver, and ventral prostate of 42 days old SD rats (Fig. 1). 
This age was selected because of the absence of spermatozoa in the epididymal 
lumen (41) and the high level of srd5aR2 mRNA expression in the caput 
epididymidis (42). Srd5aR1 was expressed at very high levels in the Iiver (relative 
intensity of 8.7), its expression in the other tissues, however, was significantly 
lower (Fig. 1A). Srd5aR2 mRNA expression, on the other hand, was most 
abundant in the caput epididymidis (relative intensity of 3.0), followed by the 
ventral prostate (relative intensity of 0.3); it was only slightly expressed in the Iiver 
and heart (Fig. 1 B). 
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4.2. Southern Blot Analysis of the 5' Upstream Region of the Srd5aR1 and 
Srd5aR2 Genes 
The overall pattern of DNA methylation was investigated in the 5' 
upstream region of the srd5aR1 and srd5aR2 genes by Southern blots. The high 
GC content of these regions precluded the use of the random primer labeling 
method for the generation of probes. Alternatively, radioactive PCR was done 
using a highly processive DNA polymerase and a buffer solution that facilitates 
the amplification of GC-rich sequences to produce longer probes. This adaptation 
to the standard protocol along with the optimization of prehybridization and 
hybridization conditions produced bands in ail four tissues for genomic DNA 
digested with Hpall, Mspl, Mbol, and Sau3A1. The pattern generated with the 
cytosine methylation sensitive and non-sensitive isochizomers Hpall and Mspl, 
respectively, indicated that the upstream region of both genes was predominantly 
methylated (Fig. 2A). The pattern produced using adenine methylation sensitive 
and non-sensitive isochizomers Mbol and Sau3A1, respectively, were essentially 
identical suggesting that adenine bases in the GA TC sequences were not 
methylated in the upstream region of both genes (Fig. 28). No tissue-specifie 
difference was apparent for any given enzyme, presumably due to the faintness 
of the band and the high lane background, which appear to be an innate function 
of the region. Sharp, distinct bands were visible when srd5aR1 and srd5aR2 
cDNA were used as probes (data not shown). Consequently, another method 
was used to investigate selective restriction enzyme recognition sites in the 5' 
upstream region of the srd5aR1 and srd5aR2 genes. 
4.3. The 5' Upstream Region of Srd5aR1 15 Differentially Methylated and a 
GATe Site Expresses Tissue-Specifie Differences 
The DNA methylation status of specifie restriction enzyme recognition sites 
along the 2.2 kb 5' upstream region of the srd5aR1 gene was investigated by 
qAMP in various tissues (Fig. 3). This quantitative assay infers the methylation 
profile of individual methylation-sensitive restriction sites based on differences in 
cycle threshold value from the sham digested sample. Primer pairs were 
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cycle threshold value from the sham digested sample. Primer pairs were 
designed to amplify regions of interest within the 5' upstream region of srd5aR1 
that contain unique restriction enzyme recognition sites (Fig. 3). A CpG island 
identified by http://cpgislands.usc.edu/ is also depicted in figure 3; it is 59.4% GC-
rich, has an observed to expected CpG ratio of 0.674, and spans most of the 5' 
upstream region of the gene. 
The methylation status of specifie restriction enzyme recognition sites in 
the srd5aR 1 gene was determined in the caput epididymidis, heart, liver, and 
ventral prostate (Fig. 4). An area of the srd5aR1 gene with no restriction site for 
Hhal, Hpall, or Mbol was used as a control to ensure homogeneity in DNA 
concentration (Fig. 4A); the ~Ct value for each enzyme was close to zero and 
their percent methylation around 100% in ail the tissues assayed, indicating 
similar genomic DNA concentrations between the samples and a lack of non-
specifie cleavage. The site most upstream to the transcriptional site start that was 
investigated was for Mbol; this site is outside of the gene's CpG island and was 
most methylated in the liver (83.6%), was less than 60% methylated in the heart 
and ventral prostate, and was least methylated in the caput epididymidis (36.4%) 
(Fig. 48). Further downstream of the srd5aR1 gene sequence, in the CpG island, 
a region encompassing unique recognition sites for the three restriction enzymes 
was explored. The methylation status at these sites in the caput epididymidis, 
heart, and ventral prostate was close to 10% and was considered essentially 
unmethylated (Fig. 4C). Higher percentages of methylation were seen in the liver, 
but these values were very variable especiallY with respect to the Hhal site. Hhal 
and Hpall sites found proximal to the transcriptional and translational start sites of 
srd5aR1 were also examined. These two sites were completely methylated 
(>80%) in the four tissues assayed with ACt values of less than 0.5 (Fig. 4D). 
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4.4. The 5' Upstream Region of Srd5aR2 Is Differentially Methylated and 
Significant Differences Are Seen between the Caput Epididymidis and Liver 
Similar to the srd5aR1 gene, a CpG island was found in the 5' upstream 
region of srd5aR2 (Fig. 5); this island is 62.4% GC-rich, has an observed to 
expected CpG ratio of 0.651, and spans 524 bp (http://cpgislands.usc.edu/). The 
regions of interest amplified within the 5' upstream region of the gene and the 
restriction enzyme recognition sites that were assayed for their methylation status 
are also depicted in figure 5. 
A control region with no recognition site for the restriction enzymes used 
was first evaluated by qAMP to confirm homogeneous genomic ONA samples 
between the caput epididymidis, heart, liver, and ventral prostate (Fig. 6A). 
Subsequently, 100 to 200 bp regions of the 5' upstream region of srd5aR2 gene 
were examined to determine the methylation status at different restriction enzyme 
recognition sites. The first methylation-sensitive restriction enzyme site found in 
this sequence was for Mbol; this site was methylated to the same extent in the 
caput epididymidis, heart, and ventral prostate (Iess than 11%) but was almost 
two-fold more methylated in the liver (Fig. 68). The methylation profile of this 
Mbol site was also very variable in the liver compared to the other tissues. The 
next methylation-sensitive restriction site in the 5' upstream region of srd5aR2 
belonged to Hhal; it was found to be over 75% methylated in ail four tissues with 
a ôCt value of less than 0.55 (Fig. 6C). A considerable decrease in ONA 
methylation was observed further downstream of the gene at the Hhal and Hpall 
recognition sites in the caput epididymidis, heart, and ventral prostate; these sites 
were less than 20% methylated in these tissues (Fig. 60). In the liver, the 
decrease in methylation was less prevalent and was approximately 27%. The 
methylation status of the Mbol recognition site, which is in close proximity to the 
Hhal and Hpall sites, was very similar ta the first Mbol site assayed for this gene 
(Fig. 60). The methylation-sensitive restriction enzyme recognition site most 
proximal to the transcriptional start site in the 5' direction belonged to Hhal; this 
site was less th an 7% methylated in ail four tissues, and despite these low 
methylation levels, significant differences were seen between the caput 
148 
epididymidis and liver (Fig. 6E). Recognition sites for Hpall, Hhal, and Mbol in 
srd5aR2's CpG island were also evaluated for their methylation status (Fig. 6F). 
Significant differences were found at both the Hpall and Hhal sites between the 
caput region of the epididymis «10% methylation) and the liver (25 to 30% 
methylation). While the methylation levels at these two sites in the ventral 
prostate and heart were closer to those of the caput epididymidis, they were not 
significantly different from the liver. No significant difference was found at the 
Mbol recognition site in the tissues assayed; similar to the other Mbol sites 
examined, the methylation levels at this site were less than 20% and the greatest 
difference was seen between the caput epididymidis and liver (Fig. 6F). 
5. Discussion 
This study constitutes a preliminary characterization of the DNA 
methylation status of the 5' upstream region of the srd5aR1 and srd5aR2 genes 
in tissues where the isozymes are differentially expressed. The ove ra Il cytosine 
methylation status in the CCGG sequence was evaluated in the 2.2 kb upstream 
region of each isozyme and was found to be predominantly methylated, while 
adenine methylation.at the GATC sequence was not apparent by Southern blots 
for either gene. A more in-depth analysis of the 5' upstream region of srd5aR1 
revealed very low levels of cytosine methylation in the gene's CpG island, 
upstream of the transcriptional and translational start sites, but essentially 
complete methylation in the region encompassing these two start sites, which are 
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also part of the CpG island. Levels of adenine methylation were also variable 
from one region of the srd5aR1 gene sequence to the next and even between 
tissues for a particular GA TC site. In contrast, cytosine methylation in the 5' 
upstream region of srd5aR2 decreased as the Hpall and Hhal sites assayed 
approached the transcriptional start site, and adenine methylation was similar 
throughout the 2.2 kb region of the gene. Tissue-specifie differences in DNA 
methylation were also observed in different parts of srd5aR2's 5' upstream region 
and were most pronounced between the caput epididymidis and liver. 
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No direct relationship was found between cytosine methylation and low 
gene expression in a tissue for any of the regions examined in the upstream 
region of srd5aR1 and srd5aR2. Instead, methylation patterns were found to vary 
from one region of the 5' upstream sequence of the isozymes to another but were 
consistent within the same region. The methylation state of CpG dinucleotides in 
a particular region was accurately reflected by digestion with Hhal and Hpall. For 
the srd5aR2 gene, there was a decrease in percent methylation as the sites 
assayed approached the gene promoter. The restriction enzyme recognition site 
closest to the transcription start site was for Hhal, and it was the site that was 
least methylated « 7%) in ail tissues. It was also in this region that enhancer 
elements were identified in chapter 2 of this thesis by transient transfection 
experiments; repressor elements were found just upstream of the enhancer 
elements, and no regulatory element was identified upstream of 485 bp from the 
translational start site (chapter 2) or encompassing the methylation-sensitive 
restriction sites assayed in Fig. 68-6D. These results suggest that the region 
most important in the transcriptional regulation of srd5aR2 is unmethylated 
irrespective of gene expression levels and that the latter is most likely regulated 
by the transcriptional activators and repressors recruited to the region. The 
functional significance of the higher percent methylation of CpG sites observed in 
the liver compared to the caput epididymidis in this region and further 
downstream of the translational start site, is unknown. While it may partially 
account for the lack of srd5aR2 expression in the liver, the difference in percent 
methylation required to bring about changes in gene expression remains to be 
established. Methylation differences of 4% and 20% as depicted in Fig. 6E and 
Fig. 6F, respectively, may or may not be sufficient to functionally affect gene 
expression in the tissue. In addition, the heart, which has a relative srd5aR2 
mRNA expression very similar to the liver, is methylated to the same extent as 
the caput epididymidis suggesting that if DNA methylation is involved in 
repressing srd5aR2 expression in the liver, it does so by a mechanism not 
applicable to ail tissues. In fact, in most of the sites assayed in the 5' upstream 
region of both srd5aR1 and srd5aR2, the methylation levels in the liver have a 
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tendency to differ from the other three tissues examined. Some of these sites 
also tend to be more variable in the liver compared to the caput epididymidis, 
heart, and ventral prostate. They may be a reflection of the complexity of the 
tissue, the lack of strict maintenance of methylation within some cell populations, 
and the observation that methylation at some CpG sites is more faithfully 
maintained than at others (43). 
While CpG dinucleotides have a tendency towards decreased methylation 
as they approach the srd5aR2 promoter, they become more methylated in the 
proximity of the srd5aR 1 promoter. The high methylation levels of CpG 
dinucleotides within the 50 bases upstream of the transcriptional start site explain 
the very low levels of srd5aR1 mRNA in the caput epididymidis, heart, and 
ventral prostate; methylation of CpG dinucleotides within CpG islands of gene 
promoters is usually associated with transcriptional repression of the gene (44). 
Methylation of CpG dinucleotides in the liver, however, was very surprising 
considering that this tissue expresses the highest levels of srd5aR1. The reason 
for this disparity is unknown; perhaps the expression of srd5aR1 in the liver is 
regulated using a mechanism that is specific to the tissue. This mechanism does 
not involve the use of an alternate transcriptional start site specific for the tissue 
as the gene's start site was itself investigated in the rat liver (45). It may instead 
be related to the bidirectionality of the srd5aR1 promoter, which possesses an 
asymmetric activity favoring the expression of the housekeeping 
methyltransferase NSun2 (45). Perhaps after having transcribed high levels of 
srd5aR1 in this tissue, CpG sites in the proximity of the gene promoter are 
methylated to allow transcription in the negative orientation. The relative 
expression of Nsun2 in the liver and the methylation status of ail CpG 
dinucleotides in the proximal promoter region along with their role in regulating 
gene expression would need to be evaluated to help explain the methylated gene 
promoter of a highly transcribed gene. 
Adenine methylation was found to be more prevalent in the srd5aR2 gene 
of the rat testis and epididymis using the gene's cDNA as a probe (31). This 
study, however, found no difference in adenine methylation levels at the GATC 
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sites investigated in the 2.2 kb 5' upstream region of srd5aR2 in any of the 
tissues examined, including the caput epididymidis and ventral prostate, where 
srd5aR2 was expressed. While this lack of difference at these particular GATC 
sites between tissues does not preclude a role for this epigenetic modification at 
other GATC sites along the 2.2 kb 5' upstream region of the gene, it is unlikely as 
the sites examined spanned the entire sequence (1.8 kb upstream of the 
transcriptional start site, just upstream of the CpG island, and in the proximity of 
the start codon). In contrast, tissue-specific differences in methylation at the 
adenine position were observed for the srd5aR1 gene at the GATC site upstream 
of the CpG island; this site was over 80% methylated in the liver, which is 
consistent with the transcriptional activity of the gene in this tissue. Adenine 
methylation was less than 60% in the heart and ventral prostate and less than 
half in the cap ut epididymis, suggesting that adenine methylation at this particular 
site may be important in regulating gene expression. While addition of methylated 
adenine was shown to affect binding of a nuclear factor to its responsive element 
(46), decrease the activity of adenoviral E1A promoter (47), and generate a 
steroid hormone response element (48) in mammalian cells, the role of adenine 
methylation and its presence in mammals have yet to be elucidated. Traditionally, 
adenine methylation was assumed not to occur in higher eukaryotes, possibly 
because of the high levels of cytosine methylation in the genome and the higher 
detection limits of experiments carried out over 30 years ago (49). Although direct 
evidence for this epigenetic modification by mass spectrometry is stilliacking, 
restriction enzymes sensitive to adenine methylation have indicated the presence 
of methylated adenine bases in the mouse Myo-D1 (50) and rat srd5aR2 (31) 
genes. Preliminary evidence is provided in this study for a role of adenine 
methylation in the rat srd5aR1 gene. 
This study is the first characterization of DNA methylation at selected 
cytosine and adenine bases in the 2.2 kb 5' upstream region of the steroid 50-
reductase type 1 and type 2 genes. The presence of a CpG island in the 5' 
upstream region of both genes and the extension of this GC-rich sequence into 
the gene promoter and first exon suggested that these two genes may be 
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regulated by DNA methylation (44). While Southem blot analysis was unable to 
provide an overall assessment of adenine and cytosine methylation in the 5' 
upstream region of the genes, qAMP has revealed potential CpG sites that are 
differentially regulated in the srd5aR2 gene between the caput epididymidis and 
liver. This assay has also identified a potential role for adenine methylation in the 
regulation of the srd5aR1 gene. To complete this study, bisulfite sequencing of 
the 5' upstream region of both genes would need to be done to confirm the qAMP 
results and survey additional CpG sites that are not recognized by methylation 
sensitive restriction enzymes. Differences in the methylation status between 
tissues at these CpG may reveal the presence of important regulatory elements. 
ln addition, a smaller portion of the 5' upstream region of srd5aR1 , upstream of 
the CpG island, may be examined by Southem blots to confirm the differences in 
adenine methylation observed in the various tissues. Finally, the functional 
significance of a differentially niethylated base would need to be elucidated by 
transiently transfecting differentially methylated constructs into various cell lines. 
Thus, these studies, once completed, will help define the role of DNA methylation 
in the regulation of tissue-specifie expression of srd5aR1 and srd5aR2. They will 
also provide further insights into the role of adenine methylation in mammals. 
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Table 1. Real-time PCR ~rimers 
Gene Accession Forward Primer Reverse Primer 
Gene Name 
Symbol Number Sequence (5' ---+3') Sequence (5' ---+3') 
18S RNA a Rn18s X01117 AAACGGCTACCA CCTCCAATGGAT 
CATCCAGG CCTCGTTA 
steroid 5a-reductase 1 Srd5a1 NM_017070 GAGCCAGTTTGC CAGGATGTGGTC 
GGTTTATG TGAGTGGA 
steroid 5a-reductase 2 Srd5a2 NM_022711 AGAGAAGGGGAG TAGTTGGTTGGC 
GAGGATTG TGGTTGGT 
a Reference (39) 
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Table 2. gAMP real-time PCR primers 
Forward Primer Reverse Primer 
Regions of Interest 
Sequence (5' --+3') Sequence (5' --+3') 
Steroid 5a-reductase 1 gene 
srd5aR1 control ACCCCAAAACAAATGA GCTGACTTACAAACTAT 
CAGG GGCTCAA 
srd5aR 1 GATC CAGTAATCGAAAGAGG AAGGTGTGTGCAATCT 
AGAGTTGT GTGG 
srd5aR 1 CpG island ACGCCACTAAGCGTGA CTTTGCTCGAAACCGA 
ATCT ATCT 
srd5aR1 pre-exon GAGGGTATCGTCTGGT GGACACGAAGGCCATG 
GGTG AA 
Steroid 5a-reductase 2 gene 
srd5aR2 control CACTTTGTTTCCTGGG GCCCTTTCTTCCTGAT 
GATG GTTG 
srd5aR2 first GATC upstream CGTTGAGTTGGTTTGG TCTCTCTGGGTTTTGG 
AGTG TTGG 
srd5aR2 first GCGC upstream TGGAAGGCATCTAAGT GGAAATAGCCAGGTGT 
GGTG TGGT 
srd5aR2 upstream1 CGGTTCAGAGAGCATC GAAAAGTTTGTCCCTC 
AACA AGATGC 
srd5aR21ast GCGC upstream GCAGCCCAAAGAACCA CCCTCCCCACTCTCTC 
GA CA 
srd5aR2 CpG island GCAGCTACCAACTGTG ACTCCCGACGACACAC 
AC CA TC TC 
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Figure 1. Relative rnRNA Expression of Steroid 5a-Reductase Type 1 (A) 
and Type 2 (6) in the Caput Epididyrnidis, Heart, Liver, and Ventral Prostate 
of 42 Days Old Sprague-Dawley (SD) Rats. 
Real-time RT -PCR was used to determine the expression levels of 5a-reductase 
type 1 (A) and 5a-reductase type 2 (B) in selected tissues in 42 days old SD rats. 
The vertical axis corresponds to mRNA expression normalized to 18S RNA, and 
the horizontal axis to the different tissues examined. Values are expressed as 
mean ± SEM (3 replicates/tissue, assayed in duplicate). Significant differences 
(P<O.05) in expression levels between tissues are depicted by *. 
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Figure 2. Analysis of the 5' Upstream Region of Steroid 5a-Reductase Type 
1 (A) and Type 2 (B) by Southern Blot Analysis 
Representative Southern blots are depicted for the 5' upstream region of srd5aR1 
(A) and srd5aR2 (B) digested with enzymes sensitive and non-sensitive to 
cytosine methylation Hpall and Mspl, respectively (Ieft panel), and with enzymes 
sensitive and non-sensitive to adenine methylation Mbol and Sau3A1, 
respectively (right panel). Briefly, genomic DNA from the caput epididymidis, 
heart, liver, and ventral prostate was digested with these enzymes and hybridized 
with a labeled probe encompassing 2.1 kilobases (kb) of the 5' upstream region 
of srd5aR1 (A) and 2.2 kb of the 5' upstream region of srd5aR2 (B). 
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Figure 3. The 2.1 Kb 5' Upstream Region of Steroid 5a-Reductase Type 1. 
The sequence of the cloned 5' upstream region of the rat steroid 5a-reductase 
type 1 gene is depicted in this figure along with the CpG island (highlighted in 
grey), transcriptional start site (bold, enlarged font A), and translational start site 
(bold, enlarged font ATG). Ali Mbol (GATC), Hhal (GCGC), and Hpall (CCGG) 
sites are in bold. Regions investigated by quantitative analysis of DNA 
methylation by real-time PCR (qAMP) are within parentheses [] and underlined, 
and the methylation-sensitive restriction sites examined within these regions are 
enlarged and in bold. 
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Figure 4. The Methylation Status of Selected Methylation-Sensitive 
Restriction Sites within the 2.1 Kb 5' Upstream Region of Steroid 50-
Reductase Type 1. 
Quantitative analysis of DNA methylation by real-time PCR (qAMP) was done to 
determine the methylation status of various methylation-sensitive restriction sites 
(Hhal, Hpall, and Mbol) within the 5' upstream region of the steroid 5a-reductase 
type 1 gene. The diagram above each graph indicates the position of the region 
and of the methylation-sensitive restriction sites (arrow) investigated relative to 
the CpG island (grey rectangle) and to the transcriptional and translational start 
sites of the gene. A) Control region with no restriction site for Hhal, Hpall, and 
Mbol; B) Recognition site for Mbol upstream of the gene's CpG island; C) 
Recognition sites for Hhal, Hpall, and Mbol in the gene's CpG island; 0) 
Recognition sites for Hhal and Hpall in the gene's CpG island, less than 50 bp 
upstream of the transcriptional start site. The vertical axis corresponds to the 
percent methylation and the horizontal axis to genomic DNA of caput 
epididymidis, heart, liver, and ventral prostate that has been digested with 
different methylation-sensitive restriction enzymes. 
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Figure 5. The 2.2 Kb 5' Upstream Region of Steroid 5a-Reductase Type 2. 
The gene sequence of the cloned 5' upstream region of rat steroid 5a-reductase 
type 2 is shown in this figure. The position of the CpG island (highlighted in grey), 
transcriptional start site (bold, enlarged font G), and translational start site (bold, 
enlarged font ATG) are also depicted. Ali Mbol (GATC), Hhal (GCGC), and Hpall 
(CCGG) sites in this sequence are in bold. Regions investigated by quantitative 
analysis of DNA methylation by real-time PCR (qAMP) are underlined and within 
parentheses [ ], and the methylation-sensitive restriction sites examined within 
these regions are enlarged and in bold. 
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CIAAGIAAICAAAGGIGAGACAAGAAGAIGGGAGACIGAAGGGAACAGCCCGGIGGGAAGAGAIGIGGGGIAAGAA 
GGTCAGGCCAGAAGGGAGACGGGGAGGAAGGCGACAGGGAGGAAGAAAAAGCAGClAAGAAGAGCTGGIGCAGAG 
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Figure 6. The Methylation Status of Selected Methylation-Sensitive 
Restriction Sites within the 2.2 Kb 5' Upstream Region of 5a-Reductase 
Type 2. 
Quantitative analysis of DNA methylation by real-time PCR (qAMP) was done to 
determine the methylation status of various methylation-sensitive restriction sites 
(Hhal, Hpall, and Mbol) within the 5' upstream region of the steroid 5a-reductase 
type 2 gene. The diagram found above each graph indicates the position of the 
region and of the methylation-sensitive restriction sites (arrow) assayed relative 
to the gene's CpG island (grey rectangle), transcriptional start site, and start 
codon. A) Control region with no restriction site for Hhal, Hpall, and Mbol; B) First 
Mbol site in the gene's 2.2 kb 5' upstream region; C) First Hhal site in the 2.2 kb 
5' upstream region; C) Recognition sites for Hhal, Hpall, and Mbol upstream of 
the gene's CpG island; D) Methylation-sensitive restriction enzyme recognition 
site most proximal to the gene's transcriptional start site; E) Recognition sites for 
Hhal, Hpall, and Mbol in the gene's CpG island, downstream of the start codon. 
The vertical axis corresponds to the percent methylation and the horizontal axis 
to genomic DNA of caput epididymidis, heart, liver, and ventral prostate that has 
been digested with different methylation-sensitive restriction enzymes. 
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CONNECTING TEXT 
ln the previous chapter, the role of DNA methylation was examined in the 
tissue-specifie expression of srd5aR1 and srd5aR2. For both genes, the overall 
methylation pattern of their 5' upstream region as weil as particular methylation-
sensitive restriction sites along this region were investigated in four tissues with 
very different expression levels of the isozymes. Different portions of the 5' 
upstream region of each gene exhibited distinct levels of methylation. While 
methylation of a particular site could not be directly correlated with the 
transcriptional activity of srd5aR1 and srd5aR2 in the tissues assayed, tissue-
specifie variations in adenine methylation were identified at a particular site, 
upstream of the srd5aR1 's CpG island. Significant differences were also found 
between liver and caput epididymidis in the proximal srd5aR2 promoter region. 
The studies presented in this chapter indicate a possible role for DNA methylation 
in the regulation of both isozymes through mechanisms that may be unique to 
each one. This chapter concludes the first part of this thesis, which examined the 
transcriptional and epigenetic regulation of srd5aR2 in the rat epididymis. 
The next chapter of this thesis will focus on another key aspect of 
androgen action in the epididymis. It will investigate the consequences of 
androgen manipulations on principal cells, the major cell type of the tissue and 
the one most sensitive to androgen levels. Androgen-regulated genes will be 
identified and their response to androgen deprivation and DHT supplementation 
following androgen deprivation will be characterized for the proximal caput 
epididymidis PC-1 ceilline. The effects of androgens on the mediators of 
androgen action (AR, srd5aR1, and srd5aR2) will also be determined. 
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CHAPTER4 
Time Dependent Rescue of Gene Expression by Androgens in 
the Mouse Proximal Caput Epididymidis (PC-1) Cell Line after 
Androgen Withdrawal 
Shayesta Seenundun 1 and Bernard Robaire 1.2* 
Departments of Pharmacology & Therapeutics 1 and of Obstetrics & Gynecology2, 
McGiII University, 3655 Promenade Sir William Osier, Montreal, H3G 1Y6, 
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literature at the time of publication. 
Published as: Seenundun S, Robaire B. (2007) Time-dependent rescue of gene 
expression by androgens in the mouse proximal caput epididymidis-1 ceilline 
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1. Abstract 
Androgens are the primary regulators of epididymal structure and 
functions. Principal cells are the major cell type of the tissue and are particularly 
sensitive to androgen removal. To distinguish the direct etfects of androgens on 
this cell type, DNA microarrays were used to identify androgen-regulated genes 
in the mouse proximal caput epididymidis (PC-1) cellline. PC-1 cells display 
tissue- and caput-specific gene expression. We examined changes in gene 
expression occurring 2, 4, and 6 days following androgen deprivation and 2 days 
following androgen supplementation after being deprived of androgen for 2 or 4 
days. Changes in transcript levels were investigated for mediators of androgen 
action; selected genes were analyzed by real-time RT-PCR, and changes at the 
protein levels were examined. Four distinct patterns of gene expression were 
activated following androgen withdrawal; the vast majority of genes displayed an 
early or late transient increase in expression levels. A ditferential ability of rescue 
was seen among androgen-regulated genes depending on time of androgen 
supplementation. Many of the genes that were rescued at 4 days were 
functionally linked by direct interactions and converged on IGF1. The ability for 
rescue after 4 days of androgen deprivation was severely compromised in many 
genes belonging to specific functional gene families (cell adhesion, cell growth, 
apoptosis, and cell cycle) and may be mediated in part by changes in AR 
coregulator expression. These results provide novel insights into the mechanisms 
of androgen regulation in epididymal principal cells. 
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2. Introduction 
The epididymis, a single highly convoluted tubule linking the efferent ducts 
of the testis to the vas deferens, is the site of sperm maturation and storage (1). 
The epididymal epithelium is composed of four major cell types (principal, basal, 
c1ear, and halo cells); it is morphologically and functionally divided into four 
regions: initial segment, caput, corpus and cauda epididymidis (2, 3). The 
functions of the epithelium in absorption, secretion, synthesis, and metabolism 
create a highly specialized luminal environment for the acquisition of fertilizing 
ability and motility of spermatozoa (4, 5). While many factors, including 
estrogens, retinoids, growth factors and unidentified testicular factors are 
involved in the regulation of epididymal functions (6-9), androgens are recognized 
as the primary regulators of epididymal structure and functions (10, 11). Several 
in vitro and in vivo studies have shown that the main androgen acting in this 
tissue is dihydrotestosterone (DHT), the more pote nt 5a reduced metabolite of 
testosterone (12-17). 
Various approaches have been used to study the role of androgens in the 
epididymis. Androgen deprivation has been achieved through bilateral 
orchidectomy (14, 18, 19), treatment with androgen antagonists (20, 21), or 
treatment with GnRH antagonists (22, 23). Orchidectomy is the most commonly 
used method to study the changes in epididymal morphology and gene 
expression associated with androgen deprivation; it is often followed by androgen 
replacement to ascertain the ability of testosterone to reverse these changes (14, 
24). Recently, rats were treated with inhibitors of 5a-reductases, the enzymes 
responsible for the reduction of testosterone to DHT, to differentiate the effects of 
DHT from those of testosterone on gene expression in the different epididymal 
regions (25). The major drawback with ail these in vivo approaches is the 
difficulties in interpreting the results because of the different cell types present in 
the tissue; consequently, it has been impossible to distinguish the direct effects of 
androgens on a particular cell type. 
Several pure epididymal rodent celllines have been developed recently 
(26-30). The mouse PC-1 cellline is the first immortalized epithelial cellline of the 
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epididymis that has been shown to display tissue- and caput-specific gene 
expression (26). It was derived from primary cultures of epididymal cells from 
transgenic mice harboring a temperature-sensitive simian virus 40 large T-antigen 
(26). It is a pure population of caput principal cells, the most numerous cell type 
of the epididymis, and the cell of central importance in the development of the 
tissue. Although insertion of the large T -antigen is random and may compromise 
gene expression, data obtained to date indicate that the characteristics of 
principal cells are maintained in vitro (26, 31). The use of PC-1 cells in promoter 
studies and in characterizing the regulation of epididymal genes has proved 
invaluable (26, 31). 
Androgen dependence has not been explored previously in an epididymal 
ceilline. Since the caput segment is the region most active in terms of secretory 
activities of the mammalian epididymis, and principal cells are the most sensitive 
epididymal cell type to the removal of circulating androgens (2, 32, 33), the PC-1 
ceilline is particularly relevant in studying the effects of androgen withdrawal and 
supplementation on gene expression. Principal cells are very active in protein 
synthesis and in the absorption and secretion of fluid and small molecules (2); 
these functions, as weil as cell morphology, are compromised in an androgen-
deprived state (32). Understanding how androgens regulate gene expression in 
these cells is therefore crucial to elucidate the underlying causes of its impaired 
structure and functions in the absence of androgen. DNA microarrays were used 
to gain a comprehensive insight into gene expression in PC-1 cells following 
androgen withdrawal and supplementation. 
This study uncovers differential responses of genes to androgen 
withdrawal in principal cells; while the expression levels of a number of genes 
decrease and increase, the majority of genes show an early or late transient 
increase in expression. Interestingly, many of these genes lose the ability to 
respond to androgens after prolonged deprivation. 
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3. Materials and Methods 
3.1. Cell Culture, Androgen Withdrawal, and Supplementation Experiments 
For routine maintenance, the mouse proximal caput epididymidis PC-1 cell 
line (kindly provided by Dr. M.-C. Orgebin-Crist) was grown in Iscove Modified 
Dulbecco medium supplemented with 10% fetal bovine serum (FBS), 1 mM 
sodium pyruvate, 0.1 mM nonessential amine acids, 4 mM glutamine, penicillin-
streptomycin (25000 units penicillin G sodium, 25 mg streptomycin sulfate), and 
1 nM 5a-DHT. Ali cell culture products were purchased from Invitrogen-Life 
Technologies, Carlsbad, CA. PC-1 cells were cultured at 33°C with 5% CO2 . Two 
passages before the experimental procedure, FBS was replaced by charcoal-
filtered FBS (Cocalico Biologicals, Inc., Reamstown, PA) and the latter was 
subsequently used for the duration of the experiment. 
The cells were plated (2X105 cells/well) onto 6 weil plates in the media 
described above and subjected to different androgenic conditions. The control 
group was grown in 1 nM 5a-DHT for 2 days, the androgen withdrawal groups 
were grown without androgen for 2 days, 4 days, or 6 days and the androgen 
supplementation groups were grown without androgen for 2 days or 4 days, after 
which 1 nM 5a-DHT was added to the media for 2 days. Media were changed 
every 24 hours. 
3.2. Cell Viability Assay 
The effects of treatment on cell viability were assessed using the CeliTiter-
Glo luminescent cell viability assay (Promega, Madison, Wis.) according to the 
manufacturer's instructions. Briefly, cells from each experimental group as weil as 
from cells grown in 1 nM 5a-DHT for 4 days or 6 days (3 flasks/group) were 
collected, counted and an aliquot of each was seeded onto 96-well plates. The 
CeliTiter-Glo reagent was added to the aliquots, and the wells were read twice 
and compared to a standard curve using a microplate luminometer (LUMlstar 
Galaxy; BMG Lab Technologies, Durham, NC). 
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3.3. RNA Extraction and DNase Treatment 
Each experimental group was comprised of 5 replicates with 2 wells per 
replicate to ensure sufficient RNA. The cells were washed twice with phosphate-
buffered saline (PBS) pH 7.4 buffer and Iysed directly in the wells as described 
for the RNeasy Mini kit (Qiagen Inc., Mississauga, ON, Canada). Total RNA was 
then extracted from each sample and subjected to DNase1 treatment using the 
kit. RNA concentrations were determined by absorbance at 260 nm (DU7 
spectrophotometer, Beckman, Montreal, QC, Canada), and RNA quality was 
verified by conventional gel electrophoresis. 
3.4. cDNA Arrays and Hybridization 
RNA samples were used to probe cDNA arrays (Atlas Mouse 1.2K array, 
BD Biosciences, San Jose, CA, USA) consisting of 1,176 genes, according to the 
manufacturer's instructions. Five arrays per experimental group (control; 2 days, 
4 days, or 6 days androgen withdrawal; and 2 days of DHT supplementation 
following 2 days or 4 days androgen withdrawal) were probed and are referred to 
as replicates. The arrays were exposed to Phosphorlmager plates (Molecular 
Dynamics, Inc., Sunnyvale, CA) overnight at room temperature before scanning 
with a Phosphorlmager (Storm, Molecular Dynamics, Inc). Analysis of array 
images with Atlas Image (version 2.0, BD Biosciences) was done to quantify the 
intensity of each cDNA spot, which reflects the relative abundance of that RNA in 
the sample. The raw data for each gene (intensity of each spot on the array 
minus the background) were imported into GeneSpring 7.2 (Silicon Genetics, 
Redwood, CA) for further analysis. For each replicate array in a given 
experimental group, a gene was considered detected if its intensity was above 
threshold, with threshold defined as two times the average background of that 
individual array. A gene was considered expressed if it was detected in at least 
three replicates in that group. 
To minimize experimental variation and allow for comparison of different 
experimental groups, data were normalized with the standard experiment-to-
experiment normalization. More precisely, the median level of expression on 
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each array was defined as 1, and the expression of each gene on that array was 
then normalized relative to 1. This value was averaged for ail replicates in a 
group to generate what is referred to as the relative intensity for a given gene. 
We focused on changes in gene expression of at least 1.5-fold (i.e. 33% 
decrease or 50% increase). Statistical analyses were do ne using Wilcoxon-
Mann-Whitney test (significance level set at P<0.05) with the GeneSpring 
software. Genes changing by 1.5-fold that were not statistically significant were 
excluded from the analysis. For k-means cluster analysis, gene-to-gene 
normalization was do ne in addition to experiment-to-experiment normalization as 
described previously (19). This method normalizes the signal strength of each 
gene relative to the median of ail measurements taken for that gene in each 
experiment, defined as 1. It was used to visualize the expression profile of ail 
genes on the same vertical axis. Clustering was do ne on genes statistically 
changing by 1.5-fold at any time following androgen withdrawal. 
PathwayStudio 4.0 (Ariadne Genomics, Rockville, MD) and ResNet-3.0 
database were used to visualize direct relationships between genes differentially 
affected by androgen supplementation after 2 days or 4 days of androgen 
deprivation. Objects were limited to proteins and pathways. Controls were limited 
to binding, expression, protein modification, and regulation. Four starting groups 
were used: genes rescued at 4 days, genes not rescued at 4 days, genes 
rescued at 6 days, and genes not rescued at 6 days (Supplemental Tables 4A 
and 4B). Mediators of androgen action (androgen receptor and the two steroid 5 
alpha-reductases) were also included in these groups. Rescued genes are 
defined as genes for which the expression levels change significantly by at least 
1.5-fold from control after androgen deprivation but return to controllevels 
following DHT supplementation. 
Ali gene names and symbols were retrieved in April 2006 fram the Mouse 
Genome Database (MGD), Mouse Genome Informatics Web Site, The Jackson 
Laboratory, Bar Harbor, Maine (http://www.informatics.jax.org). Genes were 
classified by their primary function (or one of their primary functions) obtained 
from Mouse Genome Informatics and PathwayStudio 4.0. 
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3.5. Quantitative Real-Time Reverse-Transcriptase (RT)- PCR 
The expression of selected genes (Table 1) was quantified by real-time 
RT-PCR using the LightCycier System (Roche Diagnostics, Laval, QC, Canada). 
The genes were normalized against peptidylprolyl isomerase A (Ppia, cyclophilin 
A), a housekeeping gene with mRNA levels that do not change with androgen 
manipulation (34). Gene specific primer sequences (Table 1) were obtained from 
the literature (35-37) or designed using Primer3 software 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3.cgi/) with the exception of steroid 
5 alpha-reductase 2 (Srd5a2) (catalog number QT00128464, QuantiTect Primer 
Assays, Qiagen). The primers were synthesized by the Sheldon Biotechnology 
Centre, McGili University (Montreal, QC, Canada). Total RNA isolated for the 
microarray analysis was reversed-transcribed and amplified with the QuantiTect 
SYBR green RT-PCR kit (Qiagen) according to the manufacturer's protocol. 
Briefly, each qRT-PCR reaction contained 5 ng of RNA (50 ng RNA for Srd5a2), 
0.5 JlM of gene-specific primers, 10 JlI of the 2X QuantiTect SYBR green RT-PCR 
master mix, and 0.2 JlI of the QuantiTect RT mix. The cycling conditions were as 
follows: reverse transcription for 20 min at 50°C, followed by initial 
denaturation/enzyme activation for 15 min at 95°C and by 50 cycles of 
denaturation at 94°C for 15 s, annealing at 55-60°C for 30 s, and elongation at 
72°C for 30 s. The production of a single product was confirmed by melting curve 
analysis (temperature elevation from 65°C to 95°C at 0.2°C/s) and conventional 
gel electrophoresis. For each analysis, a standard curve was prepared from 6 
seriai dilutions of a standard containing equal amounts of RNA from the different 
experimental groups. Ali standards and samples were assayed in duplicate. One-
way ANOVA followed by Dunnett post hoc test was used to detect significant 
effects of androgen withdrawal on gene expression. The significant effects of 
androgen supplementation were determined using paired t-tests. The level of 
significance was taken as P < 0.05. 
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3.6. Western Blot Analysis 
Cytoplasmic extracts (n = 3) were collected for each experimental group 
using the cellular fractionation kit (catalog number: 40010) from Active Motif 
(Carlsbad, CA) according to the manufacturer's protocol. The protein 
concentration was determined by the Bradford method using the Bio-Rad Protein 
Assay (Bio-Rad Laboratories, Hercules, CA). 
The samples, 20 J.lg protein per lane, were boiled with loading buffer for 5 
min and fractionated by SDS-PAGE using 12.5% acrylamide gels (38). 
Prestained precision standards (Bio-Rad Laboratories) were used as molecular 
weight markers. The fractionated proteins were transferred to a Hybond-P 
membrane (Amersham Biosciences UK, Buckinghamshire, UK). The blots were 
blocked with 5% nonfat dried milk in TBS-T (137 mM NaC1, 20 mM Tris [pH 7.4], 
0.1 % Tween® 20) at room temperature for 1 h and then incubated overnight at 
4 oC with a primary goat polyclonal antibody to secreted phosphoprotein 1 (SPP1) 
(1 :500, sc-10593: Santa Cruz Biotechnology). Antibody binding was detected by 
incubating with donkey anti-goat IgG conjugated to horseradish peroxidase 
(HRP) (1 :10000, sc-2056: Santa Cruz Biotechnology). Cyclophilin A (1 :2500, 
#07-313: Upstate, Lake Placid, NY) was used as a loading control according to 
the manufacturer's instructions and was detected using a secondary, donkey 
anti-rabbit IgG-HRP antibody (1 :5000, NA934V: Amersham Biosciences UK). 
Western blots were visualized with the Enhanced Chemiluminescence 
Plus Kit (Amersham Biosciences UK) and Hyperfilm ECL (Amersham 
Biosciences UK). Quantification of Western blot data was done by line 
densitometry using a Chemilmager 4000 imaging system (Alpha Innotech, San 
Leandro, CA) with AlphaEase v5.5 software (Alpha Innotech Corp., San Leandro, 
CA). SPP1 levels for each experimental group were expressed relative to the 
corresponding cyclophilin A value. 
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4. Results 
4.1. Cell Viability Was Not Affected By Treatment 
The effects of androgen withdrawal and supplementation on cell viability 
were determined using ATP bioluminescence as a marker for metabolically active 
cells (39). Under control conditions, the average doubling time of PC-1 cells was 
approximately 36 hours after the initial 2 days in culture (Fig. 1). There was no 
change in the doubling time or number of viable cells when they were deprived of 
androgen for 2, 4, or 6 days when compared to cells grown in the presence of 
DHT for the same duration (Fig. 1). Similarly, supplementing the media with 
androgen following 2 or 4 days of androgen deprivation had no effect on cell 
viability (Fig. 1). Significant cell death was observed in over 40% of cells 8 days 
after androgen withdrawal (data not shown). 
4.2. Genes Expressed by PC·1 Cells under Control Conditions 
Under control conditions, 101 of the 167 genes detected were highly 
expressed with a relative intensity of 5 or higher (Table 2). Some of these genes 
are associated with housekeeping functions (ubiquitin 8 (Ubb), beta-actin (Actb) , 
glyceraldehyde-3-phosphate dehydrogenase (Gapdh), and ribosomal proteins 
S29 (Rps29) and SA (Rpsa)), while others are involved in DNA replication and 
cell cycle regulation (minichromosome maintenance deficient 2 mitotin (Mcm2), 
minichromosome maintenance deficient 5 (Mcm5), recombination activating gene 
1 activating protein 1 (Rag1ap1), proliferation-associated 2G4 (Pa2g4), cell 
division cycle 20 homolog (Cdc20), CDC28 protein kinase regulatory subunit 2 
(Cks2), and the cyclins A2 (Ccna2), 81 (Ccnb1), and 82(Ccnb2)). Genes 
involved in the oxidative stress response (glutathione S-transferase mu 2 
(Gstm2), glutathione S-transferase pi 1 (Gstp1), and glutathione reductase 1 
(Gsr» as weil as genes associated with calcium signalling (8100 calcium binding 
protein A10 (S100a10), RAD21 homolog (Rad21), calmodulin 1 (Calm1), stromal 
cell derived factor 4 (Sdf4) , secreted phosphoprotein 1 (Spp1), and calcitonin 
gene-related peptide-receptor component protein (Crcp)) were also highly 
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expressed. Genes that were detected but were expressed at an intensity of less 
than 5 are listed in Supplemental table 1 . 
Some of the highly expressed genes in the ceilline (Table 2) had been 
shown previously to be expressed in the epididymis (19, 40, 41). These include a 
number of transcriptional activators and repressors (Y box protein 1 (Ybx1), 
myelocytomatosis oncogene (Myc) , paired box gene 8 (Pax8) , v-rel 
reticuloendotheliosis viral oncogene homolog A (Re/a, Rel-A), and 3-
phosphoglycerate dehydrogenase (Phgdh)), some cytoskeletal proteins (vimentin 
(Vim), cofilin 1 (Cf/1), and villin 2 (Vi/2)), and genes involved in metabolism 
(glucose phosphate isomerase 1 (GpI), tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein eta polypeptide (Ywhah), and ornithine 
decarboxylase (Odc1)). Heat shock protein 90kDa alpha class B member 1 
(Hsp90ab1, HSP-90~), a chaperone associated with steroid receptor function, 
was also one of three HSPs that were very highly expressed in the ceilline. While 
most of these transcripts were identified by Northern blot and/or array analysis in 
the epididymis, only a few have been immunolocalized specifically to the principal 
cells of the caput epididymidis in various species. Protective protein for beta-
galactosidase (Ppgb, cathepsin A) (42), solute carrier family 9 member 1 (S/c9a1, 
sodium/hydrogen exchanger 1) (43) and vimentin (44) are examples of such 
genes. 
Transcripts for the kinase expressed in non-metastatic cells 2 (Nme2, 
nucleoside diphosphate kinase B) were found at very high levels in the cell line. 
This enzyme catalyzes the last step in the production of nucleoside 
triphosphates, and its high levels could most certainly provide principal cells with 
sufficient energy to carry out the extensive protein synthesis and secretion 
observed in the caput epididymidis. Transcript levels for the immunoglobulin 
protein basigin (8sg) were also abundant in PC-1 cells, suggesting a role for this 
protein in the proximal region of the epididymis. This glycoprotein is essential in 
the later stages of spermatogenesis and undergoes molecular processing and 
deglycosylation at the surface of spermatozoa during its transit in the epididymis 
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(45), but its expression in the epididymal epithelium has not been elucidated 
previously. 
4.3. Consequences of Androgen Withdrawal on Overall Gene Expression 
Androgen withdrawalled to important changes in gene expression. The 
lack of effect on cell viability for the 6-day study window indicates that the 
changes seen are the consequences of androgen deprivation and are not the 
result of cell death. Of the 167 genes detected in the PC-1 cells, 50 genes 
changed by at least 1.5-fold (increase or decrease) and 20 genes increased from 
undetected levels. There were 38 genes decreasing at any one time after 
androgen withdrawal and 33 genes increasing. HSP-90~ was the only transcript 
both increasing (at 2 days) and decreasing (at 6 days) by 1.5-fold during the 
course of the experiment. A list of genes significantly decreasing or increasing in 
expression by at least 1.5-fold from control is found in the supplemental tables 2A 
and 28, respectively. 
The number of genes increasing in expression 4 days following androgen 
deprivation was far greater than at the other two time points combined (Fig. 2), 
suggesting that removal of the inhibitory effects of androgens on gene expression 
occurred most dramatically at 4 days. The number of genes decreasing in 
expression, however, was most prominent at 6 days. There were 20 more genes 
decreasing at 6 days than at 4 days (Fig. 2), and ail the genes decreasing at 4 
days also decreased at 6 days with the exception of tubulin beta 4 (Tubb4). Thus, 
these data suggest that deprivation of the stimulatory effects of androgens on 
gene expression had the most consequences at 6 days. While there is a maximal 
effect at 4 days on the number of genes increasing, the number of genes 
decreasing displayed a graduai increase with time (Fig. 2). The few genes 
changing by at least 1.5-fold 2 days after the removal of androgens were not the 
same genes changing at 4 days and 6 days. These genes may be early 
responders of androgen withdrawal. 
K-means cluster analysis was do ne to visualize the different patterns in 
gene expression for genes changing by at least 1.5-fold following androgen 
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withdrawal (Fig. 3). These patterns were grouped into 4 distinct gene expression 
profiles: decreasing genes, early and late transiently increasing genes, and 
increasing genes. Nineteen percent of genes progressively decreased in gene 
expression during androgen withdrawal (profile 1). They were essentially 
regulators of apoptosis, cytoskeletal proteins, cell adhesion proteins, and a few 
cell cycle proteins. The removal of androgens led to the transient increase in 
expression levels of the majority of genes. This is consistent with a previous 
study that found transiently increasing genes to be most prominent in the caput 
region of the epididymis following çastration (19). These genes were further 
divided into two profiles based on time of increase. Thirty-three percent of the 
genes partitioned into profile 2, in which a transient increase occurred early at 2 
days. Most of these genes are involved in cell cycle regulation and transcription. 
Proteins involved in cell adhesion and cell proliferation/growth also belonged to 
this profile. Profile 3 consisted of 31 % of genes changing by at least 1.5-fold; their 
transient increase occurred late, between 2 days and 4 days. They regroup many 
intracellular enzymes, transcription factors, and ce Il signalling molecules. The 
early transient increase may be indicative of genes directly regulated by 
androgens, while the genes displaying a late transient increase may be indirectly 
regulated by androgens, through the intermediate of another gene or transcription 
factor. The remaining 17% of genes increased in gene expression levels (profile 
4); they displayed a sharp increase between 2 days and 4 days and their 
expression levels were maintained at 6 days. They are essentially proteins 
involved in cell adhesion, cell signalling, and transcription. While genes involved 
in transcription and cell adhesion were found in ail profiles, albeit at different 
proportions, genes with functions in cell structure, apoptosis, protein folding, and 
protein degradation were restricted to unique profiles. A list of the genes 
associated with each of these profiles is found in supplemental table 3. 
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4.4. DHT Supplementation Can Rescue Gene Expression after 2 Days of 
Androgen Deprivation 
To assess the ability of the cells to respond to androgens, PC-1 cells were 
supplemented with DHT for an additional 2 days after being deprived of DHT for 
2 days or 4 days. Figure 4 depicts the number of genes expressed at 4 days and 
6 days following the start of the experiment. Gene lists associated with each 
section of the pie chart for 4 days and 6 days are found in supplemental tables 
4A and 4B, respectively. The larger number of total genes expressed at 4 days 
was aUributed to the higher number of genes increasing from undetectable levels 
at this time point. At both 4 days and 6 days, about a quarter of the genes 
expressed were affected by androgen withdrawal. The expression of the majority 
of these genes increased at 4 days but decreased at 6 days. A significant effect 
of androgen supplementation was found in almost 60% of the genes increasing 
and decreasing in expression at 4 days, in contrast to the effects of DHT at 6 
days. At 6 days, only 33% of the genes increasing and less than 12% of the 
genes decreasing in expression had retained their ability to respond to DHT. 
Androgen supplementation was, in most instances, successful at returning gene 
expression levels to that of control (no significant difference between the two 
groups) with the exception of two genes. A partial rescue was observed with gap 
junction membrane channel protein beta 3 (Gjb3) and periostin (Postn) after 
giving back DHT 2 days or 4 days after androgen withdrawal, respectively. 
For many genes, the changes in gene expression levels following 
androgen withdrawal occurred in the same direction (increase or decrease) at 
both 4 days and 6 days. While some of these genes including, phosphoprotein 
enriched in astrocytes 15 (Pea15), Bcl2-like 1 (Bc/2/1), Phgdh, Ccnb1, and prion 
protein (Pmp) were unable to respond to androgen supplementation at either 
time point; ail decreasing genes and several of the increasing genes at 4 days 
only responded to androgens after having been deprived of androgens for 2 days 
but not after 4 days. Only one gene, periostin, was able to respond to androgen 
supplementation at both time points. Androgen supplementation had a most 
pronounced effect on gene expression after 2 days of androgen deprivation; 
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many of the genes responsive to androgens at that time point lost their ability to 
return their gene expression levels to that of control after 4 days. 
4.5. Effects of Androgen Supplementation on Related Genes at 4 Days and 
6 Days 
Known regulatory relationships between genes that were rescued after 
androgen supplementation at 4 days and 6 days and those that were not 
significantlyaffected by supplementation at the two time points were examined; 
mediators of androgen action were also included in the analysis (Fig. 5). A large 
number of genes rescued at 4 days were functionally linked using this analysis; 
they were found to directly influence the expression and/or the regulation of one 
another (Fig. SA). Sorne of the genes were also linked by protein binding. For 
example, RAD21 homolog and RAD50 homolog form a DNA repair complex that 
can possibly re-initiate collapsed replication forks during S phase (46). The 
transcription factors early growth response 1 (EGR1) and POU domain class 2 
transcription factor 1 (POU2F1, also known as OCT-1) can form complexes with 
each other and with the androgen receptor (AR) to regulate genes. While EGR1 
modulates cell growth, apoptosis, and differentiation, POU2F1 is involved in the 
regulation of a wide variety of genes and can interact positivelyor negatively with 
the AR, in a promoter-specific manner to enhance AR coactivator recruitment 
(47). Presumably, the rescue of Pou2f1 transcript levels at 4 days also allows the 
transcript levels of sorne androgen-regulated genes to return to control values at 
this time point. EGR1, POU2F1, and AR are alllinked to insulin-like growth factor 
1 (IGF1). In fact, most of these genes rescued at day 4 are regulated by IGF1. 
These include genes involved in cell adhesion (breast cancer anti-estrogen 
resistance 1 (BCAR1), amyloid beta A4 precursor protein (APP), SPP1, and 
integrin beta 1 (ITGB1», apoptosis (pleckstrin homology-like domain, family A, 
member 1 (PHLDA1), APP, SPP1, and EGR1), and cell growth (EGR1 and 
insulin-like growth factor binding protein 2 (IGFBP2)). These results suggest that 
androgen may directly regulate one or more genes in this pathway and through 
various direct interactions at the protein level, other genes are indirectly regulated 
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by androgens. Only one direct association was revealed among genes not 
rescued at day 4; proviral integration site 1 (PIM1) was found to influence the 
expression of BCL2L 1 (not shown). 
Among the six genes rescued at 6 days, YWHAH was found to positively 
influence the regulation of mitogen activated protein kinase 14 (MAPK14) which 
in turn positively influences both the expression and regulation of POSTN (data 
not shown). While the relationship between YWHAH and POSTN is positive in 
the rat pulmonary arterial smooth muscle cells (48), in epididymal principal cells 
their expression profiles suggest a negative relationship. Both Ywhah and 
Mapk14 are highly expressed under control conditions and their expression levels 
decrease, while that of Postn increases, following androgen deprivation. Many 
genes whose transcript levels were not affected by androgens at this time point 
are also related by various direct interactions (Fig. SB); a large number of them 
are involved in cell cycle regulation (CCNA2, CCNB1, cyclin D1 (CCND1), and 
cyclin E1 (CCNE1), CDC20, and budding uninhibited by benzimidazoles 1 
homolog beta (BUB1 B)). This functional association map includes four genes that 
were rescued at day 4 (Egr1, Spp1, Rad21, fibroblast growth factor receptor 1 
(Fgfr1)), of which FGFR1 directly influences the regulation of SPP1. It also 
highlights three AR coregulators (amino-terminal enhancer of split (AES), 
CCND1, and CCNE1) whose expression levels were not rescued at day 6, 
suggesting there is inadequate AR signalling at the promoter region of certain 
genes and consequently, the ability of these androgen-regulated genes to 
respond to androgen is compromised. 
4.6. Mediators of Androgen Action and Their Responses to Androgens 
Quantitative real-time RT -PCR was done to determine the effects of 
androgen withdrawal and supplementation on the transcript levels of Ar, Srd5a1, 
and Srd5a2. The Ar transcript was undetected in the arrays while the 5a-
reductases, the enzymes responsible for the reduction of testosterone to the 
more potent DHT, were not on the array. These genes displayed distinct patterns 
of expression (Fig. 6). There was a small, progressive increase in Ar mRNA 
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levels following androgen withdrawal. When DHT was added back to the media 
after 2 days of deprivation, Ar transcript levels decreased to that of control (P = 
0.01) (Fig. 6A). This rescue in expression levels observed after the addition of 
DHT was absent if the cells were deprived of androgen for an additional two days 
(Fig. 5A). The 5a-reductases responded differently to androgens. Srd5a1 mRNA 
levels decreased slightly following androgen removal and there was a partial 
return to controllevels when DHT was added after 2 days (P = 0.14) or 4 days (P 
= 0.05) of androgen deprivation (Fig. 68). In contrast, Srd5a2 mRNA levels 
showed a transient increase 2 days after androgen removal and decreased to 
undetectable levels for the duration of the treatment (Fig. 6C). Srd5a2 transcript 
levels were unexpectedly very low under control conditions, and the low levels 
were not found to be a consequence of the charcoal-filtered FPS (data not 
shown). 
4.7. Re/a, /gfbp2, Postn, and Spp1 Have Distinct Responses to Androgens 
Four genes with distinct responses to androgens were chosen for 
quantitative real-time RT-PCR (Fig. 7, panel 8) to confirm the expression data 
from the microarray study (Fig. 7, panel A). The expression profiles of the four 
genes were found to be practically identical with the two methods. Rela transcript 
levels were essentially unaffected by androgens. DHT supplementation after 2 
days of androgen deprivation led to a small increase in transcript levels, closer to 
the levels of control. The removal of androgens resulted in a decrease in Igfbp2 
transcripts between 2 days and 4 days and adding DHT had no effect on gene 
expression at 4 days or 6 days. While the role of androgens in regulating Rela 
and Igfbp2 expression was found to be minor, androgen withdrawal and 
supplementation had considerable consequences on Postn and Spp1 expression 
levels. Postn expression increased sharply from undetectable levels 4 days after 
androgen withdrawal followed by a smaller increase 2 days later. DHT 
supplementation after 2 days of deprivation successfully suppressed the increase 
in Postn transcripts, but after 4 days of deprivation led only to a slight decrease in 
transcript levels. Spp1 was a highly expressed gene under control conditions. 
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Androgen withdrawal resulted in a steep decline in Spp1 transcripts at 4 days, 
which levelled off at 6 days. DHT supplementation was able to prevent this 
decrease when added back after 2 days of withdrawal, but had no significant 
effect if it was added 4 days after the removal of androgens. Western blots were 
done to confirm if the changes observed at the mRNA level following androgen 
manipulations were also seen at the protein level. Similar to its mRNA levels, 
SPP1 protein levels decreased following androgen removal from the cell culture 
media (Fig. 8). The decrease at 2 days following androgen deprivation was more 
pronounced than that observed at the mRNA level and may be due to a higher 
proportion of protein that is secreted into the extracellular matrix. The decrease 
was also not as significant as that observed at 4 days and 6 days following the 
removal of androgens. The stability of the protein may account for this 
discrepancy. The decrease in expression levels was prevented when androgen 
was added back to the media after 2 days, but not after 4 days, of androgen 
deprivation (Fig. 8). 
Periostin and Spp1 are examples of genes for which DHT 
supplementation, if given early enough following androgen withdrawal, was able 
to at least partially restore gene expression levels to those of control. Igfbp2 
expression, on the other hand, was not restored at either 2 days or 4 days 
following androgen withdrawal despite being affected by the removal of 
androgens. It is possible that more than 2 days of supplementation would have 
been required to see a rescue Igfbp2, or that its expression is regulated by 
something other than or in addition to DHT. 
5. Discussion 
This study characterizes, for the first time, androgen dependence in an 
epididymal cell line. We have identified genes expressed under control conditions 
in the PC-1 ceilline and specifically localized many of the genes previously found 
to be expressed in the epididymis to the principal cells. Withdrawing androgens 
from these cells and then adding it back at different times had no effect on the 
viability of these cells but had selective effects on their gene expression. This 
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selectivity was manifested in terms of the differential response of genes to the 
removal of androgens (decreasing expression, increasing expression, and early 
and late transiently increasing expression). The ability of androgen 
supplementation to retum gene expression levels to that of control following 
androgen withdrawal for 4 days was severely compromised. 
The regulation of genes by androgens has been investigated in many 
studies, but their differential response to time of supplementation following 
androgen withdrawal has not. The loss in the ability of the majority of genes to 
restore gene expression levels to that of control after 4 days of androgen 
deprivation may be the consequence of inadequate AR function. AR coregulators 
are important components of AR signalling; for instance, type 1 coregulators 
facilitate ONA occupancy, chromatin remodelling, and the recruitment of general 
transcription factors associated with the RNA polymerase Il holocomplex (49). At 
4 days, we identified direct interactions between POU2F1 and the AR among the 
genes rescued with OHT supplementation, but at 6 days, the transcript levels of 
three AR coregulators were not rescued. Cyclin E1 is a strong co-activator of the 
AR and has been shown to increase the transactivation activity of the AR in the 
presence of OHT by binding to the COOH terminus portion of the receptor's AB 
domain (50). Cyclin 01, on the other hand, was found to inhibit ligand-dependent 
AR transactivation in the prostate; this function of cyclin 01 was independent of 
its role in cell cycle progression and is likely elicited through its ability to form a 
specific complex with AR (51). AES is another selective repressor of ligand-
dependent AR-mediated transcription but it specifically acts by targeting the basal 
transcription machinery (52). The inability of these AR coregulators to respond to 
OHT after 4 days of OHT deprivation presumably would have profound 
consequences at the promoter of many androgen-regulated genes. The 
implications may even be broader;following physiological conditions of temporary 
androgen suppression such as, hormonal contraception or the therapeutic 
adm.inistration of testosterone in aging men, the inability of AR coregulators to 
respond to androgens will affect the expression of many androgen-:regulated 
genes, thereby affecting many physiological processes. In the epididymis, three 
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members of the 160 kDa protein family were recently described (53); they recruit 
protein complexes containing histone acetyltransferases and histone 
methyltransferases to the target gene promoter. One of the members, 
p/CIP/RAC3/ACTRlAIB1/TRAM-1 (p/CIP), was immunolocalized mainly to the 
cytoplasm of epithelial cells in the caput epididymidis (53), but the consequences 
of prolonged androgen deprivation on its transcript levels or localization are 
unknown. 
Many of the genes rescued by DHT supplementation at 4 days were 
functionally linked by direct interactions, and ail but two of these genes (Rad21 
and Rad50) converged on IGF1. The role of this growth factor appears to be 
central as it can directly influence the regulation and expression of many genes 
rescued at this time point. IGF1 is involved in a variety of biological processes, 
some of which are illustrated by the genes it regulates, and it is an important 
element controlling tissue growth and differentiation (54). Igf1 transcripts increase 
from undetected levels in the ceilline with removal of androgen from the media, 
presumably leading to the induction of AR activation. IGF1 was shown to regulate 
AR-mediated transcription in the absence of, or at low levels of, ligand in the 
prostate by increasing cellular levels of beta catenin, an activator of the receptor 
(55). When androgen is added back to the media, IGF1 is presumably no longer 
needed and its levels decrease to below threshold, becoming undetected. While 
its specific role and localization within adult epithelial epididymal cells is 
unknown, IGF1 induced the maturation of epididymal principal cells in vitro (56) 
and was immunolocalized to the subapical and apical cytoplasmic compartments 
of principal cells in prepubescent rat caput epididymidis (57). Similarly, IGF1 
plays a crucial role in Leydig cell maturation in the testis and absence of this 
growth factor results in undifferentiated cells, altered expression of testosterone 
biosynthetic and metabolizing enzymes leading to decrease levels of androgens, 
and infertility (58, 59). The distal portions of the epididymis are also severely 
affected in IGF1 null mice (58). We hypothesize that during development and 
conditions of androgen deprivation, IGF1 expression serves to amplify AR 
signalling. 
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While many genes rescued at 4 days seem to converge to IGF1, it is 
particularly interesting that most of the directly related genes not rescued at 6 
days belong to the cell cycle pathway. Ali but cyclin 81 display an early transient 
increase in expression levels after the removal of androgens from the media. This 
increase in expression occurs at 2 days, but by 6 days transcript levels of these 
genes have decreased to more than 1.5-fold below controllevels, indicating that 
androgens inhibit cell cycle genes in principal cells under physiological 
conditions. In fact, the lack of effect of androgens on mitotic rate in the adult 
epididymis distinguishes it from other androgen-dependent tissues such as the 
prostate and seminal vesicles (60). The increase in gene expression is transient 
and, presumably, transcription factors and cell signalling molecules capable of 
inhibiting cell proliferation are upregulated before an increase in cell viability is 
observed when compared to control conditions. 
Many studies, including those using DNA microarrays, have explored 
androgen regulation in the epididymis. Androgen withdrawal and supplementation 
were examined in only one such study; this study compared the gene expression 
profiles of mice 9 days post-orchidectomy with those supplemented with oil or 
DHT for the last 2 days and identified androgen-regulated genes in the caput, 
corpus, and cauda epididymidis (61). Our study focussed on the early responses 
of a specific cell type of the epididymis to androgen deprivation and examined the 
time-dependence of rescue with DHT supplemention. Another gene expression 
study investigated changes in the different regions of the rat epididymis occurring 
at several time points within the first week after orchidectomy (19); this study 
profiled 474 stress-related genes and described four patterns of gene expression 
that were similar to the on es we identified by cluster analysis. The transient 
increase in gene expression levels observed in the different regions within the 
first week after orchidectomy was particularly prevalent in our study, with the 
majority of genes displaying an early or late transient increase in expression 
levels. While the aim of this study was to examine the effects of testicular factors 
and androgens on gene expression, our focus was directed to androgens and 
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their ability to rescue specifie genes in the most androgen sensitive epididymal 
cell type (32). 
Androgens regulate the expression of many genes and gene families in 
the epididymis, most likely through interactions with the androgen receptor 
present in the tissue. Previous studies have established that the androgen 
receptor itself is regulated by androgens. Both androgen-mediated up-regulation 
and down-regulation of Ar mRNA have been described in many cell lines and 
tissues (62-65). In the rat epididymis, Ar mRNA levels were increased almost 1.5-
fold with androgen withdrawal and decreased below controllevels after androgen 
stimulation (63). Similarly, we observed a small progressive increase in mRNA 
levels following the removal of androgens, but androgen supplementation was 
only successful at bringing the levels down to those of control after 2 days and 
not after 4 days of androgen deprivation. 
Other important mediators of androgen action are the steroid 5a-
reductases. Although both the type 1 and type 2 enzymes catalyze the same 
reaction, they differ with respect to their biochemical properties, their 
pharmacological characterization and their tissue distribution patterns (66-68). 
Their mRNA levels are also differentially regulated in the rat epididymis (69). 
Srd5a1 mRNA levels decreased in PC-1 cells following androgen removal. This 
decrease was not as significant as the one described for the rat epididymis 
following orchidectomy (70), but the time points examined were also earlier. 
Unlike for the majority of genes described in this study, androgen 
supplementation after either 2 or 4 days of androgen deprivation leads to an 
increase in Srd5a1 transcript levels. The ability to rescue gene expression levels 
to those of control was not compromised with time and was also observed in the 
rat caput epididymidis after testosterone-filled capsules were implanted 
subdermally immediately after orchidectomy (70). Steady state Srd5a2 mRNA 
expression in the PC-1 cells was remarkably low; it was almost 10-fold lower than 
that of Srd5a1. This was in sharp contrast to the high levels of Srd5a2 mRNA 
expressed in the proximal caput region of both the mouse and rat epididymides, 
where its expression levels were more th an 10-fold higher than the type 1 
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enzyme (69, 71). The low levels of Srd5a2 in the PC-1 ceilline may be due to its 
sensitivity to in vitro culture conditions or to the absence of one or many 
regulatory factors crucial at maintaining its high expression levels. Its expression 
levels in other caput epididymal cell lines would need to be investigated to 
ascertain if its low levels were specific to PC-1 cells or to ail epididymal ceillines. 
Srd5a2 mRNA decreased to undetectable levels 4 days following androgen 
deprivation and remained undetected for the duration of the treatment, 
suggesting that it is particularly sensitive to the androgen levels in culture media. 
Androgen manipulations led to small, non-significant changes in Rela and 
Igfbp2 transcript levels in the PC-1 ceilline. Rel-A is a ubiquitous member of the 
NF-KB family of transcription factors and is often found as a heterodimer with the 
p50 subunit (reviewed in (72)). Among its numerous functions, it has been 
described as both an activator and a repressor of the androgen receptor gene. 
Androgens, however, have not been reported to regulate the transcript levels of 
any of the NF-KB subunits, nor have they resulted in the activation and 
translocation of the complex to the nucleus. Although, our study supports the lack 
of effect on the transcript levels, the possibility does remain that Rel-A is 
regulated post-translationally by androgens. 
Igfbp2 belongs to the family of insulin-like growth factor binding proteins 
(IGFBPs) that modulate cellular growth and differentiation directly (73, 74) or 
through their interactions with insulin-like growth factors (75). It is the second 
most abundant IGFBP in the circulation and is found in a variety of mammalian 
fluids and tissues (reviewed in (76, 77)). The regulation of Igfbp2 expression and 
abundance is highly complex and influenced by multiple growth factors and 
hormones, including androgens (reviewed in (78)). While castration had no 
significant effect on Igfbp2 expression in a model of androgen-dependent 
neoplasia (79), it stimulated Igfbp2 production in both LNCaP cells (80) and in the 
rat (81). Androgens have also been shown to stimulate Igfbp2 production in the 
LNCaP prostate cancer cell line (82) and increase Igfbp2 mRNA and protein in 
human fetal osteoblastic cells (83). In the PC-1 cells, androgen withdrawalled to 
a non-significant decrease in Igfbp2 expression levels and androgen 
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supplementation after 2 or 4 days of deprivation had no effect on expression 
levels. Androgens appear to play a lesser role in regulating Igfbp2 expression in 
PC-1 cells compared to other tissues and cell lines; whether this also holds true 
for the epididymis still remains to be determined. 
Periostin and Spp1 are examples of two genes differentially regulated by 
androgen manipulations. Periostin, formerly known as osteoblast-specific factor 
2, is a cell-adhesion molecule that was first described in bone in the context of 
bone formation (84, 85). It has since been found to be expressed in a wide range 
of adult normal tissues, with negligible expression in the prostate and testis (86). 
Recently, mouse prostate stromal cells were found to express a number of 
osteogenic molecules, including periostin (87). This secreted protein binds 
members of the integrin family of receptors and is consequently involved in 
cytosolic signalling cascades mediating cell proliferation, cell survival and cell 
migration in addition to its role in cell adhesion (86, 88-90). It has also been 
demonstrated that stress responses can stimulate periostin transcription (91-93). 
Similarly, periostin mRNA levels increase from undetected levels following 
androgen withdrawal, and alleviation of this stressor after 2 days returns the 
expression levels to control. Its up-regulation may prevent stress-induced 
apoptosis in the ceilline by activating the AktlPKB signalling pathway, as 
described for colon cancer cells (88). Although the role of periostin in the 
epididymis remains to be elucidated, our studies establish, for the first time, the 
androgen dependence of this protein. 
Spp1, also known as osteopontin, is a cell surface protein with many 
isoforms and proposed functions (reviewed in (94, 95)) which can be regulated by 
many factors. Pou2f1, Igf1, Igfbp2, Gpi, and Fgfr1 have ail been identified 
through direct functional association studies as factors that can bind or influence 
the expression or regulation of Spp1. The role of these factors in ceU 
proliferation/growth, apoptosis, metabolism, development, and organogenesis 
provide testimony to the numerous functions of Spp1. In the rat epididymis, Spp1 
expression was found to be region- and cell-specific, with principal cells of the 
distal caput epididymidis exhibiting the highest expression levels (96). This 
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glycoprotein is proposed to be an important means by which the epididymis 
regulates calcium ions in the lumen to prevent minerai accumulation and eventual 
decrease in sperm fertilizing ability (96). Although no androgen-responsive 
elements have been identified (94), Spp1 was found to be regulated by 
androgens. This regulation was restricted to the principal cells of the epididymis 
(96). Consistent with castration studies, Spp1 expression in PC-1 cells decreased 
following the removal of androgens from the media. The effects on its protein 
levels have also been previously investigated in the rat proximal caput 
epididymidis after orchidectomy and testosterone supplementation (96); rescue 
was seen at ail the time points examined when testosterone was administered 
immediately after orchidectomy. 
We have characterized gene expression in a proximal caput epididymidis 
cell line under control conditions and following androgen manipulations. We have 
observed four distinct responses of genes to the removal of androgens and, for 
the first time, identified a differential rescue of gene expression levels in principal 
cells deprived of DHT for different lengths of time. This differential rescue is 
associated with particular gene families and is mediated in part by changes in AR 
coregulator expression following androgen manipulations. Our study presents a 
novel approach for understanding mechanisms of androgen regulation in the 
epididymis and provides an in-depth look into the regulation of gene expression 
in its most abundant and androgen-sensitive cell type. 
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Table 1. Real-time PCR I2rimers 
Gene Accession Forward Primer Reverse Primer 
Gene name 
Symbol Number Sequence (5'-3') Sequence (5'-3') 
ACACGCCATAATG ATTTGCCATGGACA 
peptidylprolyl isomerase A a Ppia NM_OO8907 
GCACTGG AGATGCC 
androgen receptor b 
GCCCCCATCCAAG GCTAGTCTCCTGCC 
Ar M37890 
ACCTATCG TCTGCTG 
ACCCTGCTGTTCA CAGTTTCCCCTGGT 
steroid 5 alpha-reductase 1 Srd5a1 NM_175283 
CCTTTGT TTTCTC 
steroid 5 alpha-reductase 2 Srd5a2 NM_053188 
v-rel reticuloendotheliosis GCGTACACATTCT GTTAATGCTCCTGC 
Rela M61909 
viral oncogene homolog A GGGGAGT GAAAGC 
insulin-like growth factor TGGAGGAGTTCCC CAGAAGCAAGGGAG 
Igfbp2 X81580 
binding protein 2 AGTTTTG GTTCAG 
CGAAGGGGACAG CAGGTCGGTGAAAG 
periostin Postn D13664 
TATCTCCA TGGTTT 
secreted phosphoprotein 1 c 
TCTGATGAGACCG AGGTCCTCATCTGT 
Spp1 X13986 
TCACTGC GGCATC 
a Reference (35) 
b Reference (36) 
c Reference (37) 
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Table 2. Genes expressed at an intensity ~ 5 in PC-1 cells under control 
conditions 
Genbank 
Common Gene Name a 
Gene Normalized 
Symbol b 
Accession 
Data 
Number 
Apoptosis-Related 
bcI2-antagonist/killer 1 Bak1 Y13231 5.46 
bcl2-associated athanogene 1 Bag1 U17162 13.97 
caspase 1 Casp1 L28095 10.72 
max binding protein Mnt Y07609 5.06 
pleckstrin homology-like domain, family A, member 1 Phlda1 U44088 23.57 
thymoma viral proto-oncogene 1 Akt1 M94335 15.39 
transformation related protein 53 TrpS3 K01700 11.33 
Binding Molecules 
basigin Bsg 000611 24.50 
Calcium Binding 
dystroglycan 1 Oag1 U43512 5.41 
S100 calcium binding protein A10 (calpactin) S100a10 M16465 90.03 
stromal cell derived factor 4 Sdf4 U45977 6.44 
Cell Adhesion 
cadherin 2 Cdh2 M31131 7.60 
OiGeorge syndrome critical region gene 6 Ogcr6 AF021031 7.02 
fibronectin 1 Fn1 X82402 20.69 
integrin alpha 3 Itga3 013867 11.15 
integrin beta 1 (fibronectin receptor beta) Itgb1 Y00769 9.94 
laminin, alpha 5 LamaS U37501 5.85 
laminin, gamma 1 Lame 1 X05211 7.00 
secreted phosphoprotein 1 Spp1 J04806 6.52 
thrombospondin 1 Thbs1 M87276 13.95 
zyxin Zyx X99063 12.86 
Cell Proliferation/Growth 
colony stimulating factor 1 Csf1 X05010 5.38 
insulin-like growth factor binding protein 2 Igfbp2 X81580 145.97 
Cell Signalling 
calcitonin gene-related peptide-receptor component 
Crep AF028242 6.82 
protein 
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SEM 
0.77 
1.91 
2.14 
0.98 
4.72 
2.92 
3.32 
4.94 
1.07 
21.05 
1.28 
2.16 
1.28 
1.13 
4.64 
3.65 
1.25 
2.32 
1.30 
2.07 
2.42 
1.57 
40.98 
1.44 
dishevelled 2, dsh homolog Dv/2 U24160 6.16 1.42 
fibroblast growth factor receptor 1 Fgfr1 M28998 5.93 0.60 
frizzled homolog 6 Fzd6 U43319 5.36 1.68 
integrin linked kinase IIk U94479 6.79 1.89 
Cytoskeletal Proteins 
beta-actin Actb M12481 279.24 55.37 
cell division cycle 42 homolog Cdc42 U37720 5.26 2.58 
cofilin 1, non-muscle Cf/1 000472 15.37 1.89 
dynein light chain LC8-type 1 Dynl/7 AF020185 82.09 15.93 
keratin complex 1, acidic, gene 19 Krt1-19 M28698 5.97 1.19 
myosin, light polypeptide 6 My/6 U04443 46.96 3.69 
thymosin, beta 4 , X chromosome Tmsb4x X16053 5.28 0.98 
villin 2 Vi/2 X60671 12.51 2.94 
vimentin Vim X51438 64.47 15.83 
DNA Repair 
RA021 homolog Rad21 049429 24.23 4.51 
RA023b homo log Rad23b X92411 13.89 2.21 
split hand/foot malformation (ectrodactyly) type 1 Shfm1 U41626 56.32 11.52 
DNA Replication and Cell Cycle Regulation 
calmodulin 1 Ca/m1 X61432 9.03 2.48 
COC28 protein kinase regulatory subunit 2 Cks2 AA289122 7.30 0.79 
cell division cycle 20 homolog Cdc20 A8045313 10.45 1.65 
cyclin A2 Ccna2 Z26580 6.21 1.09 
cyclin 81 Ccnb1 X64713 6.55 0.08 
cyclin 82 Ccnb2 X66032 7.32 0.88 
host cell factor C1 Hcfc1 U53925 7.18 0.98 
jun proto-oncogene related gene d1 Jund1 J05205 9.80 1.70 
minichromosome maintenance deficient 2 mitotin Mcm2 086725 6.84 1.59 
minichromosome maintenance deficient 5 Mcm5 026090 26.83 6.13 
mitogen activated protein kinase 14 Mapk14 U10871 8.77 1.64 
proliferation-associated 2G4 Pa2g4 U43918 24.81 4.41 
recombination activating gene 1 activating protein1 Rag1ap1 X96618 7.92 1.68 
Enzymel Enzyme Regulation 
3-phosphoglycerate dehydrogenase Phgdh L21027 8.05 0.57 
cathepsin 0 Ctsd X53337 13.38 2.83 
expressed in non-metastatic cells 2 protein Nme2 X68193 113.43 34.12 
protective protein for beta-galactosidase Ppgb J05261 6.36 1.25 
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receptor-like tyrosine kinase Ryk M98547 5.75 1.15 
serine (or cysteine) peptidase inhibitor, clade E, 
Serpine1 M33960 5.12 0.58 
member 1 
Metabolism 
glucose phosphate isomerase 1 Gpi1 M14220 62.71 11.66 
glutathione reductase 1 Gsr X76341 7.29 1.71 
glutathione S-transferase, mu 2 Gstm2 J04696 30.94 7.49 
glutathione S-transferase, pi 1 Gstp1 D30687 17.76 4.66 
glyceraldehydes-3-phosphate dehydrogenase Gapdh M32599 217.46 73.55 
GNAS (guanine nucleotide binding protein, alpha 
Gnas Y00703 29.63 7.23 
stimulating) complex locus 
ornithine decarboxylase, structural 1 Ode1 M10624 8.28 3.20 
tissue inhibitor of metalloproteinase 2 Timp2 X62622 13.85 2.94 
mRNA Processingl Degradation 
THO complex 4 Thoe4 U89876 20.30 3.17 
zinc finger protein 36, C3H type-like 1 Zfp36/1 M58566 12.86 3.11 
Protein Biosynthesis 
ribosomal protein S29 Rps29 L31609 153.78 46.92 
ribosomal protein SA Rpsa J02870 14.59 6.25 
Protein Folding 
heat shock protein 90kDa alpha class A member1 Hsp90aa1 M36830 15.74 4.59 
heat shock protein 90kDa alpha class B member 1 Hsp90ab1 M36829 34.52 6.81 
serine (or cysteine) peptidase inhibitor, clade H, 
Serpinh1 J05609 9.97 0.98 
member 1 
Protein Modification 
ubiquitin B Ubb X51703 536.77 133.05 
Receptor 
colony stimulating factor 2 receptor, alpha Csf2ra M85078 36.92 6.20 
nuclear receptor subfamily 2, group F, member 6 Nr2f6 X76654 6.91 1.42 
sema domain, seven thrombospondin repeats (type 1 
and type 1-like), transmembrane domain (TM) and Sema5b X97818 13.21 1.72 
short cytoplasmic domain, (semaphorin) 5B 
Transcription (Factors and Regulators) 
activating transcription factor 4 Atf4 M94087 6.77 2.80 
amino-terminal enhancer of split Aes L12140 24.19 3.42 
Cbp/p300-interacting transactivator, with Glu/Asp-rich 
Cited2 Y15163 7.83 1.89 
carboxy-terminal domain, 2 
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early growth response 1 Egr1 M20157 37.45 8.20 
general transcription factor Il 1 Gtf2i AF017085 5.23 0.52 
high mobility group nucleosomal binding domain 1 Hmgn1 X53476 27.65 6.45 
homeo box B9 Hoxb9 M34857 11.50 1.94 
max protein Max M63903 5.78 1.21 
myelocytomatosis oncogene Mye X01023 35.86 9.14 
paired box gene 8 Pax8 X57487 11.95 1.96 
prothymosin alpha Ptma X56135 98.68 8.77 
structure specifie recognition protein 1 Ssrp1 550213 8.97 1.47 
transcription factor Op 1 Tfdp1 X7231 0 9.97 0.55 
transcription termination factor 1 Ttf1 X83974 5.70 1.25 
tripartite motif protein 24 Trim24 Q64127 6.25 1.58 
v-rel reticuloendotheliosis viral oncogene homolog A Rela M61909 9.48 1.53 
Y box protein 1 Ybx1 X57621 98.70 14.36 
Transport 
RAB2, member RAS oncogene family Rab2 X95403 10.28 2.39 
solute carrier family 6 (neurotransmitter transporter, 
SIe6a9 X67056 7.01 2.10 
glycine), member 9 
solute carrier family 9 (sodium/hydrogen exchanger), 
SIc9a1 U51112 5.80 1.75 
member 1 
tyrosine 3-monooxygenase/tryptophan 5-
Ywhah U57311 30.58 0.51 
monooxygenase activation protein, eta polypeptide 
tyrosine 3-monooxygenase/tryptophan 5-
Ywhaz 078647 17.52 4.36 
monooxygenase activation protein, zeta polypeptide 
Unknown 
immediate early response 2 ler2 M31042 9.90 2.01 
a,b Common gene name, gene symbol, and gene function obtained from Mouse Genome 
Informatics (http://www.informatics.jax.org) 
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Figure 1. Effects of Androgen Deprivation and Supplementation on PC-1 
Cel! Vi a bility . 
Cell viability was evaluated using the CeliTiter-Glo luminescent cell viability assay 
from Promega. Cells were either grown for 2,4 or 6 days in media supplemented 
with androgen (control groups: DHT 2d, DHT 4d, and DHT 6d, respectively), in 
media deprived of androgen (n02d, n04d, or n06d, respectively) or in media 
supplemented with androgen for 2 days after 2 days or 4 days of androgen 
deprivation (n02d+DHT and n04d+DHT, respectively). Numbers of cells/well are 
expressed as mean ± SEM (3 replicates/group, in duplicate). There is no change 
in the number of viable cells after androgen deprivation and supplementation 
(black bars) when compared to cells grown in the presence of DHT (grey bars) 
for the same duration. 
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Figure 2. Number of Genes Changing in Expression Levels Following the 
Removal of Androgens from the Media. 
The vertical axis represents the total number of genes that showed a significant 
1.5-fold change or more in expression in either direction (50% increase or 33% 
decrease). The horizontal axis represents the number of days following androgen 
withdrawal. The white bars indicate the number of genes increasing in expression 
(above x-axis) and the dark bars indicate those decreasing (below x-axis). Each 
number was obtained independently at each time point relative to control. 
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Figure 3. Four Distinct Profiles of Gene Expression Were Obtained by K-
Means Cluster Analysis in the Ce" Line After Androgen Withdrawal. 
Genes changing significantly by at least 1.5-fold following androgen deprivation 
were classified as decreasing genes (13 genes), early and late transiently 
increasing genes (23 genes and 22 genes, respectively), and increasing genes 
(12 genes). The y-axis represents the relative intensity of gene expression and 
was obtained by normalizing the signal for any given gene relative to the median 
intensity of ail the measurements for that gene, defined as 1. The control group 
(cells grown in the presence of DHT for 2 days) and time following androgen 
deprivation are indicated on the horizontal axis. The gene expression profile 
depicted corresponds to the mean relative intensity of the set of genes grouped in 
that profile. The functional classification of the gene products for each profile is 
iIIustrated by pie-charts. Genes were classified according to their primary function 
obtained from Mouse Genome Informatics and PathwayStudio. Each function is 
represented bya difterent pattern. 
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Figure 4. Dissection of Gene Expression at 4 Days and 6 Days Following 
the Start of the Experiment. 
Pie-charts were used to describe the proportion of genes not significantly 
changing by at least 1.5-fold (white area), those increasing (genes j) and those 
decreasing (genes ~) following androgen withdrawal. The genes with increasing 
and decreasing expression were subdivided into those where androgen 
supplementation had a significant effect and rescued gene expression (diagonal 
stripes) and those where it did not (solid black). The number of genes 
corresponding to each piece of the chart is indicated adjacent to the piece and 
the total number of genes expressed at each time point is indicated at the bottom 
of the chart. The difference in the total number of genes expressed at 4 days and 
6 days is attributed to the genes increasing from undetected levels. 
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Figure 5. Potential Direct Functional Linkages between Genes Rescued by 
DHT Supplementation After 2 Days of Androgen Deprivation (A) and Those 
Not Rescued After 4 Days of Deprivation (B). 
Genes significantly changing by at least 1.5-fold following androgen withdrawal 
and rescued by DHT supplementation at 4 days and not rescued at 6 days were 
used as the starting group for A and B, respectively. Mediators of androgen 
action were also included in the analysis. Only genes that have been directly 
linked to one another via a primary interaction in the literature to date are shown. 
Arrows indicate the direction of the interactions, + indicate positive influence, T 
junctions indicate inhibition, and color and shape of the linkages indicate the type 
of interaction between the two gene products (expression, regulation, binding, or 
phosphorylation) . 
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Figure 6. Response of Several Mediators of Androgen Action to Androgen. 
Real-time RT -PCR analysis was done to determine the expression levels of 
androgen receptor (AR), steroid 5 alpha-reductase 1 (Srd5a1), and steroid 5 
alpha-reductase 2 (Srd5a2) following androgen withdrawal (solid line) and 
supplementation (broken line). Androgen was added back to the media for an 
additional 2 days either 2 days or 4 days after it was removed. The vertical axis 
corresponds to mRNA expression normalized to cyclophilin A and the horizontal 
axis corresponds to time (days). The control group is depicted in the graph at day 
o since it describes basal gene expression in the cell line. Values are expressed 
as mean ± SEM (5 replicates/group, assayed in duplicate). Significant effects 
(P<O.05) of androgen deprivation on gene expression when compared to control 
are depicted by * and of androgen supplementation when compared to the 
corresponding time of androgen deprivation by t. 
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Figure 7. Distinct Expression Profiles of Four Genes in Response to 
Androgen Withdrawal and Supplementation. 
Gene expression profiles for Rel-A, Igfbp2, periostin, and Spp1 are depicted 
following microarray analysis (panel A) and real-time RT-PCR (panel B). Gene 
expression (mean ± SEM, 5 replicates/group) is represented by solid lines after 
androgen withdrawal and by broken lines when androgen is added back to the 
media, after either 2 days or 4 days of androgen deprivation. The vertical axis 
corresponds to relative intensity and the horizontal axis to time (days). The 
control or DHT group is indicated at day 0 in the graph since it describes gene 
expression levels before any androgen manipulation. In panel B, replicates of 
each group were read in duplicate and the relative intensity was normalized to 
cyclophilin A mRNA. Significant changes in gene expression levels (P<O.05) are 
depicted by * when androgen withdrawal groups are compared to control and by 
twhen androgen supplementation is compared to the corresponding androgen 
withdrawal group (on the same day). 
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Figure 8. Analysis of SPP1 Protein Expression after Androgen 
Manipulations. 
Cytoplasmic extracts (3 replicates/group) were collected from cells subjected to 
different androgenic conditions. Twenty micrograms of protein extractlgroup were 
fractionated by SOS-PAGE, transferred to a PVOF membrane and probed by 
Western blot analysis with an anti-SPP1 antibody. A band at approximately 66 
KOa was detected. Cyclophilin A was used as an internai control for protein 
loading. The vertical axis of the graph represents relative intensity that was 
measured by densitometry and is expressed as a ratio of SPP1 to cyclophilin A 
relative to control. The horizontal axis indicates the different treatment groups 
(OHT: control; n02d: androgen deprivation for 2 days; n04d: androgen deprivation 
for 4 days; n02d+OHT: androgen deprivation for 2 days followed by 2 days of 
androgen supplementation; n06d: androgen de privation for 6 days; and 
n04d+OHT: androgen deprivation for 4 days followed by 2 days of androgen 
supplementation). Data are presented as mean ± SEM (n = 3). 
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Supplemental Table 1. Genes expressed at an intensity < 5 in PC-1 cells 
under control conditions 
Genbank 
Gene Normalized 
Common Gene Name a 
Symbol b 
Accession 
Data 
Number 
Apoptosis-Related 
B-cell translocation gene 2, anti-proliferative 8tg2 M64292 4.80 
bcl2-associated X protein Bax L22472 4.64 
sequestosome 1 Sqstm1 U40930 4.59 
Binding Proteins 
caudal type homeo box 2 Cdx2 S74520 3.61 
MARCKS-like 1 Marcksl1 X61399 2.94 
translin Tsn X81464 3.82 
Cell Adhesion 
RAS-related C3 botulinum substrate 1 Rac1 X57277 4.10 
syndecan 1 Sdc1 Z22532 3.24 
syndecan 2 Sdc2 U00674 4.16 
Cell Signalling (Signal Transduction and Intracellular) 
adenylate cyclase 6 Adcy6 M96653 4.40 
cd 14 antigen Cd14 M34510 2.35 
disheveled, dsh homolog 1 (Drosophila) Dvl1 U10115 2.52 
guanine nucleotide binding protein, alpha 
Gnai2 M13963 
inhibiting 2 2.63 
guanine nucleotide binding protein, beta 2 Gnb2 U34960 4.20 
neuroblastoma ras oncogene Nras X13664 2.27 
Rous sarcoma oncogene Src M17031 4.58 
signal transducer and activator of 
Stat6 L47650 3.77 
transcription 6 
v-abl Abelson murine leukemia oncogene 1 Abl1 L10656 3.35 
v-raf murine sarcoma 3611 viral oncogene 
Araf M13071 4.83 
homolog 
DNA Repair 
RAD23a homo log (S. cerevisiae) Rad23a X9241 0 3.73 
ubiquitin-conjugating enzyme E2B, RAD6 
Ube2b X96859 3.76 
homology (S. cerevisiae) 
220 
SEM 
1.49 
0.90 
1.40 
1.07 
0.98 
1.08 
0.81 
0.69 
1.50 
1.09 
0.84 
1.41 
0.89 
1.10 
0.46 
1.24 
1.03 
1.05 
1.01 
0.75 
0.13 
DNA Replication and Cell Cycle Regulation 
budding uninhibited by benzimidazoles 1 
Bub1b AF107296 2.80 0.52 
homolog beta 
cyclin 01 Gend1 S78355 3.28 0.24 
cyclin E1 Gene 1 X75888 3.00 0.26 
cyclin F Genf Z47766 3.19 0.74 
cyclin-dependent kinase 4 Gdk4 L01640 4.49 0.35 
proliferating cell nuclear antigen Pena X53068 4.51 0.65 
Enzymel Enzyme Regulation 
cystatin C est3 M59470 4.57 1.28 
MAP kinase-activated protein kinase 2 Mapkapk2 X76850 3.32 0.41 
protein disulfide isomerase associated 4 Pdia4 J05186 3.14 0.56 
protein tyrosine phosphatase, non-receptor 
Ptpn13 083966 4.02 0.93 
type 13 
RAN GTPase activating protein 1 Rangap1 U08110 2.45 0.65 
Guanyl-Nucleotide Exchange Factor Activity 
rho/rac guanine nucleotide exchange factor 
Arhgef2 U28495 2.79 0.63 (GEF) 2 
Growth Factor 
growth differentiation factor 9 Gdf9 X77113 4.42 0.99 
Metabolism 
hypoxanthine guanine phosphoribosyl 
Hprt1 J00423 3.70 1.75 
transferase 1 
lecithin cholesterol acyltransferase Leat J05154 3.33 1.07 
Protein Degradation 
calcyclin binding protein Gaeybp U97327 2.55 0.93 
221 
Protein Folding 
dnaJ (Hsp40) homolog, subfamily C, 
Dnajc3 U28423 2.52 0.33 
member 3 
heat shock 70kO protein 5 
Hspa5 078645 4.49 0.96 (glucose-regulated protein) 
Receptor 
coagulation factor Il (thrombin) receptor F2r L03529 3.64 0.37 
nuclear receptor subfamily 1, group H, 
Nr1h2 U09419 3.71 0.77 
member 2 
retinoic acid receptor, gamma Rarg M34476 3.85 0.58 
retinoid X receptor alpha Rxra M84817 4.41 0.74 
thyroid hormone receptor alpha Thra X51983 4.80 1.60 
tumor necrosis factor receptor superfamily, 
Tnfrsf1b M59378 2.85 0.74 
member 1b 
Transcription (Factors and Regulators) 
Ets2 repressor factor Erf U58533 3.48 0.68 
forkhead box F1 a Foxf1a L35949 3.05 0.51 
forkhead box G 1 Foxg1 U36760 3.82 0.84 
kruppel-like factor 3 (basic) Klf3 U36340 4.03 0.62 
LlM domain binding 1 Ldb1 U69270 4.31 0.84 
Ngfi-A binding protein 1 Nab1 U47008 2.91 0.23 
C1d 
nuclear ONA binding protein AF031426 3.60 0.62 (Interim) 
nuclear factor of kappa light chain gene 
Nfkbib U19799 2.87 0.45 
enhancer in B-cells inhibitor, beta 
purine rich element binding proteinA Pura U02098 2.95 0.56 
TAF6 RNA polymerase Il, TATA box binding 
Taf6 049439 2.04 0.59 
protein (TBP)-associated factor 
T-box 3 Tbx3 U57328 2.10 0.55 
upstream binding transcription factor, RNA 
Ubtf X60831 2.73 0.38 
polymerase 1 
a, b Common gene name, gene symbol, and gene function obtained from Mouse 
Genome Informatics (htt(2://www.informatics.jax.org) 
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Supplemental Table 2A. Genes significantly decreasing by at least 1.5-fold following androgen withdrawal 
compared to control a 
Genbank Day 0 (Control) Day 2 Day 4 
Gene 
Common Gene Name Accession Norm. SEM Norm. SEM Norm. SEM Norm. 
symbol 
number data data data data 
DAY 2 ONLY 
kruppel-like factor 3 K/f3 U36340 4.03 0.62 2.03 0.37 4.35 1.00 3.08 
purine rich element binding protein A Pura U02098 2.95 0.56 1.51 0.24 2.89 0.24 2.48 
DAY40NLY 
tubulin, beta 4 Tubb4 M28730 2.47 0.27 1.81 0.67 1.22 0.25 1.75 
DAY 4 AND DAY 6 
3-phosphoglycerate dehydrogenase Phgdh L21027 8.05 0.57 5.62 0.74 4.12 0.69 3.65 
bcl2-like 1 Bc/2/1 L35049 3.04 0.20 2.14 0.39 1.74 0.34 1.43 
breast cancer anti-estrogen resistance 1 Bcar1 U48853 3.47 0.86 3.12 0.45 1.41 0.25 0.97 
cyclin 81 Ccnb1 X64713 6.55 0.08 6.27 1.50 3.40 0.47 2.69 
dynein light chain Lc8-type 1 Dynl/4 AF020185 82.09 15.93 55.85 12.39 44.20 10.50 36.22 
early growth response 1 Egr1 M20157 37.45 8.20 48.95 6.11 17.79 2.21 17.37 
keratin complex 1, acidic, gene 19 Krt1-19 M28698 5.97 1.19 4.84 0.45 2.53 0.44 1.54 
laminin, alpha 5 Lama5 U37501 5.85 1.25 6.40 2.18 2.94 0.58 2.11 
phosphoprotein enriched in astrocytes 15 Pea15 X86694 4.55 0.65 3.38 0.80 2.66 0.73 2.56 
pleckstrin homology-like domain, family A, 
Ph/da 1 U44088 23.57 4.72 12.93 3.85 7.85 1.73 5.87 
member 1 
proliferation-associated 2G4 Pa2g4 U43918 24.81 4.41 37.22 8.69 14.37 3.15 11.19 
RA021 homolog Rad21 049429 24.23 4.51 17.60 7.47 5.92 1.14 6.13 
secreted phosphoprotein 1 Spp1 X13986 6.52 1.30 7.09 0.74 1.21 0.30 2.64 
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Day 6 
SEM 
0.56 
0.36 
0.28 
0.64 
0.24 
0.27 
0.50 
8.60 
3.55 
0.27 
0.64 
0.61 
1.31 
2.09 
1.62 
0.33 
't 
DAY 6 ONLY 
mitogen activated protein kinase 14 Mapk14 U10871 8.77 1.64 11.59 2.39 11.19 1.46 4.40 0.59 
amino-terminal enhancer of split Aes L12140 24.19 3.42 19.29 3.92 22.46 1.54 13.73 1.44 
budding uninhibited by benzimidazoles 1 homo log 2.80 0.52 3.96 0.92 1.78 0.29 1.68 0.10 
Bub1b AF107296 
beta 
calcyclin binding protein Gaeybp U97327 2.55 0.93 2.50 0.66 1.65 0.37 0.79 0.05 
cell division cycle 20 homolog Gde20 AB045313 10.45 1.65 11.11 1.61 6.21 1.14 5.51 0.77 
cyclin A2 Gena2 Z26580 6.21 1.09 10.13 2.17 4.50 1.16 3.01 0.73 
cyclin B2 Genb2 X66032 7.32 0.88 9.56 3.13 5.86 1.14 3.66 0.46 
cyclin 01 Gend1 S78355 3.28 0.24 4.34 1.97 2.41 0.53 1.71 0.12 
cyclin E1 Gene 1 X75888 3.00 0.26 3.33 0.31 2.02 0.30 1.34 0.12 
OiGeorge syndrome critical region gene 6 Dger6 AF021031 7.02 1.28 10.37 3.66 6.03 1.42 3.35 0.63 
general transcription factor" 1 Gtf2i AF017085 5.23 0.52 5.97 1.48 3.96 0.42 2.08 0.18 
glucose phosphate isomerase 1 Gpi1 M14220 62.71 11.66 68.82 15.00 48.89 6.42 32.91 4.61 
heat shock protein 90kDa alpha (cytosolic), class B Hsp90a 
M36829 34.52 6.81 62.86 7.60 23.55 9.57 16.17 2.68 
member 1 b1 
high mobility group nucleosomal binding domain 1 Hmgn1 X53476 27.65 6.45 50.91 15.92 27.90 9.49 11.16 2.56 
minichromosome maintenance deficient 5, cell 
Mem5 026090 26.83 6.13 22.85 3.32 17.59 2.43 11.78 3.09 
division cycle 46 
RAB2, member RAS oncogene family Rab2 X95403 10.28 2.39 11.28 1.03 7.94 1.81 4.09 1.28 
retinoic acid receptor, gamma Rarg M34476 3.85 0.58 3.33 0.12 3.18 0.83 1.60 0.42 
structure specifie recognition protein 1 Ssrp1 S50213 8.97 1.47 8.97 1.67 5.91 0.89 3.41 0.85 
THO complex 4 Thoe4 U89876 20.30 3.17 17.39 4.93 12.64 1.21 10.75 1.05 
thrombospondin 1 Thbs1 M87276 13.95 2.07 19.19 4.73 11.78 1.84 7.71 1.89 
tyrosine 3-monooxygenasel tryptophan 5-
Ywhah U57311 30.58 0.51 34.33 8.33 32.78 7.08 13.29 2.77 
monooxygenase activation protein, eta polypeptide 
a Genes changing by 1.5-fold that were not statistically significant were excluded fram the analysis. 
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Su~~lemental Table 28. Genes significantlï increasing bï at least 1.5-fold following androgen withdrawal 
com~ared to control a 
Genbank Day 0 (Control) Day 2 Day 4 Day 6 
Gene 
Common Gene Name Accession Norm. SEM Norm. SEM Norm. SEM Norm. SEM 
symbol 
number data data data data 
DAY20NLY 
colony stimulating factor 1 Csf1 X05010 5.38 1.57 10.05 0.76 4.54 0.78 5.01 0.57 
heat shock protein 90kDa alpha, class B member 1 Hsp90ab1 M36829 34.52 6.81 62.86 7.60 23.55 9.57 16.17 2.68 
protein disulfide isomerase associated 4 Pdia4 J05186 3.14 0.56 5.04 0.48 4.91 1.07 5.01 1.13 
DAY40NLY 
amyloid beta (A4) precursor protein App X59379 4.89 0.42 3.81 0.58 7.67 0.81 4.71 1.20 
AT motif binding factor 1 Atbf1 D026046 3.20 0.81 3.70 0.55 5.63 0.80 4.27 1.34 
casein kinase Il, alpha 1 polypeptide Csnk2a1 U51866 1.22 0.37 1.84 0.72 2.96 0.36 1.03 0.27 
catenin, alpha 1 Ctnna1 X59990 2.26 0.81 6.97 2.86 5.90 1.39 3.93 1.25 
cathepsin L Ctsl X06086 1.91 0.11 2.32 0.21 3.30 0.47 3.00 0.52 
CCCTC-binding factor Ctcf U51037 1.20 0.22 1.63 0.20 2.56 0.34 1.98 0.31 
coagulation factor Il (thrombin) receptor F2r L03529 3.64 0.37 3.80 0.72 6.95 0.87 3.54 1.36 
cut-like 2 Cut/2 U45665 0.73 0.05 0.94 0.38 2.61 0.47 1.71 0.42 
epimorphin Epim D10475 2.27 0.57 3.34 0.74 5.45 0.97 3.45 0.50 
follistatin Fst Z29532 2.43 0.85 4.77 1.00 5.97 0.46 4.23 0.50 
frizzled homolog 6 Fzd6 U43319 5.36 1.68 5.43 1.27 9.80 1.03 4.55 1.00 
gap junction membrane channel protein beta 3 Gjb3 X63099 0.10 0.05 0.52 0.15 2.92 0.68 1.87 0.41 
insulin-like growth factor 1 Igf1 X04480 0.94 0.33 1.75 0.92 3.12 0.88 2.36 0.48 
insulin-like growth factor binding protein 6 Igfbp6 X81584 2.61 0.63 2.07 0.40 7.19 1.54 4.51 1.53 
integrin beta 1 Itgb1 Y00769 9.94 3.65 7.83 2.75 20.63 2.89 16.81 5.13 
nucleobindin 1 Nucb1 M96823 2.80 0.28 2.29 0.55 5.52 1.00 5.48 1.60 
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phospholipid transfer protein P/tp U37226 3.11 0.83 2.73 0.65 5.79 0.63 6.21 1.86 
POU domain class 2 transcription factor 1 Pou2f1 X56230 2.75 0.28 2.11 0.54 4.74 0.68 3.34 0.72 
protein phosphatase 1 A, magnesium dependent, 
Ppm1a 028117 2.29 0040 4.63 1.65 4.78 0.61 2.13 0.37 
alpha isoform 
proviral integration site 1 Pim1 M13945 2.20 0.18 3.06 0.77 5.58 1.05 3.22 0.45 
RA023b homolog Rad23b X92411 13.89 2.21 12.02 2.63 24.98 2.97 10.79 3.60 
RA050 homolog Rad50 U66887 1.60 0.66 0.70 0.07 3.40 0.28 1.93 0.22 
serine (or cysteine) peptidase inhibitor, clade B, 
Serpinb6a U25844 2.00 0.26 4.92 1.57 4.56 0.62 1.86 0.34 
member6a 
tumor susceptibility gene 101 Tsg 10 1 U52945 1.26 0.29 1.87 0.27 2.37 0.35 2047 0.61 
DAY 4 and DAY 6 
fibroblast growth factor receptor 1 Fgfr1 M28998 5.93 0.60 5.07 1.24 10.56 0.95 9046 1.26 
periostin Postn 013664 0.10 0.05 0.50 0040 9.26 2.12 8.95 3.33 
prion protein Prnp M13685 3.31 0.47 4.81 1.30 8.84 2.54 6.13 0.67 
syndecan 3 Sdc3 U52826 3.23 0.38 2.70 0.67 11.30 2.19 9.14 2.15 
DAY60NLY 
procollagen, type VI, alpha 1 Co/6a1 X66405 2.22 0.36 3.21 1.35 4.81 1.04 5.36 1.62 
transducer of ErbB-2.1 Tob1 078382 2.64 0.32 2.81 0.80 3.29 0.39 4.29 0.44 
a Genes changing by 1.5-fold that were not statistically significant were excluded fram the analysis. 
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Supplemental Table 3. Gene lists for the four expression profiles of genes significantly changing by at least 1.5-
fold following androgen withdrawal (k-means cluster analysisl a 
A. Profile 1 (genes with decreasing expression) 
Genbank Day 0 (Control) Day 2 Day 4 Day 6 
Gene 
Common Gene Name Accession Norm. SEM Norm. SEM Norm. SEM Norm. 
symbol 
number data data data data 
Cytoskeletal 
dynein light chain lc8-type 1 Dynl/4 AF020185 82.09 15.93 55.85 12.39 44.20 10.50 36.22 
keratin complex 1, acidic, gene 19 Krt1-19 M28698 5.97 1.19 4.84 0.45 2.53 0.44 1.54 
tubulin, beta 4 Tubb4 M28730 2.47 0.27 1.81 0.67 1.22 0.25 1.75 
Apoptosis-Related 
bcl2-like 1 Be/2/1 l35049 3.04 0.20 2.14 0.39 1.74 0.34 1.43 
phosphoprotein enriched in astrocytes 15 Pea15 X86694 4.55 0.65 3.38 0.80 2.66 0.73 2.56 
pleckstrin homology-like domain, family A, member 1 Ph/da 1 U44088 23.57 4.72 12.93 3.85 7.85 1.73 5.87 
Cell Cycle 
cyclin 81 Cenb1 X64713 6.55 0.08 6.27 1.50 3.40 0.47 2.69 
minichromosome maintenance deficient 5, cell division 
Mcm5 D26090 26.83 6.13 22.85 3.32 17.59 2.43 11.78 
cycle 46 
Enzyme 
3-phosphoglycerate dehydrogenase Phgdh l21027 8.05 0.57 5.62 0.74 4.12 0.69 3.65 
Cell Adhesion 
breast cancer anti-estrogen resistance 1 Bcar1 U48853 3.47 0.86 3.12 0.45 1.41 0.25 0.97 
secreted phosphoprotein 1 Spp1 X13986 6.52 1.30 7.09 0.74 1.21 0.30 2.64 
mRNA Processing 
THO complex 4 Thoc4 U89876 20.30 3.17 17.39 4.93 12.64 1.21 10.75 
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SEM 
8.60 
0.27 
0.28 
0.24 
0.61 
1.31 
0.50 
3.09 
0.64 
0.27 
0.33 
1.05 
DNA Repair 
RA021 homolog Rad21 049429 24.23 4.51 
B. Profile 2 (genes with early transiently increasing expression) 
Genbank Day 0 (Control) 
Gene 
Common Gene Name Accession Norm. SEM 
symbol 
number data 
Ce" Cycle 
mitogen activated protein kinase 14 Mapk14 U10871 8.77 1.64 
budding uninhibited by benzimidazoles 1 homolog beta Bub1b AF107296 2.80 0.52 
cell division cycle 20 homolog Gde20 A8045313 10.45 1.65 
cyclin A2 Gena2 Z26580 6.21 1.09 
cyclin 82 Genb2 X66032 7.32 0.88 
cyclin 01 Gend1 878355 3.28 0.24 
cyclin E1 Gene 1 X75888 3.00 0.26 
Transcription 
early growth response 1 Egr1 M20157 37.45 8.20 
general transcription factor Il 1 Gtf2i AF017085 5.23 0.52 
high mobility group nucleosomal binding domain 1 Hmgn1 X53476 27.65 6.45 
proliferation-associated 2G4 Pa2g4 U43918 24.81 4.41 
retinoic acid receptor. gamma Rarg M34476 3.85 0.58 
structure specifie recognition protein 1 Ssrp1 850213 8.97 1.47 
228 
17.60 7.47 5.92 1.14 6.13 1.62 
Day 2 Day 4 Day 6 
Norm. SEM Norm. SEM Norm. SEM 
data data data 
11.59 2.39 11.19 1.46 4.40 0.59 
3.96 0.92 1.78 0.29 1.68 0.10 
11.11 1.61 6.21 1.14 5.51 0.77 
10.13 2.17 4.50 1.16 3.01 0.73 
9.56 3.13 5.86 1.14 3.66 0.46 
4.34 1.97 2.41 0.53 1.71 0.12 
3.33 0.31 2.02 0.30 1.34 0.12 
48.95 6.11 17.79 2.21 17.37 3.55 
5.97 1.48 3.96 0.42 2.08 0.18 
50.91 15.92 27.90 9.49 11.16 2.56 
37.22 8.69 14.37 3.15 11.19 2.09 
3.33 0.12 3.18 0.83 1.60 0.42 
8.97 1.67 5.91 0.89 3.41 0.85 
Cell Adhesion 
DiGeorge syndrome critical region gene 6 Dgcr6 AF021031 7.02 1.28 10.37 3.66 6.03 1.42 3.35 0.63 
laminin, alpha 5 Lama5 U37501 5.85 1.25 6.40 2.18 2.94 0.58 2.11 0.64 
thrombospondin 1 Thbs1 M87276 13.95 2.07 19.19 4.73 11.78 1.84 7.71 1.89 
Cell Proliferationl Growth 
colony stimulating factor 1 Csf1 X05010 5.38 1.57 10.05 0.76 4.54 0.78 5.01 0.57 
insulin-like growth factor binding protein 2 Igfbp2 
Metabolism 
glucose phosphate isomerase 1 Gpi1 M14220 62.71 11.66 68.82 15.00 48.89 6.42 32.91 4.61 
Protein Transport 
RAB2, member RAS oncogene family Rab2 X95403 10.28 2.39 11.28 1.03 7.94 1.81 4.09 1.28 
tyrosine 3-monooxygenase/ tryptophan 5-
Ywhah U57311 30.58 0.51 34.33 8.33 32.78 7.08 13.29 2.77 
monooxygenase activation protein, eta polypeptide 
Protein Folding 
heat shock protein 90kOa alpha (cytosolic), class B 
Hsp90ab1 M36829 34.52 6.81 62.86 7.60 23.55 9.57 16.17 2.68 
member 1 
Unknown 
calcyclin binding protein Cacybp U97327 2.55 0.93 2.50 0.66 1.65 0.37 0.79 0.05 
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c. Profile 3 (genes with late transiently increasing expression) 
Genbank Day 0 (Control) Day 2 Day 4 Day 6 
Gene 
Common Gene Name Accession Norm. SEM Norm. SEM Norm. SEM Norm. SEM 
symbol 
number data data data data 
Enzymel Enzyme Regulation 
casein kinase Il, alpha 1 polypeptide Gsnk2a1 U51866 1.22 0.37 1.84 0.72 2.96 0.36 1.03 0.27 
cathepsin L Gtsl X06086 1.91 0.11 2.32 0.21 3.30 0.47 3.00 0.52 
protein disulfide isomerase associated 4 Pdia4 J05186 3.14 0.56 5.04 0.48 4.91 1.07 5.01 1.13 
protein phosphatase 1 A, magnesium dependent, alpha 
Ppm1a 028117 2.29 0.40 4.63 1.65 4.78 0.61 2.13 
isoform 
0.37 
proviral integration site 1 Pim1 M13945 2.20 0.18 3.06 0.77 5.58 1.05 3.22 0.45 
serine (or cysteine) peptidase inhibitor, clade B, 
Serpinb6a U25844 2.00 0.26 4.92 1.57 4.56 0.62 1.86 0.34 
member6a 
Transcription 
amino-terminal enhancer of split Aes L12140 24.19 3.42 19.29 3.92 22.46 1.54 13.73 1.44 
AT motif binding factor 1 Atbf1 0026046 3.20 0.81 3.70 0.55 5.63 0.80 4.27 1.34 
GGGTG-binding factor Gtcf U51037 1.20 0.22 1.63 0.20 2.56 0.34 1.98 0.31 
kruppel-like factor 3 Klf3 U36340 4.03 0.62 2.03 0.37 4.35 1.00 3.08 0.56 
POU domain class 2 transcription factor 1 Pou2f1 X56230 2.75 0.28 2.11 0.54 4.74 0.68 3.34 0.72 
purine rich element binding protein A Pura U02098 2.95 0.56 1.51 0.24 2.89 0.24 2.48 0.36 
Cell Signalling 
coagulation factor Il (thrombin) receptor F2r L03529 3.64 0.37 3.80 0.72 6.95 0.87 3.54 1.36 
fo/listatin Fst Z29532 2.43 0.85 4.77 1.00 5.97 0.46 4.23 0.50 
frizzled homolog 6 Fzd6 U43319 5.36 1.68 5.43 1.27 9.80 1.03 4.55 1.00 
transducer of ErbB-2.1 Tob1 078382 2.64 0.32 2.81 0.80 3.29 0.39 4.29 0.44 
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Cell Adhesion 
amyloid beta (A4) precursor protein App X59379 4.89 0.42 3.81 0.58 7.67 0.81 4.71 1.20 
catenin, alpha 1 Ctnna1 X59990 2.26 0.81 6.97 2.86 5.90 1.39 3.93 1.25 
Protein Transport 
epimorphin Epim 010475 2.27 0.57 3.34 0.74 5.45 0.97 3.45 0.50 
tumor susceptibility gene 101 Tsg101 U52945 1.26 0.29 1.87 0.27 2.37 0.35 2.47 0.61 
DNA Repair 
RA023b homolog Rad23b X92411 13.89 2.21 12.02 2.63 24.98 2.97 10.79 3.60 
Metabolisml Oxidative Stress 
prion protein Pmp M13685 3.31 0.47 4.81 1.30 8.84 2.54 6.13 0.67 
D. Profile 4 (genes with increasing expression) 
Genbank Day 0 (Control) Day 2 Day 4 Day 6 
Gene 
Common Gene Name Accession Norm. SEM Norm. SEM Norm. SEM Norm. SEM 
symbol 
number data data data data 
Cell Adhesion 
integrin beta 1 Itgb1 Y00769 9.94 3.65 7.83 2.75 20.63 2.89 16.81 5.13 
periostin Postn 013664 0.10 0.05 0.50 0.40 9.26 2.12 8.95 3.33 
procollagen, type VI, alpha 1 Col6a1 X66405 2.22 0.36 3.21 1.35 4.81 1.04 5.36 1.62 
syndecan 3 Sdc3 U52826 3.23 0.38 2.70 0.67 11.30 2.19 9.14 2.15 
Cell Signalling 
fibroblast growth factor receptor 1 Fgfr1 M28998 5.93 0.60 5.07 1.24 10.56 0.95 9.46 1.26 
insulin-like growth factor 1 Igf1 X04480 0.94 0.33 1.75 0.92 3.12 0.88 2.36 0.48 
insulin-like growth factor binding protein 6 Igfbp6 X81584 2.61 0.63 2.07 0.40 7.19 1.54 4.51 1.53 
231 
Transcription 
cut-like 2 Cut/2 U45665 0.73 0.05 0.94 0.38 2.61 0.47 1.71 0.42 
nucleobindin 1 Nucb1 M96823 2.80 0.28 2.29 0.55 5.52 1.00 5.48 1.60 
Cel! Communication 
gap junction membrane channel protein beta 3 Gjb3 X63099 0.10 0.05 0.52 0.15 2.92 0.68 1.87 0.41 
DNA Repair 
RAD50 homolog Rad50 U66887 1.60 0.66 0.70 0.07 3.40 0.28 1.93 0.22 
Transport 
phospholipid transfer protein P/tp U37226 3.11 0.83 2.73 0.65 5.79 0.63 6.21 1.86 
a Genes changing by 1.5-fold that were not statistically significant were excluded fram the analysis. 
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Su~~lemental Table 4A: Gene lists for ail genes ex~ressed at 4 da~s a 
Genbank 
Day 0 (Control) Day 2 Day 4 Day 4 Day 6 Day 6 
Gene (With Rescue) (With Rescue) 
Common Gene Name Accession 
symbol Norm. SEM Norm. SEM Norm. SEM Norm. SEM Norm. SEM Norm. SEM 
number 
data data data data data data 
Increasing Expression, DHT Rescue 
amyloid beta (A4) precursor 
App X59379 4.89 0.42 3.81 0.58 7.67 0.81 4.70 0.83 4.71 1.20 6.49 0.99 
protein 
cathepsin L Gtsl X06086 1.91 0.11 2.32 0.21 3.30 0.47 2.02 0.23 3.00 0.52 2.75 0.25 
coagulation factor Il (thrombin) 
F2r L03529 3.64 0.37 3.80 0.72 6.95 0.87 2.96 0.80 3.54 1.36 5.45 0.86 
receptor 
cut-like 2 Gut/2 U45665 0.73 0.05 0.94 0.38 2.61 0.47 0.96 0.27 1.71 0.42 1.05 0.11 
fibroblast growth factor receptor 1 Fgfr1 M28998 5.93 0.60 5.07 1.24 10.56 0.95 5.81 0.87 9.46 1.26 6.70 1.36 
follistatin Fst Z29532 2.43 0.85 4.77 1.00 5.97 0.46 3.94 0.36 4.23 0.50 3.25 0.64 
frizzled homolog 6 Fzd6 U43319 5.36 1.68 5.43 1.27 9.80 1.03 4.94 0.67 4.55 1.00 6.51 0.90 
gap junction membrane channel 
Gjb3 X63099 0.10 0.05 0.52 0.15 2.92 0.68 0.58 0.19 1.87 0.41 1.48 0.46 
protein beta 3 
insulin-like growth factor 1 Igf1 X04480 0.94 0.33 1.75 0.92 3.12 0.88 0.84 0.14 2.36 0.48 1.61 0.38 
integrin beta 1 Itgb1 Y00769 9.94 3.65 7.83 2.75 20.63 2.89 9.73 3.99 16.81 5.13 16.31 3.65 
nucleobindin 1 Nucb1 M96823 2.80 0.28 2.29 0.55 5.52 1.00 2.57 0.30 5.48 1.60 6.54 0.69 
periostin Postn 013664 0.10 0.05 0.50 0.40 9.26 2.12 0.41 0.19 8.95 3.33 2.69 0.99 
POU domain class 2 transcription 
Pou2f1 X56230 2.75 0.28 2.11 0.54 4.74 0.68 2.54 0.42 3.34 0.72 3.92 1.07 
factor 1 
RA050 homolog Rad50 U66887 1.60 0.66 0.70 0.07 3.40 0.28 0.63 0.13 1.93 0.22 3.65 1.22 
serine (or cysteine) peptidase 
Serpinb6a U25844 2.00 0.26 4.92 1.57 4.56 0.62 2.74 0.53 1.86 0.34 2.67 0.45 
inhibitor, clade B, member 6a 
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syndecan 3 Sdc3 
Increasing Expression, No OHT Rescue 
AT motif binding factor 1 Atbf1 
casein kinase Il, alpha 1 
polypeptide 
catenin, alpha 1 
CCCTC-binding factor 
Epimorphin 
insulin-like growth factor binding 
protein 6 
phospholipid transfer prote in 
prion protein 
protein phosphatase 1 A, 
magnesium dependent, alpha 
isoform 
proviral integration site 1 
RA023b homolog 
tumor susceptibility gene 101 
Csnk2a1 
Ctnna1 
Ctcf 
Epim 
Igfbp6 
Pltp 
Prnp 
Ppm1a 
Pim1 
Rad23b 
Tsg101 
Oecreasing Expression, OHT Rescue 
breast cancer anti-estrogen 
resistance 1 
early growth response 1 
keratin complex 1, acidic, gene 19 
laminin, alpha 5 
pleckstrin homology-like domain, 
family A, member 1 
proliferation-associated 2G4 
Bcar1 
Egr1 
Krl1-19 
Lama5 
Phlda1 
Pa2g4 
U52826 
0026046 
U51866 
X59990 
U51037 
010475 
X81584 
U37226 
M13685 
028117 
M13945 
X92411 
U52945 
U48853 
M20157 
M28698 
U37501 
U44088 
U43918 
3.23 
3.20 
1.22 
2.26 
1.20 
2.27 
2.61 
3.11 
3.31 
2.29 
2.20 
13.89 
1.26 
3.47 
37.45 
5.97 
5.85 
23.57 
24.81 
0.38 
0.81 
0.37 
0.81 
0.22 
0.57 
0.63 
0.83 
0.47 
0.40 
0.18 
2.21 
0.29 
0.86 
8.20 
1.19 
1.25 
4.72 
4.41 
2.70 
3.70 
1.84 
6.97 
1.63 
3.34 
2.07 
2.73 
4.81 
4.63 
3.06 
12.02 
1.87 
3.12 
48.95 
4.84 
6.40 
12.93 
37.22 
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0.67 
0.55 
0.72 
2.86 
0.20 
0.74 
0.40 
0.65 
1.30 
1.65 
0.77 
2.63 
0.27 
0.45 
6.11 
0.45 
2.18 
3.85 
8.69 
11.30 
5.63 
2.96 
5.90 
2.56 
5.45 
7.19 
5.79 
8.84 
4.78 
5.58 
24.98 
2.37 
1.41 
17.79 
2.53 
2.94 
7.85 
14.37 
2.19 
0.80 
0.36 
1.39 
0.34 
0.97 
1.54 
0.63 
2.54 
0.61 
1.05 
2.97 
0.35 
0.25 
2.21 
0.44 
0.58 
1.73 
3.15 
3.16 
4.94 
1.69 
4.86 
1.89 
3.35 
3.50 
3.75 
5.15 
3.39 
3.60 
14.36 
2.15 
0.45 
1.02 
0.52 
0.99 
0.47 
0.57 
0.74 
0.72 
0.54 
0.69 
0.34 
2.83 
0.42 
4.01 0.51 
51.98 12.06 
5.81 0.73 
6.75 1.30 
21.32 4.63 
30.73 4.11 
9.14 
4.27 
1.03 
3.93 
1.98 
3.45 
4.51 
6.21 
6.13 
2.13 
3.22 
10.79 
2.47 
0.97 
17.37 
1.54 
2.11 
5.87 
11.19 
2.15 
1.34 
0.27 
1.25 
0.31 
0.50 
1.53 
1.86 
0.67 
0.37 
0.45 
3.60 
0.61 
0.27 
3.55 
0.27 
0.64 
1.31 
2.09 
10.88 
4.62 
1.90 
3.69 
2.32 
3.87 
5.73 
6.70 
8.36 
2.98 
2.62 
18.48 
2.38 
1.17 
19.66 
2.51 
2.87 
6.57 
10.95 
0.98 
0.71 
0.52 
0.80 
0.61 
1.03 
1.01 
0.72 
1.28 
0.59 
0.48 
3.19 
0.34 
0.21 
2.74 
0.26 
0.61 
1.04 
1.80 
RAD21 homolog Rad21 D49429 24.23 4.51 17.60 7.47 5.92 1.14 20.00 2.77 6.13 1.62 7.36 0.91 
secreted phosphoprotein 1 Spp1 X13986 6.52 1.30 7.09 0.74 1.21 0.30 6.60 1.20 2.64 0.33 1.78 0.41 
Decreasing Expression, No DHT Rescue 
3-phosphoglycerate 8.05 0.57 
Phgdh L21027 5.62 0.74 4.12 0.69 7.34 1.34 3.65 0.64 3.30 0.44 
dehydrogenase 
bcl2-like 1 Bc/2/1 L35049 3.04 0.20 2.14 0.39 1.74 0.34 2.06 0.39 1.43 0.24 1.46 0.37 
cyclin 81 Ccnb1 X64713 6.55 0.08 6.27 1.50 3.40 0.47 7.18 1.48 2.69 0.50 2.85 0.51 
dynein light chain Lc8-type 1 Dynl/4 AF020185 82.09 15.93 55.85 12.39 44.20 10.50 56.25 15.82 36.22 8.60 20.63 5.64 
phosphoprotein enriched in 
Pea15 X86694 4.55 0.65 3.38 0.80 2.66 0.73 4.11 0.62 2.56 0.61 3.19 0.50 
astrocytes 15 
insulin-like growth factor binding 
/gfbp2 X81580 112.52 18.12 98.96 34.34 118.32 13.16 
protein 2 145.97 40.98 168.16 31.11 74.53 15.65 
tubulin, beta 4 Tubb4 M28730 2.47 0.27 1.81 0.67 1.22 0.25 1.42 0.27 1.75 0.28 1.00 0.23 
Genes Not Affected Sy Androgen Withdrawal 
activating transcription factor 4 Atf4 M94087 6.77 2.80 6.11 2.45 3.56 0.56 6.70 1.55 3.91 0.77 4.33 0.77 
adenylate cyclase 6 Adcy6 M96653 4.40 1.09 4.25 0.33 5.69 1.05 6.61 1.03 2.44 0.41 5.51 0.63 
amino-terminal enhancer of split Aes L12140 24.19 3.42 19.29 3.92 22.46 1.54 26.75 2.96 13.73 1.44 18.09 1.67 
basigin Bsg D00611 24.50 4.94 20.47 5.58 18.56 3.89 25.47 4.12 18.82 5.37 22.92 2.35 
b-cell translocation gene 2, anti-
Btg2 M64292 4.80 1.49 4.36 1.68 3.72 0.95 4.83 1.08 2.16 0.36 3.10 0.38 
proliferative 
bcl2-antagonistikiller 1 Bak1 Y13231 5.46 0.77 4.72 0.75 5.07 0.86 4.74 0.78 3.45 0.77 1.42 0.23 
bcl2-associated athanogene 1 Bag1 U17162 13.97 1.91 19.47 6.30 14.30 3.39 13.63 2.26 8.86 1.40 4.84 1.16 
bcl2-associated X protein Bax L22472 4.64 0.90 3.67 0.51 2.98 0.41 4.43 0.80 2.97 0.67 1.92 0.46 
beta-actin Actb M12481 279.24 55.37 255.30 53.42 167.82 51.17 317.08 56.20 166.33 53.35 189.48 34.86 
b-raf oncogene Braf M64429 6.25 1.58 8.81 1.42 7.10 1.02 8.42 0.92 6.84 1.60 8.16 0.40 
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budding uninhibited by 
benzimidazoles 1 homolog, beta 
(S. cerevisiae) 
cadherin 2 
calcitonin gene-related peptide-
receptor component protein 
calcyclin binding protein 
calmodulin 1 
caspase 1 
cathepsin 0 
caudal type homeo box 2 
Cbp/p300-interacting 
transactivator, with Glu/Asp-rich 
carboxy-terminal domain, 2 
cd 14 antigen 
cdc28 protein kinase regulatory 
subunit 2 
cell division cycle 20 homo log 
cell division cycle 42 homolog 
cofilin 1, non-muscle 
colony stimulating factor 1 
colony stimulating factor 2 
receptor, alpha 
cyclin A2 
cyclin B2 
cyclin 01 
cyclin E1 
Bub1b 
Cdh2 
Crcp 
Cacybp 
Calm 1 
Casp1 
Ctsd 
Cdx2 
Cited2 
Cd14 
Cks2 
Cdc20 
Cde42 
Cf/1 
Csf1 
Csf2ra 
Ccna2 
Ccnb2 
Ccnd1 
Cene 1 
AF107296 
M31131 
AF028242 
U97327 
X61432 
L28095 
X53337 
S74520 
Y15163 
M34510 
AA289122 
AB045313 
U37720 
000472 
X05010 
M85078 
Z26580 
X66032 
S78355 
X75888 
2.80 
7.60 
6.82 
2.55 
9.03 
10.72 
13.38 
3.61 
7.83 
2.35 
7.30 
10.45 
5.26 
15.37 
5.38 
36.92 
6.21 
7.32 
3.28 
3.00 
0.52 
2.16 
1.44 
0.93 
2.48 
2.14 
2.83 
1.07 
1.89 
0.84 
0.79 
1.65 
2.58 
1.89 
1.57 
6.20 
1.09 
0.88 
0.24 
0.26 
3.96 
6.92 
8.42 
2.50 
7.06 
8.66 
18.62 
3.91 
6.46 
1.97 
8.78 
11.11 
3.47 
10.83 
10.05 
35.10 
10.13 
9.56 
4.34 
3.33 
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0.92 
1.64 
2.75 
0.66 
1.48 
2.64 
6.64 
0.72 
1.26 
0.44 
1.26 
1.61 
1.16 
3.42 
0.76 
7.98 
2.17 
3.13 
1.97 
0.31 
1.78 
5.10 
5.87 
1.65 
8.76 
8.19 
18.78 
3.75 
8.16 
1.37 
6.38 
6.21 
2.72 
14.44 
4.54 
27.81 
4.50 
5.86 
2.41 
2.02 
0.29 
0.79 
1.14 
0.37 
1.70 
2.07 
3.62 
0.72 
1.02 
0.28 
1.01 
1.14 
0.55 
2.73 
0.78 
4.08 
1.16 
1.14 
0.53 
0.30 
4.02 
7.36 
5.76 
2.00 
8.77 
9.69 
16.66 
3.44 
6.82 
3.74 
7.86 
12.82 
5.98 
15.78 
7.65 
24.35 
7.42 
7.11 
3.20 
3.18 
0.46 
2.43 
1.37 
0.50 
2.20 
2.41 
1.56 
0.73 
2.03 
0.25 
1.82 
0.81 
1.81 
3.50 
1.03 
4.57 
2.25 
1.69 
1.16 
0.33 
1.68 
5.20 
4.17 
0.79 
3.66 
8.45 
11.38 
1.27 
10.14 
0.99 
6.02 
5.51 
1.57 
20.88 
5.01 
21.34 
3.01 
3.66 
1.71 
1.34 
0.10 
1.51 
0.92 
0.05 
0.89 
1.83 
2.38 
0.29 
1.68 
0.12 
0.55 
0.77 
0.27 
6.44 
0.57 
3.40 
0.73 
0.46 
0.12 
0.12 
1.26 
9.64 
3.20 
1.19 
7.80 
6.31 
14.33 
2.58 
13.73 
2.40 
7.10 
5.43 
2.43 
18.97 
7.56 
23.69 
2.19 
5.51 
1.96 
1.79 
0.29 
1.67 
0.56 
0.54 
0.83 
1.12 
1.29 
0.46 
2.77 
0.15 
0.74 
0.65 
0.59 
1.42 
0.71 
4.49 
0.77 
0.66 
0.60 
0.40 
cyclin F 
cyclin-dependent kinase 4 
cystatin C 
diGeorge syndrome critical region 
gene 6 
disheveled 2, dsh homolog 
disheveled, dsh homo log 1 
(Drosophila) 
dnaJ (Hsp40) homolog, subfamily 
C, member3 
dystroglycan 1 
ets2 repressor factor 
expressed in non-metastatic cells 2 
protein 
fibronectin 1 
forkhead box F1 a 
general transcription factor Il 1 
glucose phosphate isomerase 1 
glutathione reductase 1 
glutathione S-transferase, mu 2 
glutathione S-transferase, pi 1 
glyceraldehydes-3-phosphate 
dehydrogenase 
GNAS (guanine nucleotide binding 
protein, alpha stimulating) complex 
locus 
growth differentiation factor 9 
Cenf 
Cdk4 
Cst3 
Dger6 
Dv/2 
Dvl1 
Dnaje3 
Dag1 
Erf 
Nme2 
Fn1 
Foxf1a 
Gtf2i 
Gpi1 
Gsr 
Gstm2 
Gstp1 
Gapdh 
Gnas 
Gdf9 
Z47766 
L01640 
M59470 
AF021031 
U24160 
U10115 
U28423 
U43512 
U58533 
X68193 
X82402 
L35949 
AF017085 
M14220 
X76341 
J04696 
D30687 
M32599 
Y00703 
X77113 
3.19 
4.49 
4.57 
7.02 
6.16 
2.52 
2.52 
5.41 
3.48 
113.43 
20.69 
3.05 
5.23 
62.71 
7.29 
30.94 
17.76 
217.46 
29.63 
4.42 
0.74 
0.35 
1.28 
1.28 
1.42 
1.41 
0.33 
1.07 
0.68 
34.12 
1.13 
0.51 
0.52 
11.66 
1.71 
7.49 
4.66 
73.55 
7.23 
0.99 
2.70 0.47 
6.84 1.39 
3.76 1.54 
10.37 3.66 
6.83 1.55 
2.95 0.54 
2.28 0.39 
7.86 1.08 
2.54 0.68 
203.94 48.18 
2.77 0.52 
3.39 0.49 
5.97 1.48 
68.82 15.00 
11.85 3.68 
35.73 3.99 
16.98 1.24 
168.36 32.46 
30.32 7.61 
7.56 2.90 
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2.46 
3.99 
2.81 
6.03 
8.16 
1.32 
2.73 
5.59 
3.70 
86.61 
3.02 
4.54 
3.96 
48.89 
4.29 
29.19 
9.75 
108.22 
43.61 
4.24 
0.91 
0.68 
0.63 
1.42 
1.43 
0.27 
0.44 
1.47 
0.62 
20.30 
0.29 
0.72 
0.42 
6.42 
0.89 
4.62 
1.60 
26.40 
7.35 
0.90 
2.50 
4.27 
3.97 
7.86 
7.32 
3.26 
2.05 
7.84 
3.67 
158.44 
3.68 
4.42 
5.78 
86.65 
13.58 
62.06 
25.25 
243.76 
27.47 
4.14 
0.81 
0.72 
0.40 
1.02 
0.60 
0.63 
0.25 
1.73 
0.87 
17.03 
0.87 
0.44 
0.57 
15.67 
1.91 
7.34 
3.84 
64.87 
2.56 
0.96 
2.67 
3.96 
3.10 
3.35 
4.43 
0.61 
1.98 
3.95 
3.71 
70.40 
2.08 
2.51 
2.08 
32.91 
4.05 
26.48 
7.12 
76.21 
30.75 
3.32 
0.66 
0.71 
0.73 
0.63 
0.63 
0.12 
0.66 
1.07 
1.36 
15.88 
0.32 
0.48 
0.18 
4.61 
0.53 
6.08 
1.10 
33.01 
11.59 
0.57 
3.39 
4.22 
3.20 
4.83 
5.80 
0.99 
2.51 
5.38 
4.22 
64.51 
2.25 
3.87 
2.56 
29.26 
3.76 
30.05 
9.70 
109.99 
33.91 
5.98 
0.46 
0.58 
0.51 
0.65 
0.61 
0.17 
0.55 
0.92 
0.67 
6.40 
0.35 
0.59 
0.26 
2.59 
0.68 
4.23 
0.77 
13.79 
5.03 
1.08 
guanine nucleotide binding protein, 
alpha inhibiting 2 
guanine nucleotide binding protein, 
beta 2 
heat shock 70kO protein 5 
(glucose-regulated protein) 
heat shock protein 90kOa alpha , 
class 8 member 1 
heat shock protein 90kOa alpha, 
class A member 1 
high mobility group nucleosomal 
binding domain 1 
homeo box 89 
host cell factor C1 
hypoxanthine guanine 
phosphoribosyl transferase 1 
immediate early response 2 
integrin alpha 3 
integrin linked kinase 
jun proto-oncogene related gene 
d1 
kruppel-like factor 3 (basic) 
laminin, gamma 1 
lecithin cholesterol acyltransferase 
LlM domain binding 1 
MAP kinase-activated protein 
kinase 2 
Gnai2 
Gnb2 
Hspa5 
Hsp90ab1 
Hsp90aa1 
Hmgn1 
Hoxb9 
Hcfc1 
Hprt1 
ler2 
Itga3 
IIk 
Jund1 
Klf3 
Lamc1 
Lcat 
Ldb1 
Mapkapk2 
M13963 
U34960 
078645 
M36829 
M36830 
X53476 
M34857 
U53925 
J00423 
M31042 
013867 
U94479 
J05205 
U36340 
X05211 
J05154 
U69270 
X76850 
2.63 
4.20 
4.49 
34.52 
15.74 
27.65 
11.50 
7.18 
3.70 
9.90 
11.15 
6.79 
9.80 
4.03 
7.00 
3.33 
4.31 
3.32 
0.89 
1.10 
0.96 
6.81 
4.59 
6.45 
1.94 
0.98 
1.75 
2.01 
4.64 
1.89 
1.70 
0.62 
2.32 
1.07 
0.84 
0.41 
1.84 
4.78 
6.81 
62.86 
28.79 
50.91 
15.13 
5.52 
2.63 
7.83 
17.51 
10.01 
11.09 
2.03 
6.96 
3.14 
4.57 
2.96 
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0.62 
1.31 
1.79 
7.60 
7.88 
15.92 
4.69 
1.07 
0.54 
0.98 
5.78 
1.63 
1.94 
0.37 
1.90 
0.83 
1.33 
0.70 
2.45 
5.00 
6.96 
23.55 
15.94 
27.90 
15.40 
9.03 
2.46 
12.59 
8.00 
5.62 
7.70 
4.35 
10.49 
2.33 
3.13 
2.82 
0.46 
0.89 
0.83 
9.57 
4.32 
9.49 
2.26 
0.96 
1.06 
2.27 
2.12 
1.07 
1.39 
1.00 
2.17 
0.57 
0.39 
0.70 
2.68 
5.11 
5.84 
45.59 
18.96 
31.22 
15.71 
8.95 
2.47 
9.93 
14.15 
9.66 
16.68 
4.72 
7.45 
3.59 
4.55 
3.19 
0.81 
0.81 
1.57 
13.24 
5.56 
6.72 
3.44 
1.51 
0.80 
1.06 
1.40 
0.55 
1.03 
0.62 
0.78 
0.33 
1.77 
0.72 
2.37 
5.02 
7.78 
16.17 
17.83 
11.16 
10.30 
8.73 
1.90 
7.94 
3.78 
5.64 
9.82 
3.08 
7.55 
2.00 
3.45 
2.34 
0.58 
1.72 
1.48 
2.68 
5.38 
2.56 
2.48 
1.87 
0.60 
1.72 
1.45 
0.80 
2.38 
0.56 
2.29 
0.44 
0.64 
0.62 
3.24 
5.72 
6.55 
33.95 
20.54 
11.66 
11.48 
10.01 
3.11 
11.53 
5.48 
5.38 
14.16 
3.90 
7.97 
2.91 
3.31 
2.62 
0.54 
0.98 
0.92 
3.26 
3.39 
5.12 
2.70 
2.16 
0.91 
0.56 
1.11 
0.61 
1.86 
0.81 
1.21 
0.34 
0.38 
0.62 
MARCKS-like 1 Mareks/1 X61399 2.94 0.98 2.56 0.89 1.39 0.35 3.72 0.67 1.36 0.36 1.28 0.38 
max binding protein Mnt Y07609 5.06 0.98 3.37 0.68 6.28 1.00 5.25 0.57 4.49 0.56 4.70 0.39 
max protein Max M63903 5.78 1.21 5.16 1.06 3.57 0.70 6.13 0.80 2.96 0.62 4.18 0.41 
minichromosome maintenance 
Mem2 086725 6.84 1.59 5.98 0.57 5.76 
deficient 2 mitotin 
0.94 8.37 1.17 4.76 0.90 5.78 0.39 
minichromosome maintenance 
Mem5 026090 26.83 6.13 22.85 3.32 17.59 2.43 26.06 2.69 11.78 3.09 20.05 2.35 
deficient 5 
mitogen activated protein kinase14 Mapk14 U10871 8.77 1.64 11.59 2.39 11.19 1.46 8.85 1.01 4.40 0.59 7.35 0.57 
myelocytomatosis oncogene Mye X01023 35.86 9.14 46.15 8.59 21.70 3.09 48.99 10.11 21.86 4.27 27.18 3.40 
myosin, light polypeptide 6 My/6 U04443 46.96 3.69 43.88 6.01 51.72 8.26 42.55 5.51 44.66 11.66 41.64 5.24 
N-acetylglucosamine-1-
phosphodiester alpha-N- Nagpa U36760 3.82 0.84 2.35 0.75 3.14 0.70 4.16 0.69 2.62 0.84 4.08 0.71 
acetylglucosaminidase 
neuroblastoma ras oncogene Nras X13664 2.27 0.46 4.27 0.86 3.61 0.57 2.87 0.55 2.61 0.26 2.12 0.40 
Ngfi-A binding protein 1 Nab1 U47008 2.91 0.23 2.22 0.66 2.97 0.52 2.74 0.71 2.06 0.66 2.75 0.73 
C1d 
nuclear ONA binding protein AF031426 3.60 0.62 2.28 1.01 3.98 1.38 2.92 0.69 2.68 0.72 1.55 0.42 (Interim) 
nuclear factor of kappa light chain 
gene enhancer in B-cells inhibitor, Nfkbib U19799 2.87 0.45 2.78 0.60 1.98 0.37 3.43 0.71 1.76 0.25 2.18 0.28 
beta 
nuclear receptor subfamily 2, 
Nr2f6 X76654 6.91 1.42 2.96 0.70 2.82 0.70 3.19 0.72 2.34 0.62 2.62 0.62 
group F, member 6 
ornithine decarboxylase, 
Ode 1 M10624 8.28 3.20 12.14 2.33 6.89 1.31 10.08 1.13 2.74 0.79 5.81 0.75 
structural1 
paired box gene 8 Pax8 X57487 11.95 1.96 3.20 0.74 2.60 0.40 3.13 0.75 1.95 0.34 1.93 0.29 
proliferating cell nuclear antigen Pena X53068 4.51 0.65 3.03 0.29 4.58 0.66 3.55 0.76 3.99 0.53 5.25 0.35 
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protective prote in for beta-
galactosidase 
protein disulfide isomerase 
associated 4 
protein tyrosine phosphatase, non-
receptor type 13 
prothymosin alpha 
purine rich element binding 
proteinA 
RAB2, member RAS oncogene 
family 
RAD23a homolog (S. cerevisiae) 
RAN GTPase activating protein 1 
RAS-related C3 botulinum 
substrate 1 
receptor-like tyrosine kinase 
recombination activating gene 1 
activating protein 1 
retinoic acid receptor, gamma 
retinoid X receptor alpha 
rho/rac guanine nucleotide 
exchange factor (GEF) 2 
ribosomal protein S29 
ribosomal protein SA 
nuclear receptor subfamily 1 , 
group H, member 2 
Rous sarcoma oncogene 
Ppgb 
Pdia4 
Ptpn13 
Ptma 
Pura 
Rab2 
Rad23a 
Rangap1 
Rae1 
Ryk 
Rag1ap1 
Rarg 
Rxra 
Arhgef2 
Rps29 
Rpsa 
Nr1h2 
Src 
J05261 
J05186 
D83966 
X56135 
U02098 
X95403 
X9241 0 
U08110 
X57277 
M98547 
X96618 
M34476 
M84817 
U28495 
L31609 
J02870 
U09419 
M17031 
6.36 
3.14 
4.02 
98.68 
2.95 
10.28 
3.73 
2.45 
4.1 
1.25 
0.56 
0.93 
8.77 
0.56 
2.39 
0.75 
0.65 
0.81 
5.44 0.65 
5.04 0.48 
6.25 1.15 
85.90 16.48 
1.51 0.24 
11.28 1.03 
2.77 0.52 
3.08 0.55 
3.49 0.39 
4.39 0.71 7.84 1.13 4.53 0.94 
4.91 1.07 5.42 0.77 5.01 1.13 
4.61 0.75 6.22 1.02 2.59 0.68 
105.29 19.40 102.19 25.61 81.67 25.81 
2.89 0.24 1.44 0.35 2.48 0.36 
7.94 1.81 11.70 1.90 4.09 1.28 
3.02 0.29 3.68 0.87 2.08 0.32 
1.96 0.28 2.89 0.39 1.55 0.39 
3.96 1.02 4.25 1.24 3.96 0.97 
5.75 1.15 6.38 2.29 7.90 1.39 5.08 1.08 4.88 1.03 
7.92 1.68 6.61 0.81 9.51 0.93 7.78 0.96 6.82 1.72 
3.85 0.58 3.33 0.12 3.18 0.83 4.86 0.68 1.60 0.42 
4.41 0.74 5.50 1.43 6.36 0.90 5.31 0.67 3.34 0.72 
2.79 0.63 6.26 2.32 2.49 0.70 3.60 1.22 2.55 0.48 
153.78 46.92 226.71 66.21 119.13 29.08 268.14 49.81 107.12 25.07 
14.59 6.25 3.14 0.83 2.33 0.57 3.59 0.33 2.00 0.44 
3.71 0.77 2.95 0.73 5.93 1.08 4.65 0.26 4.83 1.32 
4.58 1.24 5.33 0.19 1.97 0.4 7 6.00 0.72 3.11 0.92 
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5.87 0.90 
4.55 0.53 
3.50 0.74 
126.80 23.61 
3.19 0.57 
6.08 1.11 
2.25 0.35 
1.87 0.21 
3.45 0.95 
3.09 0.34 
7.11 1.31 
2.20 0.43 
4.28 0.66 
1.78 0.31 
126.35 18.97 
2.91 0.34 
6.95 0.72 
3.41 0.41 
S100 calcium binding protein A10 
S100a10 M16465 90.03 21.05 95.51 18.55 (calpactin) 62.41 13.54 102.41 11.11 40.76 7.84 67.19 6.39 
sema domain, seven 
thrombospondin repeats (type 1 
and type 1-like), transmembrane Sema5b X97818 13.21 1.72 13.40 2.03 14.86 1.99 13.78 2.78 12.68 1.86 14.33 1.57 
domain (TM) and short cytoplasmic 
domain, (semaphorin) 5B 
sequestosome 1 Sqstm1 U40930 4.59 1.40 5.86 1.65 2.86 0.85 8.24 1.76 2.98 0.52 5.11 0.91 
serine (or cysteine) peptidase 
Serpine1 M33960 5.12 0.58 4.49 1.59 
inhibitor, clade E, member 1 
5.94 1.44 4.31 1.76 6.11 2.04 5.80 0.85 
serine (or cysteine) peptidase 
Serpinh1 J05609 9.97 0.98 16.87 5.53 11.54 2.30 8.77 0.77 7.81 1.47 8.25 0.38 
inhibitor, clade H, member 1 
signal transducer and activator of 
Stat6 L47650 3.77 1.03 3.51 0.66 3.88 0.56 3.79 0.87 2.65 0.55 2.64 0.26 
transcription 6 
solute carrier family 6 
(neurotransmitter transporter, SIc6a9 X67056 7.01 2.10 6.28 1.27 4.72 1.23 9.44 1.15 4.50 1.29 5.40 0.66 
glycine), member 9 
solute carrier family 9 
(sodium/hydrogen exchanger), SIc9a1 U51112 5.8 1.75 5.67 1.54 4.89 1.19 9.09 0.93 5.69 1.38 8.73 1.21 
member 1 
split ha nd/foot malformation 
Shfm1 U41626 56.32 11.52 49.16 5.00 51.69 7.51 70.53 5.52 43.97 11.51 31.88 4.95 (ectrodactyly) type 1 
stromal cell derived factor 4 Sdf4 U45977 6.44 1.28 9.04 2.34 6.68 1.17 6.30 0.85 8.63 1.96 8.42 0.94 
structure specifie recognition 
Ssrp1 S50213 8.97 1.47 8.97 1.67 5.91 0.89 9.12 1.32 3.41 0.85 4.58 0.43 
protein 1 
syndecan 1 Sdc1 Z22532 3.24 0.69 5.88 2.75 4.04 0.71 3.74 0.57 2.95 0.81 4.40 0.53 
syndecan 2 Sdc2 U00674 4.16 1.50 2.99 0.31 2.45 0.66 3.09 0.60 2.24 0.42 2.04 0.44 
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TAF6 RNA polymerase Il, TATA 
box binding protein (TBP)- Taf6 049439 2.04 0.59 1.74 0.65 1.36 0.45 1.97 0.45 1.70 0.64 0.86 0.14 
associated factor 
T-box 3 Tbx3 U57328 2.10 0.55 1.76 0.40 2.97 0.38 2.00 0.55 2.33 0.64 2.26 0.61 
THO complex 4 Thoc4 U89876 20.30 3.17 17.39 4.93 12.64 1.21 21.48 4.26 10.75 1.05 7.89 1.57 
thrombospondin 1 Thbs1 M87276 13.95 2.07 19.19 4.73 11.78 1.84 11.25 3.05 7.71 1.89 7.47 1.43 
thymoma viral proto-oncogene 1 Akt1 M94335 15.39 2.92 12.55 5.37 14.13 2.88 9.95 2.26 13.05 2.51 6.69 0.74 
thymosin, beta 4, X chromosome Tmsb4x X16053 5.28 0.98 8.58 2.32 2.84 0.58 5.70 0.87 3.39 0.78 2.63 0.58 
thyroid hormone receptor alpha Thra X51983 4.80 1.60 6.30 0.69 9.24 2.15 7.92 1.39 7.04 1.29 9.10 0.98 
tissue inhibitor of 
Timp2 X62622 13.85 2.94 17.77 2.43 13.34 1.19 13.40 1.77 9.85 2.22 13.62 2.21 
metalloproteinase 2 
transcription factor Op 1 Tfdp1 X7231 0 9.97 0.55 12.44 3.17 9.58 0.87 10.93 2.15 9.09 1.51 7.29 1.30 
transcription termination factor 1 Ttf1 X83974 5.70 1.25 8.77 4.25 10.42 3.35 6.35 1.64 9.51 3.86 7.57 2.02 
transformation related protein 53 Trp53 K01700 11.33 3.32 10.61 5.04 6.06 1.29 12.30 2.55 7.97 1.23 8.24 1.10 
translin Tsn X81464 3.82 1.08 4.12 1.14 4.12 0.54 3.77 0.76 2.29 0.44 3.80 1.09 
tumor necrosis factor receptor 
Tnfrsf1b M59378 2.85 0.74 2.66 0.33 2.12 0.27 5.16 0.93 2.12 0.49 1.91 0.25 
superfamily, member 1 b 
tyrosine 3-
monooxygenase/tryptophan 5-
Ywhah U57311 30.58 0.51 34.33 8.33 32.78 7.08 39.26 6.91 13.29 2.77 38.56 7.07 
monooxygenase activation protein, 
eta polypeptide 
tyrosine 3-
monooxygenase/tryptophan 5-
Ywhaz 078647 17.52 4.36 14.91 5.19 19.50 4.41 16.05 4.89 12.13 1.62 12.12 2.70 
monooxygenase activation protein, 
zeta polypeptide 
133.0 152.1 
ubiquitin B Ubb X51703 536.77 631.89 560.63 93.76 425.24 79.12 425.33 86.26 320.57 68.85 
5 8 
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ubiquitin-conjugating enzyme E2B, 
Ube2b X96859 3.76 0.13 2.77 0.70 3.80 0.77 3.00 0.55 2.75 0.64 3.09 0.37 
RAD6 homology (S. cerevisiae) 
upstream binding transcription 
Ubtf X60831 2.73 0.38 3.20 0.74 2.60 0.40 3.13 0.75 1.95 0.34 1.93 0.29 
factor, RNA polymerase 1 
v-abl Abelson murine leukemia 
Abl1 L10656 3.35 1.05 4.64 0.42 1.56 0.56 2.68 0.73 2.11 0.35 3.41 0.39 
oncogene 1 
villin 2 Vi/2 X60671 12.51 2.94 12.26 2.86 16.25 2.06 18.40 2.61 17.71 3.30 18.42 3.21 
vimentin Vim X51438 64.47 15.83 82.01 9.91 91.18 30.90 91.00 8.81 67.09 12.91 65.13 7.04 
v-raf murine sarcoma 3611 viral 
Araf M13071 4.83 1.01 6.47 1.10 5.43 0.94 5.90 0.98 5.28 1.26 5.06 0.39 
oncogene homolog 
v-rel reticuloendotheliosis viral 
Rela M61909 9.48 1.53 7.26 1.74 10.09 2.45 10.03 1.57 9.25 2.63 12.54 1.40 
oncogene homolog A 
y box protein 1 Ybx1 X57621 98.70 14.36 84.43 17.93 129.33 18.30 135.82 23.27 145.46 27.57 117.65 23.74 
zinc finger protein 36, C3H type-
Zfp3611 M58566 12.86 3.11 7.62 1.05 10.60 1.30 10.16 2.57 8.10 1.74 15.00 4.53 
like 1 
zyxin Zyx X99063 12.86 2.42 15.93 2.76 11.65 1.11 10.19 1.42 12.01 2.57 13.46 1.08 
a Increasing and decreasing genes are defined as genes statistically changing (increasing or decreasing) by at least 1.5-
fold following the removal of androgens. Genes changing by 1.5-fold that were not statistically significant were considered 
not aftected by androgen withdrawal. 
243 
SURRlemental Table 48. Gene lists for ail genes eXRressed at 6 daïs a 
Genbank 
Day 0 (Control) Day 2 Day 4 Day4 
Day 6 
Day 6 
Gene (With Rescue) (With Rescue) 
Common Gene Name Accession 
symbol Norm. SEM Norm SEM Norm. SEM Norm. SEM Norm. SEM Norm. SEM 
number 
data . data data data data data 
Increasing Expression, DHT Rescue 
periostin Postn 013664 0.10 0.05 0.50 0.40 9.26 2.12 0.41 0.19 8.95 3.33 2.69 0.99 
transducer of Erb8-2.1 Tob1 078382 2.64 0.32 2.81 0.80 3.29 0.39 3.06 0.68 4.29 0.44 2.38 0.60 
Increasing Expression, No DHT Rescue 
fibroblast growth factor receptor 1 Fgfr1 M28998 5.93 0.60 5.07 1.24 10.56 0.95 5.81 0.87 9.46 1.26 6.70 1.36 
prion protein Prnp M13685 3.31 0.47 4.81 1.30 8.84 2.54 5.15 0.54 6.13 0.67 8.36 1.28 
procollagen, type VI, alpha 1 Co/6a1 X66405 2.22 0.36 3.21 1.35 4.81 1.04 1.78 0.24 5.36 1.62 3.88 0.25 
syndecan 3 Sdc3 U52826 3.23 0.38 2.70 0.67 11.30 2.19 3.16 0.45 9.14 2.15 10.88 0.98 
Decreasing Expression, DHT Rescue 
mitogen activated protein kinase 14 Mapk14 U10871 8.77 1.64 11.59 2.39 11.19 1.46 8.85 1.01 4.40 0.59 7.35 0.57 
cyclin 82 Ccnb2 X66032 7.32 0.88 9.56 3.13 5.86 1.14 7.11 1.69 3.66 0.46 5.51 0.65 
heat shock protein 90kOa alpha 
Hsp90ab1 M36829 34.52 6.81 62.86 7.60 23.55 9.57 45.59 13.23 16.17 2.68 33.95 3.26 (cytosolic), class 8 member 1 
tyrosine 3-monooxygenase/ 
tryptophan 5-monooxygenase Ywhah U57311 30.58 0.51 34.33 8.33 32.78 7.08 39.26 6.91 13.29 2.77 38.56 7.07 
activation protein, eta polypeptide 
244 
Decreasing Expression, No DHT Rescue 
3-phosphoglyeerate 
dehydrogenase 
ami no-terminal enhancer of split 
bcl2-like 1 
breast cancer anti-estrogen 
resistance 1 
budding uninhibited by 
benzimidazoles 1 homolog beta 
ealcyclin binding protein 
cell division cycle 20 homolog 
cyclin A2 
cyclin B1 
cyclin D1 
cyclin E1 
Di George syndrome critical region 
gene 6 
dynein light chain Le8-type 1 
early growth response 1 
general transcription factor Il 1 
glucose phosphate isomerase 1 
high mobility group nucleosomal 
binding domain 1 
keratin complex 1, acidic, gene 19 
laminin, alpha 5 
minichromosome maintenance 
deficient 5, cell division cycle 46 
Phgdh 
Aes 
Be/2/1 
Bear1 
Bub1b 
Gaeybp 
Gde20 
Gena2 
Genb1 
Gend1 
Gene 1 
Dger6 
Dyn/14 
Egr1 
Gtf2i 
Gpi1 
Hmgn1 
Krl1-19 
Lama5 
Mem5 
L21027 
L12140 
L35049 
U48853 
AF107296 
U97327 
AB045313 
Z26580 
X64713 
S78355 
X75888 
AF021031 
AF020185 
M20157 
AF017085 
M14220 
X53476 
M28698 
U37501 
D26090 
8.05 
24.19 
3.04 
3.47 
2.80 
2.55 
10.45 
6.21 
6.55 
3.28 
3.00 
7.02 
82.09 
37.45 
5.23 
62.71 
27.65 
5.97 
5.85 
26.83 
0.57 5.62 
3.42 19.29 
0.20 2.14 
0.86 3.12 
0.52 
0.93 
1.65 
1.09 
0.08 
0.24 
0.26 
1.28 
15.93 
8.20 
0.52 
11.66 
6.45 
1.19 
1.25 
3.96 
2.50 
11.11 
10.13 
6.27 
4.34 
3.33 
10.37 
55.85 
48.95 
5.97 
68.82 
50.91 
4.84 
6.40 
6.13 22.85 
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0.74 
3.92 
0.39 
0.45 
0.92 
0.66 
1.61 
2.17 
1.50 
1.97 
0.31 
3.66 
12.39 
6.11 
1.48 
15.00 
15.92 
0.45 
2.18 
3.32 
4.12 
22.46 
1.74 
1.41 
1.78 
1.65 
6.21 
4.50 
3.40 
2.41 
2.02 
6.03 
44.20 
17.79 
3.96 
48.89 
27.90 
2.53 
2.94 
17.59 
0.69 
1.54 
0.34 
0.25 
0.29 
0.37 
1.14 
1.16 
0.47 
0.53 
0.30 
1.42 
10.50 
2.21 
0.42 
6.42 
9.49 
0.44 
0.58 
2.43 
7.34 
26.75 
2.06 
4.01 
4.02 
2.00 
12.82 
7.42 
7.18 
3.20 
3.18 
7.86 
56.25 
51.98 
5.78 
86.65 
31.22 
5.81 
6.75 
26.06 
1.34 
2.96 
0.39 
0.51 
0.46 
0.50 
0.81 
2.25 
1.48 
1.16 
0.33 
1.02 
15.82 
12.06 
0.57 
15.67 
6.72 
0.73 
1.30 
2.69 
3.65 
13.73 
1.43 
0.97 
1.68 
0.79 
5.51 
3.01 
2.69 
1.71 
1.34 
3.35 
36.22 
17.37 
2.08 
32.91 
11.16 
1.54 
2.11 
11.78 
0.64 
1.44 
0.24 
0.27 
0.10 
0.05 
0.77 
0.73 
0.50 
0.12 
0.12 
0.63 
8.60 
3.55 
0.18 
4.61 
2.56 
0.27 
0.64 
3.09 
3.30 
18.09 
1.46 
1.17 
1.26 
1.19 
5.43 
2.19 
2.85 
1.96 
1.79 
4.83 
20.63 
19.66 
2.56 
29.26 
11.66 
2.51 
2.87 
20.05 
0.44 
1.67 
0.37 
0.21 
0.29 
0.54 
0.65 
0.77 
0.51 
0.60 
0.40 
0.65 
5.64 
2.74 
0.26 
2.59 
5.12 
0.26 
0.61 
2.35 
phosphoprotein enriched in 
astrocytes 15 
pleckstrin homology-like domain, 
family A, member 1 
proliferation-associated 2G4 
RAB2, member RAS oncogene 
family 
RA021 homolog 
retinoic acid receptor, gamma 
secreted phosphoprotein 1 
structure specifie recognition 
protein 1 
THO complex 4 
Pea15 
Phlda1 
Pa2g4 
Rab2 
Rad21 
Rarg 
Spp1 
Ssrp1 
Thoc4 
thrombospondin 1 Thbs1 
Genes Not Affected By Androgen Withdrawal 
activating transcription factor 4 Atf4 
adenylate cyclase 6 Adcy6 
amyloid beta (A4) precursor protein App 
AT motif binding factor 1 Atbf1 
basigin 
B-cell translocation gene 2, anti-
proliferative 
bcI2-antagonist/killer 1 
bcl2-associated athanogene 1 
bcl2-associated X protein 
beta-actin 
b-raf oncogene 
Bsg 
Btg2 
Bak1 
Bag1 
Bax 
Actb 
Braf 
X86694 
U44088 
U43918 
X95403 
049429 
M34476 
X13986 
S50213 
U89876 
M87276 
M94087 
M96653 
X59379 
0026046 
000611 
M64292 
Y13231 
U17162 
L22472 
M12481 
M64429 
4.55 0.65 3.38 
23.57 4.72 12.93 
24.81 4.41 37.22 
10.28 2.39 11.28 
24.23 4.51 17.60 
3.85 0.58 3.33 
6.52 1.30 7.09 
8.97 
20.30 
13.95 
1.47 8.97 
3.17 17.39 
2.07 19.19 
6.77 2.8 6.11 
4.40 1.09 4.25 
4.89 0.42 3.81 
3.20 0.81 3.70 
24.50 4.94 20.47 
4.80 
5.46 
13.97 
4.64 
279.24 
6.25 
1.49 
0.77 
1.91 
0.90 
55.37 
1.58 
4.36 
4.72 
19.47 
3.67 
255.3 
8.81 
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0.80 
3.85 
8.69 
1.03 
7.47 
0.12 
0.74 
1.67 
4.93 
4.73 
2.45 
0.33 
0.58 
0.55 
5.58 
1.68 
0.75 
6.30 
0.51 
53.42 
1.42 
2.66 
7.85 
14.37 
7.94 
5.92 
3.18 
1.21 
5.91 
12.64 
11.78 
3.56 
5.69 
7.67 
5.63 
18.56 
3.72 
5.07 
14.30 
2.98 
167.82 
7.10 
0.73 
1.73 
3.15 
1.81 
1.14 
0.83 
0.30 
0.89 
1.21 
1.84 
0.56 
1.05 
0.81 
0.80 
3.89 
0.95 
0.86 
3.39 
0.41 
51.17 
1.02 
4.11 
21.32 
30.73 
11.70 
20.00 
4.86 
6.60 
9.12 
21.48 
11.25 
6.70 
6.61 
4.70 
4.94 
25.47 
4.83 
4.74 
13.63 
4.43 
317.08 
8.42 
0.62 
4.63 
4.11 
1.90 
2.77 
0.68 
1.20 
1.32 
4.26 
3.05 
1.55 
1.03 
0.83 
1.02 
4.12 
1.08 
0.78 
2.26 
0.80 
56.20 
0.92 
2.56 0.61 
5.87 1.31 
11.19 2.09 
4.09 1.28 
6.13 1.62 
1.60 0.42 
2.64 0.33 
3.41 
10.75 
7.71 
3.91 
2.44 
4.71 
4.27 
18.82 
2.16 
3.45 
8.86 
2.97 
166.33 
6.84 
0.85 
1.05 
1.89 
0.77 
0.41 
1.20 
1.34 
5.37 
0.36 
0.77 
1.40 
0.67 
53.35 
1.60 
3.19 
6.57 
10.95 
6.08 
7.36 
2.20 
1.78 
4.58 
7.89 
7.47 
4.33 
5.51 
6.49 
4.62 
22.92 
3.10 
1.42 
4.84 
1.92 
189.48 
8.16 
0.50 
1.04 
1.80 
1.11 
0.91 
0.43 
0.41 
0.43 
1.57 
1.43 
0.77 
0.63 
0.99 
0.71 
2.35 
0.38 
0.23 
1.16 
0.46 
34.86 
0.40 
cadherin 2 
calcitonin gene-related peptide-
receptor component protein 
calmodulin 1 
caspase 1 
cathepsin D 
caudal type homeo box 2 
Cbp/p300-interacting 
transactivator, with Glu/Asp-rich 
carboxy-terminal domain, 2 
C014 antigen 
COC28 protein kinase regulatory 
subunit 2 
cell division cycle 42 homolog 
coagulation factor Il (thrombin) 
receptor 
cofilin 1, non-muscle 
colony stimulating factor 1 
colony stimulating factor 2 receptor, 
alpha 
cyclin F 
cyclin-dependent kinase 4 
cystatin C 
disheveled 2, dsh homolog 
disheveled, dsh homolog 1 
(Orosophila) 
Cdh2 
Crep 
Calm 1 
Casp1 
Ctsd 
Cdx2 
Cited2 
Cd14 
Cks2 
Cde42 
F2r 
Cf/1 
Csf1 
Csf2ra 
Cenf 
Cdk4 
Cst3 
Dvl2 
Dvl1 
M31131 
AF028242 
X61432 
L28095 
X53337 
S74520 
Y15163 
M34510 
AA289122 
U37720 
L03529 
000472 
X05010 
M85078 
Z47766 
L01640 
M59470 
U24160 
U10115 
7.60 
6.82 
9.03 
10.72 
13.38 
3.61 
7.83 
2.35 
7.30 
5.26 
3.64 
15.37 
5.38 
36.92 
3.19 
4.49 
4.57 
6.16 
2.52 
2.16 6.92 
1.44 8.42 
2.48 7.06 
2.14 8.66 
2.83 18.62 
1.07 3.91 
1.89 6.46 
0.84 1.97 
0.79 8.78 
2.58 3.47 
0.37 3.80 
1.89 10.83 
1.57 10.05 
6.2 35.10 
0.74 2.70 
0.35 6.84 
1.28 3.76 
1.42 6.83 
1.41 2.95 
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1.64 
2.75 
1.48 
2.64 
6.64 
0.72 
1.26 
0.44 
1.26 
1.16 
0.72 
3.42 
0.76 
7.98 
0.47 
1.39 
1.54 
1.55 
0.54 
5.10 
5.87 
8.76 
8.19 
18.78 
3.75 
8.16 
1.37 
6.38 
2.72 
6.95 
14.44 
4.54 
27.81 
2.46 
3.99 
2.81 
8.16 
1.32 
0.79 
1.14 
1.70 
2.07 
3.62 
0.72 
1.02 
0.28 
1.01 
0.55 
0.87 
2.73 
0.78 
4.08 
0.91 
0.68 
0.63 
1.43 
0.27 
7.36 
5.76 
8.77 
9.69 
16.66 
3.44 
6.82 
3.74 
7.86 
5.98 
2.96 
15.78 
7.65 
24.35 
2.50 
4.27 
3.97 
7.32 
3.26 
2.43 
1.37 
2.20 
2.41 
1.56 
0.73 
2.03 
0.25 
1.82 
1.81 
0.80 
3.50 
1.03 
4.57 
0.81 
0.72 
0.40 
0.60 
0.63 
5.20 
4.17 
3.66 
8.45 
11.38 
1.27 
10.14 
0.99 
6.02 
1.57 
3.54 
20.88 
5.01 
21.34 
2.67 
3.96 
3.10 
4.43 
0.61 
1.51 
0.92 
0.89 
1.83 
2.38 
0.29 
1.68 
0.12 
0.55 
0.27 
1.36 
6.44 
0.57 
3.40 
0.66 
0.71 
0.73 
0.63 
0.12 
9.64 
3.20 
7.80 
6.31 
14.33 
2.58 
13.73 
2.40 
7.10 
2.43 
5.45 
18.97 
7.56 
23.69 
3.39 
4.22 
3.20 
5.80 
0.99 
1.67 
0.56 
0.83 
1.12 
1.29 
0.46 
2.77 
0.15 
0.74 
0.59 
0.86 
1.42 
0.71 
4.49 
0.46 
0.58 
0.51 
0.61 
0.17 
OnaJ (Hsp40) homolog, subfamily 
Dnajc3 U28423 2.52 0.33 2.28 0.39 2.73 0.44 2.05 0.25 1.98 0.66 2.51 0.55 
C, member 3 
dystroglycan 1 Dag1 U43512 5.41 1.07 7.86 1.08 5.59 1.47 7.84 1.73 3.95 1.07 5.38 0.92 
epimorphin Epim 010475 2.27 0.57 3.34 0.74 5.45 0.97 3.35 0.57 3.45 0.50 3.87 1.03 
Ets2 repressor factor Erf U58533 3.48 0.68 2.54 0.68 3.70 0.62 3.67 0.87 3.71 1.36 4.22 0.67 
expressed in non-metastatic cells 2 
Nme2 X68193 113.43 34.12 203.9 48.18 86.61 20.30 158.44 17.03 70.40 15.88 64.51 6.40 
protein 
fibronectin 1 Fn1 X82402 20.69 1.13 2.77 0.52 3.02 0.29 3.68 0.87 2.08 0.32 2.25 0.35 
follistatin Fst Z29532 2.43 0.85 4.77 1.00 5.97 0.46 3.94 0.36 4.23 0.50 3.25 0.64 
forkhead box F1 a Foxf1a L35949 3.05 0.51 3.39 0.49 4.54 0.72 4.42 0.44 2.51 0.48 3.87 0.59 
frizzled homolog 6 Fzd6 U43319 5.36 1.68 5.43 1.27 9.80 1.03 4.94 0.67 4.55 1.00 6.51 0.90 
glutathione reductase 1 Gsr X76341 7.29 1.71 11.85 3.68 4.29 0.89 13.58 1.91 4.05 0.53 3.76 0.68 
glutathione S-transferase, mu 2 Gstm2 J04696 30.94 7.49 35.73 3.99 29.19 4.62 62.06 7.34 26.48 6.08 30.05 4.23 
glutathione S-transferase, pi 1 Gstp1 030687 17.76 4.66 16.98 1.24 9.75 1.60 25.25 3.84 7.12 1.10 9.70 0.77 
glyceraldehydes-3-phosphate 
Gapdh M32599 217.46 73.55 168.4 32.46 108.22 26.40 243.76 64.87 76.21 33.01 109.99 13.79 
dehydrogenase 
GNAS (guanine nucleotide binding 
protein, alpha stimulating) complex Gnas Y00703 29.63 7.23 30.32 7.61 43.61 7.35 27.47 2.56 30.75 11.59 33.91 5.03 
locus 
growth differentiation factor 9 Gdf9 X77113 4.42 0.99 7.56 2.90 4.24 0.90 4.14 0.96 3.32 0.57 5.98 1.08 
guanine nucleotide binding protein, 
Gnai2 M13963 2.63 0.89 1.84 0.62 2.45 0.46 2.68 0.81 2.37 0.58 3.24 0.54 
alpha inhibiting 2 
guanine nucleotide binding protein, 
Gnb2 U34960 4.20 1.10 4.78 1.31 5.00 0.89 5.11 0.81 5.02 1.72 5.72 0.98 
beta 2 
heat shock 70kO protein 5 
Hspa5 078645 4.49 0.96 6.81 1.79 6.96 0.83 5.84 1.57 7.78 1.48 6.55 0.92 (glucose-regulated protein) 
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heat shock protein 90kOa alpha, 
class A member 1 
homeo box 89 
host celi factor C 1 
hypoxanthine guanine 
phosphoribosyl transferase 1 
immediate early response 2 
insulin-like growth factor binding 
protein 2 
integrin alpha 3 
integrin beta 1 
integrin linked kinase 
jun proto-oncogene related 
gene d1 
kruppel-like factor 3 (basic) 
laminin, gamma 1 
lecithin cholesterol acyltransferase 
LlM domain binding 1 
MAP kinase-activated protein 
kinase 2 
MARCKS-like 1 
max binding protein 
max protein 
minichromosome maintenance 
deficient 2 mitotin 
myelocytomatosis oncogene 
myosin, light polypeptide 6 
Hsp90aa1 
Hoxb9 
Hefe1 
Hprt1 
ler2 
Igfbp2 
Itga3 
Itgb1 
IIk 
Jund1 
Klf3 
Larne1 
Leat 
Ldb1 
Mapkapk2 
Mareksl1 
Mnt 
Max 
Mern2 
Mye 
Myl6 
M36830 
M34857 
U53925 
J00423 
M31042 
X81580 
013867 
Y00769 
U94479 
J05205 
U36340 
X05211 
J05154 
U69270 
X76850 
X61399 
Y07609 
M63903 
086725 
X01023 
U04443 
15.74 4.59 28.79 
11.50 1.94 15.13 
7.18 0.98 5.52 
3.70 1.75 2.63 
9.90 2.01 7.83 
145.97 40.98 168.2 
11.15 4.64 17.51 
9.94 3.65 7.83 
6.79 1.89 10.01 
9.80 1.70 11.09 
4.03 0.62 2.03 
7.00 2.32 6.96 
3.33 1.07 3.14 
4.31 0.84 4.57 
3.32 0.41 2.96 
2.94 0.98 2.56 
5.06 0.98 3.37 
5.78 1.21 5.16 
6.84 1.59 5.98 
35.86 9.14 46.15 
46.96 3.69 43.88 
249 
7.88 
4.69 
1.07 
0.54 
0.98 
31.11 
5.78 
2.75 
1.63 
1.94 
0.37 
1.90 
0.83 
1.33 
0.70 
0.89 
0.68 
1.06 
0.57 
8.59 
6.01 
15.94 4.32 
15.40 2.26 
9.03 0.96 
2.46 1.06 
12.59 2.27 
74.53 15.65 
8.00 2.12 
20.63 2.89 
5.62 1.07 
7.70 1.39 
4.35 1.00 
10.49 2.17 
2.33 0.57 
3.13 0.39 
2.82 0.70 
1.39 0.35 
6.28 1.00 
3.57 0.70 
5.76 0.94 
21.70 3.09 
51.72 8.26 
18.96 5.56 
15.71 3.44 
8.95 1.51 
2.47 0.80 
9.93 1.06 
112.52 18.12 
14.15 1.40 
9.73 3.99 
9.66 0.55 
16.68 1.03 
4.72 0.62 
7.45 0.78 
3.59 0.33 
4.55 "1.77 
3.19 0.72 
3.72 0.67 
5.25 0.57 
6.13 0.80 
8.37 1.17 
48.99 10.11 
42.55 5.51 
17.83 5.38 20.54 3.39 
10.30 2.48 11.48 2.70 
8.73 1.87 10.01 2.16 
1.90 0.60 3.11 0.91 
7.94 1.72 11.53 0.56 
98.96 34.34 118.32 13.16 
3.78 1.45 5.48 1.11 
16.81 5.13 16.31 3.65 
5.64 0.80 5.38 0.61 
9.82 2.38 14.16 1.86 
3.08 0.56 3.90 0.81 
7.55 2.29 7.97 1.21 
2.00 0.44 2.91 0.34 
3.45 0.64 3.31 0.38 
2.34 0.62 2.62 0.62 
1.36 0.36 1.28 0.38 
4.49 0.56 4.70 0.39 
2.96 0.62 4.18 0.41 
4.76 0.90 5.78 0.39 
21.86 4.27 27.18 3.40 
44.66 11.66 41.64 5.24 
N-acetylglucosamine-1-
phosphodiester alpha-N- Nagpa U36760 3.82 0.84 2.35 0.75 3.14 0.70 4.16 0.69 2.62 0.84 4.08 0.71 
acetylglucosaminidase 
neuroblastoma ras oncogene Nras X13664 2.27 0.46 4.27 0.86 3.61 0.57 2.87 0.55 2.61 0.26 2.12 0.40 
Ngfi-A binding protein 1 Nab1 U47008 2.91 0.23 2.22 0.66 2.97 0.52 2.74 0.71 2.06 0.66 2.75 0.73 
C1d 
nuclear ONA binding protein AF031426 3.60 0.62 2.28 1.01 3.98 1.38 2.92 0.69 2.68 0.72 1.55 0.42 (Interim) 
nuclear factor of kappa light chain 
gene enhancer in B-cells inhibitor, Nfkbib U19799 2.87 0.45 2.78 0.60 1.98 0.37 3.43 0.71 1.76 0.25 2.18 0.28 
beta 
nuclear receptor subfamily 2, group 
Nr2f6 X76654 6.91 1.42 2.96 0.70 2.82 0.70 3.19 0.72 2.34 0.62 2.62 0.62 
F, member6 
ornithine decarboxylase, structural1 Ode 1 M10624 8.28 3.20 12.14 2.33 6.89 1.31 10.08 1.13 2.74 0.79 5.81 0.75 
paired box gene 8 Pax8 X57487 11.95 1.96 3.20 0.74 2.60 0.40 3.13 0.75 1.95 0.34 1.93 0.29 
phospholipid transfer protein Pltp U37226 3.11 0.83 2.73 0.65 5.79 0.63 3.75 0.72 6.21 1.86 6.70 0.72 
proliferating cell nuclear antigen Pena X53068 4.51 0.65 3.03 0.29 4.58 0.66 3.55 0.76 3.99 0.53 5.25 0.35 
protective protein for beta-
Ppgb J05261 6.36 1.25 5.44 0.65 4.39 0.71 7.84 1.13 4.53 0.94 5.87 0.90 
galactosidase 
protein disulfide isomerase 
Pdia4 J05186 3.14 0.56 5.04 0.48 4.91 1.07 5.42 0.77 5.01 1.13 4.55 0.53 
associated 4 
protein tyrosine phosphatase, non-
Pfpn13 083966 4.02 0.93 6.25 1.15 4.61 0.75 6.22 1.02 2.59 0.68 3.50 0.74 
receptor type 13 
prothymosin alpha Pfma X56135 98.68 8.77 85.90 16.48 105.29 19.40 102.19 25.61 81.67 25.81 126.80 23.61 
purine rich element binding 
Pura U02098 2.95 0.56 1.51 0.24 2.89 0.24 1.44 0.35 2.48 0.36 3.19 0.57 
protein A 
RA023a homolog (5. cerevisiae) Rad23a X92410 3.73 0.75 2.77 0.52 3.02 0.29 3.68 0.87 2.08 0.32 2.25 0.35 
RA023b homolog Rad23b X92411 13.89 2.21 12.02 2.63 24.98 2.97 14.36 2.83 10.79 3.60 18.48 3.19 
250 
RAN GTPase activating protein 1 Rangap1 U08110 2.45 0.65 3.08 0.55 1.96 0.28 2.89 0.39 1.55 0.39 1.87 0.21 
RAS-related C3 botulinum 
Rac1 X57277 4.1 0.81 3.49 0.39 3.96 1.02 4.25 1.24 3.96 0.97 3.45 0.95 
substrate 1 
receptor-like tyrosine kinase Ryk M98547 5.75 1.15 6.38 2.29 7.90 1.39 5.08 1.08 4.88 1.03 3.09 0.34 
recombination activating gene 1 
Rag1ap1 X96618 7.92 1.68 6.61 0.81 9.51 0.93 7.78 0.96 6.82 1.72 7.11 1.31 
activating protein 1 
retinoid X receptor alpha Rxra M84817 4.41 0.74 5.50 1.43 6.36 0.90 5.31 0.67 3.34 0.72 4.28 0.66 
rho/rac guanine nucleotide 
Arhgef2 U28495 2.79 0.63 6.26 2.32 2.49 0.70 3.60 1.22 2.55 0.48 1.78 0.31 
exchange factor (GEF) 2 
ribosomal protein S29 Rps29 L31609 153.78 46.92 226.7 66.21 119.13 29.08 268.14 49.81 107.12 25.07 126.35 18.97 
ribosomal prote in SA Rpsa J02870 14.59 6.25 3.14 0.83 2.33 0.57 3.59 0.33 2.00 0.44 2.91 0.34 
nuclear receptor subfamily 1, group 
Nr1h2 U09419 3.71 0.77 2.95 0.73 5.93 1.08 4.65 0.26 4.83 1.32 6.95 0.72 
H, member2 
Rous sarcoma oncogene Src M17031 4.58 1.24 5.33 0.19 1.97 0.47 6.00 0.72 3.11 0.92 3.41 0.41 
S100 calcium binding protein A10 
S100a10 M16465 90.03 21.05 95.51 18.55 62.41 13.54 102.41 11.11 40.76 7.84 67.19 6.39 (calpactin) 
sema domain, seven 
thrombospondin repeats (type 1 
and type 1-like), transmembrane Sema5b X97818 13.21 1.72 13.40 2.03 14.86 1.99 13.78 2.78 12.68 1.86 14.33 1.57 
domain (TM) and short cytoplasmic 
domain, (semaphorin) 5B 
sequestosome 1 Sqstm1 U40930 4.59 1.4 5.86 1.65 2.86 0.85 8.24 1.76 2.98 0.52 5.11 0.91 
serine (or cysteine) peptidase 
Serpine1 M33960 5.12 0.58 4.49 1.59 5.94 1.44 4.31 1.76 6.11 2.04 5.80 0.85 
inhibitor, clade E, member 1 
serine (or cysteine) peptidase 
Serpinh1 J05609 9.97 0.98 16.87 5.53 11.54 2.30 8.77 0.77 7.81 1.47 8.25 0.38 
inhibitor, clade H, member 1 
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signal transducer and activator of 
Stat6 L47650 3.77 1.03 3.51 0.66 3.88 0.56 3.79 0.87 2.65 0.55 2.64 0.26 
transcription 6 
solute carrier family 6 
(neurotransmitter transporter, SIc6a9 X67056 7.01 2.1 6.28 1.27 4.72 1.23 9.44 1.15 4.50 1.29 5.40 0.66 
glycine), member 9 
solute carrier family 9 
(sodium/hydrogen exchanger), SIc9a1 U51112 5.80 1.75 5.67 1.54 4.89 1.19 9.09 0.93 5.69 1.38 8.73 1.21 
member 1 
split hand/foot malformation 
Shfm1 U41626 56.32 11.52 49.16 5.00 51.69 7.51 70.53 5.52 43.97 11.51 31.88 4.95 (ectrodactyly) type 1 
stromal cell derived factor 4 Sdf4 U45977 6.44 1.28 9.04 2.34 6.68 1.17 6.30 0.85 8.63 1.96 8.42 0.94 
syndecan 1 Sdc1 Z22532 3.24 0.69 5.88 2.75 4.04 0.71 3.74 0.57 2.95 0.81 4.40 0.53 
syndecan 2 Sdc2 U00674 4.16 1.50 2.99 0.31 2.45 0.66 3.09 0.60 2.24 0.42 2.04 0.44 
TAF6 RNA polymerase Il, TATA 
box binding protein (TBP)- Taf6 D49439 2.04 0.59 1.74 0.65 1.36 0.45 1.97 0.45 1.70 0.64 0.86 0.14 
associated factor 
T-box 3 Tbx3 U57328 2.10 0.55 1.76 0.40 2.97 0.38 2.00 0.55 2.33 0.64 2.26 0.61 
thymoma viral proto-oncogene 1 Akt1 M94335 15.39 2.92 12.55 5.37 14.13 2.88 9.95 2.26 13.05 2.51 6.69 0.74 
thymosin, beta 4 , X chromosome Tmsb4x X16053 5.28 0.98 8.58 2.32 2.84 0.58 5.70 0.87 3.39 0.78 2.63 0.58 
thyroid hormone receptor alpha Thra X51983 4.80 1.60 6.30 0.69 9.24 2.15 7.92 1.39 7.04 1.29 9.10 0.98 
tissue inhibitor of 
Timp2 X62622 13.85 2.94 17.77 2.43 13.34 1.19 13.40 1.77 9.85 2.22 13.62 2.21 
metalloproteinase 2 
transcription factor Dp 1 Tfdp1 X72310 9.97 0.55 12.44 3.17 9.58 0.87 10.93 2.15 9.09 1.51 7.29 1.30 
transcription termination factor 1 Ttf1 X83974 5.70 1.25 8.77 4.25 10.42 3.35 6.35 1.64 9.51 3.86 7.57 2.02 
transformation related protein 53 Trp53 K01700 11.33 3.32 10.61 5.04 6.06 1.29 12.30 2.55 7.97 1.23 8.24 1.10 
translin Tsn X81464 3.82 1.08 4.12 1.14 4.12 0.54 3.77 0.76 2.29 0.44 3.80 1.09 
tubulin, beta 4 Tubb4 M28730 2.47 0.27 1.81 0.67 1.22 0.25 1.42 0.27 1.75 0.28 1.00 0.23 
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') 
tumor necrosis factor receptor 
Tnfrsf1b M59378 2.85 0.74 2.66 0.33 
superfamily, member 1b 
2.12 0.27 5.16 0.93 2.12 0.49 1.91 0.25 
tyrosine 3-
monooxygenase/tryptophan 5-
Ywhaz D78647 17.52 4.36 14.91 5.19 
monooxygenase activation protein, 
19.50 4.41 16.05 4.89 12.13 1.62 12.12 2.70 
zeta polypeptide 
ubiquitin B Ubb X51703 536.77 133.1 631.9 152.18 560.63 93.76 425.24 79.12 425.33 86.26 320.57 68.85 
ubiquitin-conjugating enzyme E2B, 
Ube2b X96859 3.76 0.13 2.77 0.70 
RAD6 homology (8. cerevisiae) 3.80 0.77 3.00 0.55 2.75 0.64 3.09 0.37 
upstream binding transcription 
Ubtf X60831 2.73 0.38 3.20 0.74 
factor, RNA polymerase 1 
2.60 0.40 3.13 0.75 1.95 0.34 1.93 0.29 
v-abl Abelson murine leukemia 
Abl1 L10656 3.35 1.05 4.64 0.42 1.56 0.56 2.68 0.73 2.11 0.35 3.41 0.39 
oncogene 1 
villin 2 Vil2 X60671 12.51 2.94 12.26 2.86 16.25 2.06 18.40 2.61 17.71 3.30 18.42 3.21 
vimentin Vim X51438 64.47 15.83 82.01 9.91 91.18 30.90 91.00 8.81 67.09 12.91 65.13 7.04 
v-raf murine sarcoma 3611 viral 
Araf M13071 4.83 1.01 6.47 1.10 5.43 0.94 5.90 0.98 5.28 1.26 5.06 0.39 
oncogene homolog 
v-rel reticuloendotheliosis viral 
Rela M61909 9.48 1.53 7.26 1.74 10.09 2.45 10.03 1.57 9.25 2.63 12.54 1.40 
oncogene homolog A 
y box protein 1 Ybx1 X57621 98.7 14.36 84.43 17.93 129.33 18.30 135.82 23.27 145.46 27.57 117.65 23.74 
zinc finger protein 36, C3H type-
Zfp3611 M58566 12.86 3.11 7.62 1.05 10.60 1.30 10.16 2.57 8.10 1.74 15.00 4.53 
like 1 
zyxin Zyx X99063 12.86 2.42 15.93 2.76 11.65 1.11 10.19 1.42 12.01 2.57 13.46 1.08 
a Increasing and decreasing genes are defined as genes statistically changing (increasing or decreasing) by at least 1.5-
fold following the removal of androgens. Genes changing by 1.5-fold that were not statistically significant were considered 
not atfected by androgen withdrawal. 
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CHAPTER 5 
Discussion 
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Given that DHT is the main androgen acting on the epididymis (1 ;2) and 
high levels of srd5aR2 mRNA are found in this tissue (3), the first part of this 
thesis explored the transcriptional and epigenetic regulation of this gene. In 
chapter 2, the 2.2 kb 5' upstream region of srd5aR2 was cloned, regions with 
strong repressor and enhancer elements were identified, the core promoter 
region was determined, the transcriptional start site was mapped, and SP1, and 
to a lesser extent SP3, were found to interact with the upstream region of 
srd5aR2. Although SP1 and SP3 are ubiquitous proteins, they were 
predominantly immunolocalized in the epididymis to principal cells, the cell type 
expressing srd5aR, and followed distinct distribution patterns in the tissue. In 
chapter 3, the role of DNA methylation in the regulation of srd5aR1 and srd5aR2 
was examined in tissues expressing various levels of the isozymes. For both 
genes, methylation of their 5' upstream region was not homogenous; CpG 
dinucleotides in this region were least methylated in the proximity of enhancer 
elements and the gene promoter of srd5aR2 and were most methylated in the 
srd5aR1 promoter region. Also, a number of tissue-specifie differences were 
identified in adenine and cytosine methylation for the srd5aR1 and srd5aR2 
genes, respectively. Although these results do not account for the differential 
expression of these two genes in the tissues examined, they represent the first 
analysis of the 5' upstream region of srd5aR2, at both the transcriptional and 
epigenetic levels. 
The second part of this thesis examined the response of a principal cell 
line to androgen manipulations. Principal cells express srd5aR and are very 
active in terms of protein synthesis and secretion (4); they are alsothe 
epididymal œil type most sensitive to androgens (5). In chapter 4, changes in 
gene expression of PC-1 cells, a pure population of principal cells originating 
from the proximal caput epididymidis, were monitored after 2, 4, and 6 days of 
androgen deprivation and after 2 days of DHT supplementation following 2 or 4 
days of androgen deprivation. While sorne genes were up- and down-regulated in 
the absence of androgens, the majority of androgen-regulated genes displayed 
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an early or late transient increase in expression javel. Depending on the time at 
which androgen supplementation wasinitiated, a differential ability of rescue was 
seen among androgen-regulated genes. Many of the genes that were rescued at 
4 days were functionally linked by direct interactions to IGF1, while many of the 
genes not rescued at 6 days belonged to specifie functional gene families (cell 
adhesion, cell growth, apoptosis, and cell cycle). Together, these studies provide 
novel insights into the mechanisms·of androgen action in principal cells and in the 
epididymis. 
1. Mechanisms of Androgen Action in the Epididymis 
Androgens are the main regulatQrs of epididymal structure and functions, 
but very few studies have focused directly on the mechanisms by which 
androgens exert their action in this tissue. While these studies have established 
that androgen action is mediated via DHT in the epididymis (6-11) and have 
characterized the expression of AR, ABP, and srd5aRs as weil as aspects of their 
regulation in the different regions of the tissue (reviewed in (5», many other 
questions remain. Sorne of the areas that would require further examination 
include the differential roles of DHT and testosterone in the epididymis, the 
contributions of nongenomic or non-classical pathways in mediating androgen 
action in the tissue, and in particular, the transcriptional and epigenetic regulation 
of the rate-limiting enzymes in DHT synthesis from testosterone and the 
specificity of androgen signalling in the epididymis. 
1.1. Transcriptional Regulation of the Srd5aRs in the Epididymis 
The expression and regulation of srd5aR1 and srd5aR2 in the epididymis 
have been investigated at the enzyme, protein, and mRNA levels; the findings 
have been summarized in section 4.2 of the thesis introduction. Limited wOrk, 
however, has been done in trying to elucidate the transcriptional and epigenetic 
regulation of the isozymes. These studies have been initiated for srd5aR2 in 
chapters 2 and 3 of this thesis. The transcriptional regulation of srd5aR1 remains 
unresolved in the epididymis, but its promoter region was recently characterized 
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in the rat (12). Contrary to the srd5aR2 promoter, the srd5aR1 promoter is 
bidirectional with the highest activity in the negative orientation, in the direction of 
the methyltransferase NSun2 (predicted) gene (12). The lack of similarity 
between the two promoters is puzzling considering they catalyze the sa me 
reaction and have similar gene structures and substrate preferences (reviewed in 
(13)). While the different promoters of the srd5aRs and the presumably unique 
combination of transcription factors interacting with their respective upstream 
regions allow the cell more flexibility in controlling the 5a-reduction of steroids, 
the differences between srd5aR1 and srd5aR2 suggest that srd5aR1 and 
srd5aR2 may not be strict isozymes. 
1.1.1. A Novel Role for Srd5aR2? 
From an evolutionary perspective, it is surprising that two enzymes that 
catalyze the same reaction are differentially distributed, uniquely regulated, and 
have fundamentally different promoters. The expression patterns of srd5aR1 and 
srd5aR2 in the epididymis perhaps allude to an additional function of srd5aR2 in 
this tissue. The enzymatic activity of srd5aR is highest in the initial segment and 
decreases dramatically along the tissue, a pattern that corresponds to that of 
srd5aR1 mRNA (14-16). Srd5aR2 mRNA expression, on the other hand, is highly 
expressed in the caput epididymidis, at levels much greater than that of srd5aR1 
in the initial segment (16). The lack of a specifie rat antibody recognizing srd5aR2 
precludes an analysis of srd5aR2 protein expression. However, the question 
remains why a cell would spend energy transcribing a gene that has poor if any 
enzymatic activity, unless the resulting protein is involved in another process. 
This other process may be particularly important for the caput epididymidis, which 
has higher mRNA levels of srd5aR2 compared to any other rat tissue (3). A 
careful re-examination of the srd5aR2 gene sequence may reveal a novel 
enzymatic active site or functional domain that has been previously overlooked or 
that was unknown at the time. If another function is attributed to srd5aR2, the 
tissue- and species-specificity of this function will have to be evaluated. 
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The hypothesis for a function other than the 5a-reduction of steroids for 
srd5aR2 in the epididymis is not a novel concept; other proteins, including 
glutathione-S-transferases (GST), have had alternate, unrelated functions 
attributed to them in different tissues. In addition to their enzymatic conjugation 
activities, GSTs may act as enzymes in other reactions, gene expression 
regulators, and binding proteins (17-22). For example, GSTP1 acts as a 
zeaxanthin-binding protein in the macula of the human eye, leading to very high 
endogenous levels of the carotenoids, lutein and zeaxanthin at the fovea (22). 
This novel function of GSTP1 was elucidated only after investigating proteins that 
copurify with xanthophyll carotenoids in the human macula; similarly, a novel role 
for srd5aR2 may only be demonstrated through the study of various processes in 
the epididymis. 
1.2. Specificity of Androgen Action in the Epididymis 
Most of our knowledge of the mechanisms by which androgens exert their 
action comes from studies that have been carried out in another androgen-
dependent tissue, the prostate, using various prostatic celilines. The absence of 
epididymal cell lines until a few years ago have limited such studies in the 
epididymis. While it has been suggested that the characteristics and mode of 
action of the AR in the epididymis resemble those of other tissues (5), aspects of 
AR signalling, such as the AR coregulators involved, are likely to be tissue-, 
region-, and/or cell-specific. For example, as was mentioned in the thesis 
introduction, three p160 coactivators of the AR exhibited cell type-specifie 
expression in the rat epididymis and differential localization within the cell; 
p/CIP/RAC3/ACTR/AIB1/TRAM-1 expression was especially strong in the 
cytoplasm of principal cells in the caput region of the epididymis (23). The 
differential expression of the p160 coactivators in the tissue may lead to and/or 
reflect variations in the mechanisms of androgen action along the tissue and 
within the various cell types. The nature and/or combination of the AR 
coregulators expressed in principal cells may also contribute to the sensitivity of 
principal cells to androgen levels by rendering the AR competent to direct gene 
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expression and by enhancing or repressing the transcription of androgen-
regulated genes by various mechanisms. In chapter 4 of this thesis, the 
expression of AR coregulators was suggested to be involved in the time 
dependent rescue of genes that have been deprived of androgens by OHT. In 
this study, direct interactions between POU2F1 and the AR were identified 
among the genes rescued with OHT supplementation at 4 days, and similarly, 
three AR coregulators (cyclin E1, cyclin 01, and AES) were among the majority 
of genes not rescued at 6 days. The functional role of the se coregulators in 
principal cells of the caput epididymidis would need to be investigated, as will be 
discussed in section 4.4.1., to ascertain their relative role in the expression of 
androgen-regulated genes. 
2. Immortalized Ceillines as a Tooi for Understanding Mechanisms of 
Androgen Action in the Epididymis 
The initial segment, caput, corpus, and cauda regions of the epididymis 
have been investigated under various androgenic conditions to help elucidate the 
functions and regulation of this tissue. These studies have provided a wealth of 
knowledge on epididymal epithelial physiology, sperm maturation, sperm storage, 
and sperm transport, but androgen action in the epididymis has reached a 
plateau. The epithelium of each region of the tissue is composed of different cell 
types, the proportion and distribution of which differ from one region to the other 
(24). The cell types of the epididymis have distinct functions, and the extent of 
their interactions remains unknown. Also, each cell type, parlicularly principal 
cells, is thought to have unique functions in the different regions of the tissue (24-
26). Therefore, toobtain a more thorough understanding of how androgens or 
other factors exert their effects on the epididymis, it is useful to study the cell 
types of each region in isolation. 
The most practical approach to study the cell types of each epididymal 
region in isolation is through the generation of region-specifie epithelial ceillines. 
They have been particularly useful to elucidate the molecular workings of the 
epididymis. For example, mE-Cap ceUs have been used to characterize the 
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regulation of PEA3 mRNA, which was found to be regulated in the epididymis via 
protein kinase A and ERK signalling cascades (27). DC-2 cells have been used 
to identify cis-DNA regulatory elements responsible for the middle/distal caput 
epididymidis-specific gene expression of lipocalin 5 (28). In this thesis, PC-1 cells 
were used for promoter studies of srd5aR2 (chapter 2) as weil as to examine the 
consequences of androgens on principal cell gene expression in the proximal 
caput epididymidis (chapter 4). These studies constitute only a few examples of 
the potential uses for region-specifie cell lines of the epididymis. 
Ali the region-specifie epididymal ceillines published to date are derived 
from the caput epididymidis and are essentially principal cells. While the caput 
epididymidis is very active in protein synthesis and secretion, and principal cells 
are the major cell type of the tissue, one cannot understand the tissue's functions 
and regulation without considering the other regions and cell types of the 
epididymis. Immortalized ceillines will need to be developed for each cell type 
from the different epididymal regions; these cell type- and region-specifie cell 
lines can then be used to compare and contrast gene expression and regulation 
between the same cell type in different regions of the tissue or between different 
cell types in the same epididymal region. Various aspects of androgen action, 
including the AR signalling cascade, the expression of AR co-regulators, non-
classical modes of androgen action, and the regulatory regions of androgen-
regulated genes can also be identified and manipulated in the different ceillines 
to establish a role for region- and/or cell-specificity. Importantly, the in vitro 
studies can be extended to include co-culture studies of different cell types ta 
elucidate their respective roles and interactions. Ali of the information gathered 
from these studies can then be pieced back together to get a more 
comprehensive understanding of the tissue (Fig. 1). 
260 
Figure 1. Understanding Epididymal Physiology and Androgen Action in 
the Epididymis. 
Elucidating the physiology and inter-relationships of.the epithelial cell types in the 
different regions of the epididymis using immortalized epithelial ceillines will 
provide a more comprehensive understanding of the tissue. 
EPIDIDYMIS 
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& ANDROGEN ACTION 
Epithelial Cell Lines 
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3. Therapeutic Implications of Studying the Mechanisms of Androgen 
Action in the Epididymis 
An in depth understanding of how androgens exert their effects on the 
epididymis and how they regulate the structure and functions of this highly 
androgen dependent tissue will help provide a sol id grasp on the tissue's 
physiology. This knowledge will, in turn, be crucial for the development of new 
therapies in the management of male infertility and in elucidating potential targets 
for an effective post-testicular male contraceptive. 
It is estimated that a male factor is responsible in almost 50% of infertile 
couples (29); given the role of the epididymis in the acquisition of sperm motility 
and fertilizing ability, it is not surprising that certain disorders of sperm function 
are attributed to a disordered epididymal function. Epididymal pathologies su ch 
as epididymitis and epididymal obstruction are treatable through antibiotics and 
surgery respectively (30,31), but conditions su ch as the presence of antisperm 
antibodies and epididymal necrozoospermia (characterized byabnormally 
shaped spermatozoa, poor sperm viability, and impaired sperm motility (32» 
require a more solid grasp of epididymal physiology so that the underlying causes 
can be treated. Other disorders resulting from faulty epididymal function are also 
likely to account for some of the unknown causes of male infertility. 
ln species such as bulls, boars, dogs, stail ions, and more recently in four 
transgenic mice models, epididymal defects resulting in angular spermatozoa 
have been associated with male infertility (reviewed in (33». These swollen 
spermatozoa are unable to regulate their volume under hypotonic conditions, 
presumably because of a blockage in either the secretion of osmolytes by the 
epididymal epithelium or in the uptake/retention of these molecules by the 
spermatozoa (33). Given that several epididymal enzymes and transporters 
responsible for osmolyte secretion are under the control of androgens (34-36), a 
better understanding of androgen action in this tissue can not only provide 
therapeutic avenues for this disorder, but it can also help elucidate appropriate 
targets for use as a male contraceptive. In chapter 4 of this thesis, genes 
involved in the secretion of osmolytes such as solute carrier family 6, member 9 
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and solute carrier family 9, member 1 were found to be highly expressed in PC-1 
cells; these cells will therefore serve as an invaluable tool in characterizing these 
molecules and possibly elucidating therapeutic avenues for swollen spermatozoa. 
The need for a male contraceptive and the interest in using post-meiotic 
approaches to achieve reversible fertility culminated in a meeting, held last year 
. in Hong Kong, that was entirely dedicated to finding potential targets for use as 
post-testicular contraceptives; the proceedings of which were published in (37). 
The epididymis is a particularly attractive site for male contraception due to its 
rapid onset of infertility, reversible nature, and fast return of fertility once therapy 
is withdrawn (38). Three major sites of action can be targeted byantifertility 
agents in this tissue: the peritubular muscle (hastening or slowing sperm 
transport), the epithelium (altering the luminal fluid composition), and the 
spermatozoa (interfering with sperm function) (39). These approaches have been 
thoroughly reviewed in the following references (38, 39), but to date most of them 
have been unable to achieve complete infertility. The G-protein coupled receptor 
HE6 (also known as GPR64), for instance, appeared to be a likely candidate due 
to its preferred epididymis-specific expr~sion pattern and the nature of the 
receptor, but was abandoned when no epididymis-specific phenotype was 
observed in knockoutmice (40). Approaches specifically targeting sperm 
glycolysis and sperm membrane ion channels have so far proven to be most 
promising (39). The complexity of the epididymis and the ability of certain 
proteins to carry out overlapping functions make it likely that the most efficacious 
post-testicular contraceptive will be comprised of a combination of compounds 
targeting sperm function as weil as the expression of various tissue-specifie 
epididymal proteins that are crucial for fertility. These targets can only be 
elucidated by acquiring a deeper and more thorough knowledge of epididymal 
physiology and its regulation. 
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4. Future Directions 
This thesis has provided novel insights on selective aspects of the 
mechanisms by which androgens exert their action in the epididymis, established 
the basic framework for further studies on the regulation of srd5aR2 at the 
transcriptional and epigenetic levels, characterized the response of principal cells 
to various androgenic conditions, and has also opened new avenues for future 
studies. This section will suggest follow-up studies for each of the aspects of 
androgen regulation investigated in this thesis. 
4.1. The Transcriptional Regulation of Srd5aR2 
The study described in chapter 2 of this thesis can be extended by 
identifying transcription factors, other than SP1 and SP3, present in the 
epididymis that may be involved in regulating the transcript levels of srd5aR2. 
Potential transcription factor binding sites in the cloned 5' upstream region of 
srd5aR2, identified by the web-based TRANSFAC database, can be assayed to 
determine the transcription factor(s) interacting with their potential binding sites in 
the rat caput epididymidis by gel shift assays, supershift assays, and mutational 
studies. Footprinting analysis can be carried out in parallel to specifically identify 
region(s) of the gene bound by the transcription factor(s). Nuclear extracts from 
the PC-1 cellline can also be used to optimize the binding conditions and 
compare the transcriptional regulation of srd5aR2 in the œil line with that of the 
rat tissue, as was done in chapter 2 of this thesis. The transcription factors 
identified can then be used in transient transfection assays to determine their 
relative importance in regulating srd5aR2 transcription. The presence of these 
transcription factors, when added to a heter?logous cell line, such as the H9C2 
rat cardiac myocyte cell line, should reconstitute or come close to reconstituting 
the high transcriptional activity observed in vivo. The interactions observed in 
vitro between the identified transcription factors and the promoter region of the 
srd5aR2 gene can also be confirmed in both PC-1 cells and the rat caput 
epididymidis using chromatin immunoprecipitation assays. Similar experiments 
can also be carried out for the srd5aR1 gene, as its 5' upstream region was 
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recently cloned and characterized (12). These results will provide a complete 
overview of the transcriptional regulation of srd5aR2 and will help elucidate why 
the expression levels of srd5aR2 in the caput epididymidis are higher than any 
other rat tissue. In addition, these results may impart clues on the transcriptional 
expression of other caput epididymidis-expressed genes. 
4.2. The Epigenetic Regulation of Srd5aR1 and Srd5aR2 
To complete the studies described in chapter 3 of this thesis, bisulfite 
sequencing should be done on the 5' upstream region of both srd5aR1 and 
srd5aR2 in the caput epididymidis, heart, liver, and ventral prostate. This method 
converts ail nonmethylated cytosines into thymines,while methylated cytosines 
remain unchanged. In addition to confirrning the changes in cytosine methylation 
identified by the qAMP assay, it will examine the methylation status of other CpG 
dinucleotides that were not part of the Hhal and Hpall recognition sites. By 
providing a more thorough depiction of the methylation status of the 5' upstream 
region of the genes in the different tissues, bisulfite sequencing may identify 
important regulatory regions for srd5aR1 and srd5aR2. 
The differences in adenine methylation of Mbol recognition sites in the 5' 
upstream region of srd5aR1 as weil as the tissue-specifie differences at a GA TC 
site upstream of the gene's CpG island suggest that adenine methylation may 
play a role in the regulation of srd5aR1. To further investigate the role of this 
epigenetic modification in the regulation of srd5aR1 , additional Mbol recognition 
sites may be investigated along the 5' upstream region of srd5aR1 by qAMP. 
These results can then be verified using Southern blots on shorter fragments of 
the gene's upstream region; given that the GA TC site where tissue-specifie 
differences were seen is outside of srd5aR1 's CpG island, Southern blots may 
not prove to be as problematic as in chapter 3. 
The functional consequences of methylation on gene expression can be 
subsequently investigated using transient transfection of in vitro methylated 5' 
upstream region/reporter constructs. The reporter gene activity of an expression 
plasmid containing various lengths or components (i.e. upstream sequence, CpG 
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island, gene promoter) of the 5' upstream region of srd5aR1 and srd5aR2 can be 
methylated with Sssl methylase (CpG methylase) or Dam methylase (GA TC 
methylase) and then assayed in different tissue-specifie œil lines. This assay will 
help determine the relative role of methylation in the different sub-regions of the 
5' upstream region of the two genes; the differential methylation pattern at 
particular bases assayed by bisulfite sequencing in the sub-region will identify the 
CpG or GA TC sites involved. Similarly, inhibiting DNA methyltransferase activity 
with 5-azacytidine can induce srd5aR mRNA in immortalized cells of a non-
expressing tissue. This·approach can also be expanded to include other tissues 
and the other regions of the epididymis. 
4.3. The Role of Srd5aR1 and Srd5aR2 in the Epididymis: The Knockout 
Approach 
Mice with null mutations for srd5aR1, srd5aR2, and for both isozymes, 
described in section 4.1 of the thesis introduction (chapter 1), can be used to 
elucidate the relative roles of srd5aR1 and srd5aR2 in the epididymis. Although 
these animais are fertile and virilizationis not affected to the same extent as in 
human srd5aR deficiency or srd5aR inhibitor treated rats, they constitute 
important tools for understanding androgen action in the tissue. Microarray 
studies can be done to examine the gene expression profile for each region of 
the epididymis in the srd5aR1 nul! mutant, srd5aR2 nul! mutant, srd5aR double 
nul! mutant, and wild- type mice. The gene expression profiles generated can be 
then compared and contrasted to determine the role of each isozyme in the 
different epididymal regions as weil as the relative role of srd5aR1 and srd5aR2 
in a given region of the epididymis. These studies may also reveal a novel role for 
srd5aR2, as was hypothesized in section 1.1.1 of this chapter. Sperm motility 
parameters can also be investigated in sperm from the caput and cauda 
epididymidis of these nul! mutants by Computer Assisted Semen Analysis 
(CASA). Together, these results will provide a greater understanding of the 
differential distribution and regulation of srd5aR1 and srd5aR2 in the epididymis 
and may help explain the high levels of srd5aR2 in the caput epididymidis. 
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4.4. Consequences of Androgen Manipulations on Epididymal Gene 
Expression in Principal CeUs 
Potential follow-up studies directly stemming from the findings of chapter 4 
are discussed in the next three sections. 
4.4.1. The Role of AR Coregulators in the Time Dependent Rescue of 
Androgen-Regulated Genes 
The expression patterns of AR, srd5aR1, and srd5aR2 make it unlikely 
that they were responsible for the time dependent loss in androgen response in 
PC-1 cells. The results from this study instead suggest a role for AR coregulators; 
POU2F1 was one of the 60% of genes rescued at 4 days, while AES, cyclin 01, 
and cyclin E1 were among the 85% genes not rescued at 6 days. Investigating 
the function of these four proteins as coregulators of the AR would be a natural 
extension of chapter 4. 
Several complementary approaches can be used to elucidate the role of 
POU2F1, AES, cyclin 01, and cyclin E1 in mediating the expression of androgen-
regulated genes. Binding of the AR coregulator to the upstream region of 
selected androgen-regulated genes can be established by supershift assays 
using PC-1 cell nuclear extracts, fragments of the 5' upstream region of selected 
androgen-regulated genes, and an AR coregulator-specific antibody. The ability 
of the AR coregulator to modulate the transcription of selected androgen-
regulated genes can be evaluated by transfection assays, where the upstream 
region of an androgen-regulated gene is cloned into a luciferase vector and 
luciferase activity is monitored following the sequential addition of AR and AR 
coregulator in a non androgen-responsive ceilline. The sa me experimental 
design as described in chapter 4 can also be used to ascertain the in vivo role of 
the four AR coregulators. The rescue of androgen-regulated genes at 4 days can 
be examined when POU2F1 expression is blocked by siRNA and similarly, the 
lack of rescue at 6 days seen in the majority of androgen-regulated genes can be 
evaluated when AES, cyclin 01, and cyclin E1 are transfected into PC-1 cells. 
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4.4.2. Novel Androgen-Regulated Genes 
Among the genes found to be androgen-regulated in principal cells of the 
proximal caput region of the epididymis, IGF-1 and periostin were particularly 
interesting due to their ability to increase from undetected levels following 
androgen deprivation. 
IGF-1 appears to play a central role in PC-1 cells by its ability to directly 
influence the regulation and expression of many genes rescued by DHT 
supplementation at 4 days. The localization of IGF-1 to the apical and subapical 
cytoplasmic compartments of the prepubescent rat caput epididymidis (41) and 
its ability to induce the maturation of epididymal principal cells in vitro (42) 
suggest that this pleiotropic growth factor is important during development in this 
tissue. The expression and specifie role of IGF-1 in the adult epididymis, 
however, are unknown, but high levels of IGF-1 receptor mRNA were found in the 
epithelium of the caput region (43). Following androgen deprivation, IGF-1 
expression increases several-fold from undetected levels in PC-1 cells for 
reasons that remain unknown. This increase in expression may serve to amplify 
AR signalling in the absence of androgens as was suggested in chapter 4, it may 
reflect a tendency of principal cells towards dedifferentiation, or it may be a 
combination of both. 
Different approaches can be undertaken to characterize the role of IGF-1 
in principal cells of the proximal caput epididymidis under various androgenic 
conditions; the consequences on gene expression can be evaluated after 
blocking the increase in IGF-1 expression with siRNA following the removal of 
androgens from the media or after an IGF-1 expression vector is added under 
control conditions. The nature of the genes affected by these different conditions 
will indicate the pathways involved and the possible role of IGF-1. IGF-1 mRNA 
and protein expression would also need to be examined in an adult epididymis 
under control conditions and following similar androgen manipulations. 
Periostin, whose androgen responsiveness has been described for the first 
time in chapter 4, is not expressed under control conditions in PC-1 cells, but its 
levels dramatically increase from undetected levels after 4 days of androgen 
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deprivation. Various approaches can be undertaken to elucidate the role and 
regulation of this gene in the epididymis. A preliminary search for AREs can be 
done in silico to confirm the ability of the AR to directly interact with the gene, 
sequential deletion analysis of the gene's 5' upstream region can be carried out 
under control conditions to identify regions with strong repressor activity, and this 
region can subsequently be used for gel shift and supershift assays to identity the 
corepressor(s) interacting with the periostin gene. Transfection assays can 
confirm the ability of the identified corepressor protein(s) to repress periostin 
expression. The in vivo significance of this interaction can then be examined 
using chromatin immunoprecipitation assays. The androgen-repressed state of 
periostin should also be confirmed at the mRNA and protein level in the caput 
epididymidis under control conditions, following orchidectomy, and following 
orchidectomy and DHT supplementation. To ascertain the role of periostin in the 
epididymis, periostin mRNA expression can be blocked by siRNA, and the effects 
on cell adhesion, cell proliferation, and cell survival assessed to determine if 
these pathways are also affected in this tissue. Given that periostin was found to 
be stimulated as part of a stress response (44-46), it would be interesting to 
examine if the increase in periostin expression following androgen withdrawal 
would be seen in other stressful conditions, su ch as oxidative stress. 
4.4.3. The Differentiai Ability of Testosterone and DHT to Rescue Gene 
Expression following Androgen Deprivation 
The study described in chapter 4 can be extended to identify testosterone-
and DHT-mediated effects on gene expression in PC-1 cells. The differential 
effects of these two androgens can be determined by having, in addition to the 
DHT group, a testosterone group and a testosterone and dual srd5aR inhibitor 
group at each time point following androgen deprivation. These results will help 
determine the relative role of the androgens in principal cells, their ability to 
specifically regulate certain gene families, and the specificity of the time 
dependent rescue of androgen-regulated genes observed with DHT. 
269 
5. Final Conclusions 
ln this thesis, two complementary approaches were used to better 
understand androgen action in the epididymis; the first approach dealt with the 
regulation of DHT biosynthesis and therefore its availability in the epididymis, and 
the other, with how a particular epididymal cell type responds to changes in 
androgen concentration. 
The 5' upstream region of srd5aR2 was analyzed at the transcriptional and 
epigenetic levels· to help elucidate the molecular mechanisms responsible for 
high srd5aR2 mRNA expression in the caput epididymidis.lnsights into the 
regulation of srd5aR2 that were provided by this approach are crucial in 
understanding the mechanisms leading to high concentrations of DHT in the 
epididymis and can help explain the caput-specific expression of a number of 
other epididymal proteins. These studies also identified an additionallevel of 
differential regulation between srd5aR1 and srd5aR2, as depicted by differences 
in the DNA methylation status of the genes. 
The second approach focused on changes in gene expression of PC-1 
cells following androgen deprivation and DHT supplementation. The majority of 
androgen-regulated genes displayed a transient increase in expression levels 
after androgen withdrawal, and their ability to respond to DHT was compromised 
after prolonged androgen deprivation. These results offer new perspectives in the 
response of the most androgen sensitive epididymal cell type to androgen levels 
and may have important implications in the therapeutic administration of 
testosterone in aging men. They also suggest an important role for AR 
coregulators in mediating androgen action in this tissue. 
This thesis, as a whole, provides novel insights into the role of androgen 
action in the epididymis. 
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LIST OF ORIGINAL CONTRIBUTIONS 
1. Designed mouse, human, and rat steroid 5a-reductase (srd5aR) type 2 specifie 
primers for reverse transcriptase- polymerase chain reaction (RT-PCR) 
2. Determined srd5aR2 mRNA expression in human prostatic PC-3 and mouse 
proximal caput epididymal PC-1 cell lines. 
3. Constructed nine luciferase expressing pGL3Basic plasmids containing 
sequentially smaller fragments of the 5' upstream sequence of the rat srd5aR2 
gene. 
4. Transfected the constructs into PC-3 and PC-1 ce" lines. 
5. Identified repressor sequences, enhancer sequences, and a minimal promoter 
in the 5' upstream region of the rat srd5aR2 gene. 
6. Determine the transcriptional start site of rat srd5aR2 using the primer 
extension assay. 
7. Precisely determine the transcriptional start site of rat srd5aR2 using the 
RACE assay and, in so doing, found it to be leaky. 
8. Mapped the transcriptional start site of the rat srd5aR2 gene to 33-basepairs 
upstream of its translation start site. 
9. Searched TRANSFAC for potential transcription factor binding sites in the 2.2 
kilobase 5' upstream region of the rat srd5aR2 gene. 
10. Designed oligonucleotides spanning different regions of the rat srd5aR2 gene 
and oligonucleotides with specifie mutations for use in electrophoretic mobility 
shift assay (EMSA). 
11. Identified interactions between transcription factors in nuclear extracts fram 
PC-1 ceUs and rat caput epididymidis and different fragments of the rat srd5aR2 
gene using EMSA. 
12. Identified the ability of SP1 and, to a lesser extent, SP3 in PC-1 cells and rat 
caput epididymidis nuclear extracts to interact with two Sp1 binding sites in the -
68 to -32 bp region of the rat srd5aR2 gene through supershift and competition 
assays. 
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13. Immunolocalized SP1 and SP3 to the different cell types and regions of the 
rat epididymis. 
14. Determined srd5aR1 and srd5aR2 mRNA expression in the caput 
epididymidis, heart, liver, and ventral prostate of 42 days old Sprague-Dawley 
rats. 
15. Investigated the methylation status of the 5' upstream region of srd5aR1 and 
srd5aR2. 
16. Searched and found a CpG island in the 5' upstream region of srd5aR2. 
17. Optimized conditions for Southern blot analysis in the 5' upstream region of 
srd5aR1 and srd5aR2. 
18. Found the 5' upstream region of srd5aR1 and srd5aR2 to be predominantly 
cytosine methylated. 
19. Used the quantitative analysis of DNA methylation by real-time PCR (qAMP) 
assay to determine the methylation status of various methylation-sensitive 
restriction enzyme sites along the 5' upstream region of srd5aR1 and srd5aR2. 
20. Elucidated a non-homogenous DNA methylation pattern along the 5' 
upstream region of srd5aR1 and srd5aR2. 
21. Found CpG dinucleotides to be essentially unmethylated in the enhancer and 
promoter regions of srd5aR2. 
22. Found methylated CpG dinucleotides in the region encompassing the 
srd5aR1 gene promoter. 
23. Identified significant differences in cytosine methylation between the caput 
epididymidis and Iiver in the proximal enhancer and promoter regions of srd5aR2. 
24. Identified a GA TC site upstream of the CpG island of srd5aR 1 that displayed 
tissue-specifie differences in adenine methylation. 
25. Examined overall gene expression in PC-1 cells under control conditions 
using cD NA microarrays. 
26. Determined the consequences of androgen withdrawal on cell viability and 
overall gene expression in PC-1 cells. 
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27. Identified four distinct patterns (decreasing, increasing, early transient 
increasing, and late transient increasing) of gene expression following androgen 
withdrawal using K-means cluster analysis. 
28. Found that the majority of androgen-regulated genes showed a transient 
increase in gene expression after being deprived of androgens. 
29. Examined the effects of supplementing PC-1 cells with dihydrotestosterone 
(DHT) at different times following the removal of androgens, which has never 
been previously explored in an epididymis in vivo or in epididymal ceillines. 
30. Identified a differential ability of rescue among androgen-regulated genes 
depending on time of DHT supplementation. 
31. Visualized direct relationships between genes differentially affected by DHT 
supplementation after 2 days and 4 days of androgen deprivation. 
32. Found many of the genes rescued at 4 days to be functionally linked by direct 
interactions to insulin-like growth factor 1. 
33. Designed gene specifie primers for real-time RT-PCR. 
34. Evaluated the consequences of androgen manipulations on mediators of 
androgen action (androgen receptor, srd5aR1, and srd5aR2) mRNA expression 
by real-time RT-PCR. 
35. Confirmed changes in v-rel reticuloendotheliosis viral oncogene homolog A, 
insulin-like growth factor binding protein 2, periostin, secreted phosphoprotein 1 
(Spp1) mRNA expression following androgen deprivation and DHT 
supplementation by real-time RT-PCR. 
36. Identified periostin as an androgen-regulated gene. 
37. Confirmed, at the protein level, the changes in Spp1 mRNA expression 
observed following various androgen manipulations. 
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